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Abstract 
Hsp90 proteins are essential and ubiquitous molecular chaperones that play 
important roles in folding, activation and assembly of a range of client proteins which are 
involved in signal transduction, cell cycle control and transcriptional regulation. Hsp90 can 
be divided into three domains which play vital roles in the protein function. The domains are 
classified as the N-terminal domain, the middle domain and the C-terminal domain. This 
thesis describes the study of the Hsp90 proteins from Homo sapiens (Hsp90a) and 
Caenorhabditis elegans. The attempt to crystallise the C-terminal proteins is also described. 
The overall goal of the project was to biochemically and biophysically characterise various 
Hsp90 constructs and use this information to elucidate the biological role of this important 
family of proteins. 
The C-terminal domain of human Hsp90 a. The work involved over-expression, 
purification and characterisation of the C-terminus of human Hsp90 a protein. The over-
expression and purification led to the production of two reproducibly pure C-terminal human 
Hsp90 a protein constructs. The characterisation of these proteins focused on the interaction 
of the C-terminus with the immunophilin Cyp40 and also with ligands such as ATP and 
novobiocin. The characterisation utilised biophysical methods such as surface plasmon 
resonance, gel filtration, tryptophan fluorescence and isothermal titration calorimetry. 
Characterisation of the interaction with Cyp40 showed that the C-terminal region of Hsp90 
binds to Cyp40 with a dissociation constant in the micromolar concentration range. In 
addition, the dissociation constants obtained from all the methods utilised in the study were 
in agreement with each other. The study of the interaction of the C-terminal domain of 
human Hsp90 a with ATP showed that ATP did bind to the protein, supporting the existence 
of second ATP binding site at the C-terminus of Hsp90. Furthermore, C-terminal human 
Hsp90 a also exhibits ATPase activity. The C-terminus of Hsp90 also binds to novobiocin in 
11 
the low micromolar concentration range. Further studies showed that novobiocin was able to 
inhibit the ATPase activity of the C-terminus suggesting the possibility that novobiocin 
binds at the same site as ATP. The inhibition constants estimated from the ATPase inhibition 
experiment show an agreement with the dissociation constants obtained from the biophysical 
methods. 
C. elegans Hsp90. The work involved the cloning, over-expression and purification of the N 
and C-terminus of C. elegans Hsp90. The cloning of genes for the N and C-termini was 
successful. Purification of the proteins only led to the production of one C-terminal protein 
but no purified N-terminal protein could be obtained. Similar characterisation studies were 
carried out to the C-terminus of C. elegans Hsp90. As for the human C- terminal protein, the 
C. elegans C-terminal protein was found to bind to Cyp40 with a dissociation constant in the 
micromolar concentration range. The protein also binds to ATP and novobiocin with an 
affinity very similar to that of the C-terminal proteins of human Hsp90 a. The C-terminus of 
C. elegans also exhibit ATPase activity but the activity was ten-fold lower than that of the C-
terminal of Hsp90 human a. 
The work presented in this thesis provides conclusive evidence of the existence of an ATP 
binding site in the C-terminal domains of the Hsp90 class of proteins. The biological 
relevance of this finding is also discussed. 
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Chapter 1: Introduction 
1.1. Heat shock protein 90 (Hsp90) 
The 90-kDa heat shock protein (Hsp90) is a ubiquitously distributed molecular 
chaperone and is an essential protein in eukaryotic cells [10]. The protein exists in most 
of the compartments of mammalian cells. For example, human Hsp90 a is present in the 
cytosol [38]; the 94-kDa glucose regulated protein (GRP94) is expressed in the lumen of 
the endoplasmic reticulum [75] and TRAP 1/Hsp75 is expressed in mitochondria [31]. 
Hsp90 homologues are also found in several species such as the high temperature 
regulated protein (htpG) in E. coli [9, 36] and daJ21 in C. elegans [24]. Hsp90 is 
involved with a variety of proteins however a primary function is as a molecular 
chaperone. 
As mentioned, Hsp90 is present in various species, however the core sequences of 
all the molecules are highly conserved. A multiple sequence alignment of Hsp90 human 
alpha and beta, yeast and daJ21 which will be frequently referred to in this thesis showed 
60 to 70% sequence identity. Only htpG gives a lower value of 50% identity as would be 
expected because htpG lacks several of the very highly conserved C-terminal sequences 
as well as showing differences in the middle domain (Figure 1.1). 
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Figure 1.1. Sequence alignment of the Hsp90 homologs that are utilised in the study. The proteins 
were very similar sharing almost 70% identity. HtpG is the most divergent, lacking 100 amino acids very 
well conserved in other molecules including the MEEVD from the C-terminus. The alignment was carried 
by using ClustaIW. 
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The interactions between Hsp90 and a number of other proteins have been 
extensively investigated. These partner proteins have been classified as co-chaperones as 
they function together with the Hsp90 and influence its interactions with client proteins 
[13]. The best characterised examples of co-chaperones are Hsp70 [16, 61, cdc37 
{Abbas-Terki, 2002 #108, 63, 74, 791 and TPR containing proteins such as Cyp40, 
FKBP51, Hop, FKBP52 [16, 18, 20, 27]. By binding to the co-chaperone, Hsp90 is able 
to bind to the client proteins promoting amongst other functions refolding and 
dissociation [93].Examples of client proteins include many kinases such as CIF-2alpha 
[26], v-Src [37, 45], Akt [13] and transcription factors including p53 [60, 62]. 
TPR proteins 	Hsp70. Hsp40, 
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Figure 1.2. Overview of interactions the Hsp90 with other chaperones and clients protein. The 
cartoon is modified from that of Caplan et. al. [13]. 
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Structurally, Hsp90 consists of three domains. Each of the domains are vital to 
Hsp90 to enable the binding seen with partner proteins and also to allow them to carry 
out specific functions. These domains are the N-, middle and the C-terminal (Figure 1.3) 
[12, 84]. The N and C-termini of Hsp90 are well conserved. The middle domain is a 
highly charged region that differs between species (Figure 1.3). The middle domain is 
largely missing in prokaryotes such as the E. coli htpG [12].Full length Hsp90 is 
elongated in shape and forms a dimer via its C-terminal domain [81, 84, 87, 105]. 
Recently, the crystal structure of the full length yeast Hsp90 was solved [3]. The 
solved crystal structure is a complex of the full length yeast Hsp90 with an ATP 
analogue and the co chaperone p23/Sbal (Figure 1.4). The crystal structure containing 
just the middle and the C-terminal protein were also solved (Figure 1.4). The crystal 
structure of the complexes (termed 'closed' structure) reveals more information on the 
structure and function of Hsp90 in binding to ATP and co-chaperone proteins p23/Sba 1. 
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Figure 1.3. Cartoons of Hsp90 from different species. The charged region is almost missing in some 
eukaryotes such as TRAP I and prokaryotes such as htpG. The N-terminal (Green) consists of the ATP 
binding site and is well conserved between species. The C-terminal domain consists of MEEVD motif 
(Black) which also well conserved except in htpG. 
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Figure 1.4. The crystal structure of full length yeast Hsp90/Sbal(p23) complex and the M-C 
domains, a) Top view of the crystal structure of the Hsp90-p23/SbaI -ATP complex. b) Side view of the 
same complex crystal structure. c) The crystal structure of the M-C domain of yeast Hsp90. The figures 
were generated with PyMol by using PDB files Id 2CGE and 2CG9. 
1.2. N-terminal domain of Hsp9O 
The N-terminal roughly consists of amino acids 1-220. The N-terminal domains 
of Hsp90 are well conserved among species. The N-terminal domains of Hsp90 human 
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a, yeast and C. elegans are 60-70% identical. However, the N-terminal domain of htpG 
is only 40% identical to other Hsp90 molecules. The N-terminal domain contains a 
binding site for ATP/ADP [40, 80, 84]. Published studies of the ATP binding site in the 
N-terminus of Hsp90 have improved our understanding of Hsp90. Details of the 
molecular interactions are also now available with the structure determinations of the 
full length yeast Hsp90 and the N-terminal domain on its own [12, 81-84, 87, 88 {Ali, 
2006 #1042, 90, 104]. Besides ATP, Hsp90 binds specifically to geldanamycin (GA) 
[91, 98] and radicicol [91]. The N-terminal structure was also solved by x-ray 
crystallography, as a complex between geldanamycin and the N-terminus of yeast Hsp90 
[81, 91] and human Hsp90 [98]. The N-terminal domain also binds to p23/Sbal, but 
p23/Sbal only binds to ATP bound Hsp90. 
1.2.1. ATP/ADP bind at the N-terminal of Hsp90 
The N-terminal domain of Hsp90 contains the site for binding to ATP. The site 
was confirmed from the crystal structure of yeast Hsp90 as well as biochemical studies. 
[34, 71, 83, 90]. In the crystal structure (Figure 1.5), the binding site is shown to lie in a 
deep pocket on the helical face of the N-terminal domain. The binding pocket is made 
up of helices from 28-50 and from 85-94 on two sides. The other two sides of the 
pocket are made by the end of the helix and loop from 117-124 and the loop from 81-
85. The base of the pocket is made up from residues Ile-77, Asp-79, Val-136, Ser-138, 
Thr-171, and Ile-173, whose side chains project up from the buried face of the 3 sheet. 
The adenine base of ATP/ADP penetrates the base of the pocket and makes the only 
direct hydrogen bond to Asp-79. The adenine base also makes other hydrogen bonds but 
1-7 
indirectly via water molecules to Leu-34, Asn-37, Asp-79, Gly-83, and Thr-171. The 
ribose of an ADP is also indirectly hydrogen bonded to the side chain of Asn-92, 
through a water molecule [80]. 
In the recent structure, the '-phosphate is located in a glycine-rich loop at the C-
terminal hinge of the lid and forms a hydrogen bond with the peptide backbone of 
Gin 119, Gly 121, Val 122 and Gly 123(Figure 1.6 b). The 13-phosphate hydrogen bonds 
with the peptides of Phe 124, and Gly 100 from the N-terminal hinge [3]. With an ATP 
analogue bound to the N-terminal domain, the small middle domain (residues 445-524) 
was brought forward to 10 A closer. The large middle domain (262-444) was brought 
closer about 20 A together. As a result, the gap remaining between the middle domain is 
too small to accommodate a folded client protein (Figure 1.6a). 
Based on Isothermal Titration Calorimetry (ITC) studies, ATP and ADP bind to 
the N-terminal of Hsp90 with a dissociation constant of 132 ± 47 and 29 ± 3 tM, 
respectively, with binding stoichiometries that have been shown to be close to 1 
nucleotide per N-domain monomer [80). ITC was also carried out using Hsp90 human 
a and the Kd was 240 ±14 jiM {McLaughlin, 2004 #6] Both of the experiments were 
carried out at 25°C. However, human Hsp90 a was shown to bind more strongly to ADP 
at 25°C with a Kd of 7.4 ± 1.1 jiM. The Kd was decreased to 41 ± 6 jiM when the 
temperature was increased to 370C [52]. 
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Figure 1.5. Overview of the complex structure of ATP/ADP bound to the N terminal domain, a) and 
b) are the same pictures show ADP bound to the molecule except b) shows ADP docking on to the surface 
of the N-terminal. c) ADP orientation on the binding pocket. Red coloured residues show the sites of the 
binding pocket. The blue coloured residues indicate the base of the pocket. The labelled light blue 
coloured residues show the amino acids that are involved in the interaction with ADP. The picture was 





Figure 1.6. Conformational changes of yeast Hsp90 when ATP binds to the N-terminal domain, a) 
The conformational changes of the M-C domains when ATP binds to the N-terminal. The binding of ATP 
brings the large middle domain 20A closer. b) The position of AMP-PNP when cradled into the glycine 
rich loop. The y-phosphate of AMP-PNP is orientated for attack by water activated by Glu-33. Arg-380 
polarizes the y-3  phosphodiester bond and neutralises the transition state. The figures were adapted from 
Ali et. al. [3]. 
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1.2.2. ATP hydrolysis by Hsp90 
ATP not only binds to Hsp90 but is also hydrolysed by the protein [2, 49, 52, 
96]. The rate of ATP hydrolysis differs between species. Yeast Hsp90 hydrolysed ATP 
with a Kcat of 0.47 min-' [52, 71, 83] which is the fastest published ATPase rate of any 
Hsp90 species. Human Hsp90 has a very weak ATPase activity which is 0.092 min-1  
[52]. The suggested mechanism of the ATPase cycle is illustrated on figure 1.7 which 
was modified from [86]. In the ATPase cycle, Hsp90 is presumed to be a dimer. When 
ATP binds to the N terminal, the Hsp90 molecule undergoes a structural transition in 
which the ATP becomes committed to hydrolysis. The conformation of Hsp90 changes 
and traps the ATP molecule at the nucleotide binding cleft of the N-terminus [104]. It 
had been reported that Hsp90 becomes more hydrophobic in the presence of ATP [99]. 
Under these conditions, the N-terminal domain of the dimer, (which usually points 
outward), closes up and lysine 342 of the Hsp90 forms an additional protein/nucleotide 
interaction that is required for maximum turnover. As the nucleotide pocket closes, ATP 
is hydrolyzed. The ATPase cycle of Hsp90 is completed by the release of ADP. 
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Figure 1.7. The suggested Hsp90 ATPase cycle. The cycle involves two conformational changes that 
lead to ATP being trapped. ATP is hydrolysed and finally ADP is released. The kinetic data was obtained 
from [104].K0/0ff refer to the rate of ATP binding and ADP dissociating from the molecule of Hsp90. 
K 0 f indicates the rate of conformational changes of Hsp90 molecule to N-terminal dimerisation. Khd 
represents the ATP hydrolysation rates. The illustration was modified from [86]. 
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Besides the above model of ATPase cycle, McLaughlin et. a!, [52] have proposed an 
alternative ATPase cycle based on their studies (Figure 1.8). In their model, ATP binds 
rapidly to Hsp90 under diffusion control (A to B). ATP induces a conformational change 
possibly involving the "ATP-lid" in the N-terminal domain and /or contact between the 
N and M domain (B to Q. At this stage, the affinity for client proteins as well as co-
chaperone p23 is very high. The ATP is then hydrolysed possibly involving the re-
arrangement of a catalytic loop in the M domain. The ADP bound state D has a lower 
affinity for both the client and p23. In this model, the dimerisation of the N-terminal 
domain when bound to ATP is not necessary, however the dimerisation of the C-
terminal is important to increase the binding as well as the hydrolysis [51, 52]. 
ATPase activity in yeast Hsp90 is vital to the in vivo function [69, 71]. The 
deletion of both Hsp90 proteins in Saccharomyces cerevisiae (hsp82 and hsc82 which 
are 97% identical) also results in cell death [10]. The mutations of Glu-33 (E33) or Asp-
79 (D79) of yeast Hsp90 which is involved in the binding and hydrolysis of ATP, 
makes the protein unable to bind to p23. This suggests that ATP binding is important for 
the interaction of Hsp90 to p23  [69, 99{Ali, 2006 #1042]. In contrast, Stil binds to 
Hsp90 independent of ATP and inhibits the ATP binding and hydrolysis [82], thus also 
inhibiting any interaction with proteins that may be dependent on ATP binding. 
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Figure 1.8. Alternative Hsp90 ATPase cycle 1521. The study was based on human Hsp90 a Hsp90 
molecule in dimer formation binds to ATP under control of rapid diffusion. The ATP is hydrolysed after 
the 'lid' formation between N and the middle domain. During the 'lid' formation, Hsp90 has high affinity 
to p23 and client proteins. The conformation was restored after the release of ADP. 
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1.2.2. Geldanamycin (GA) binds to the N-terminal domain of Hsp90 
and inhibit A TPase activity 
Besides binding to ATP at the N-terminal domain, GA has also been shown to 
bind at the same site. The binding of GA was observed from the crystal structure of the 
complex that was obtained by co-crystallization [98]. GA, a benzoquinone ansamycin 
antibiotic and natural product of Streptomyces geldanus, binds with high affinity to 
ATP-binding sites of Hsp90 (Figure 1.16)[25]. The crystal of the human Hsp90 was 
obtained from the amino terminal that corresponded to the geldanamycin binding 
domain (Hsp90-GBP). The protein consists of amino acids 9 to 236 of the human Hsp90 
human. The protein crystallized to give two distinct forms which show different local 
conformations. The two apo forms of the Hsp90-GBP diffracted to 1.65 A and 2.2 A 
respectively while the structure of the geldanamycin complex diffracted at 1.95 A [98]. 
The structure consists of nine a helices and eight anti-parallel 13-sheets that form the a+13 
sandwiches (Figure 1.9). Four of the helices (Hi, H2, H4 and H9) pack flatly onto the l 
sheet and their axes are parallel to the f3 strands. However, another helix (H7) packs 
steeper or almost perpendicular to the 13 sheet. There is also a second layer of helices (H5 
and H6) that pack onto the first layer. In addition, two other helices H3 and H8 were 
packed at the periphery of the sandwich. At the centre of the domain, the helical face of 
the sandwich has a wide opening which extends into the hydrophobic core of the 
structure and forms a pocket about 15 A deep. The pocket has a 13  sheet as its base and 
its walls are made by three helices and a loop [98]. In the crystal complex, the tip of the 
GA molecule has a ring that consists of carbamate C23 methoxy, and C25 and C26 
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methyl group substituents, which binds near the bottom of the Hsp90 pocket and form a 
large number of van der Waals contacts. 
The N-terminal structure of yeast also exhibits a similar arrangement in its 
tertiary structure. It consists of an eight- stranded highly twisted 13-sheet covered on one 
face by a helices. Even though, this is extremely similar, the quaternary structure of the 
yeast N-terminal is different. The yeast N-terminal domain crystallised as a dimer while 
the human N-terminal crystallised as a monomer. The dimer forms of the crystal 
provides a better mimic for Hsp90 in nature. In the structure of the yeast N-terminal 
domain observed from the crystal, the C-terminal of the 13 sheets of each monomer are 
antiparallel with each other and form a continuous hydrogen bonded sheet within the 
16 13 sheets of the dimer [80]. The dimer sheet folds back to form a cylindrical channel 
between the two monomers. The channel can accommodate around 8 to 10 residues of 
polypeptide chain in an extended conformation. This arrangement and shape, suggests 
that it may function as a molecular clamp (Figure 1.9). 
Geldanamycin binds to the full length dimeric Hsp90 with a Kd of 1.2 jiM with a 
stoichiometry of one molecule GA to one monomer of Hsp90 [91]. The dissociation 
constant was determined by ITC [91]. Radicicol is also shown to bind to the N-terminal 
domain of Hsp90 [1, 92, 95]. The binding was shown to be tighter than GA with a Kd of 
19 nM [91]. Both of the inhibitors above were shown to be specific inhibitors of the 





Figure 1.9. Geldanamycin- Hsp90 complex crystal structure. a) N-terminal domain of Hsp90 human—
GA complex structure .The helices are labelled. The structure was extremely similar with b) which is the 
structure of the yeast Hsp90-GA complex. However, the quaternary structure of the yeast Hsp90-GA 
complex, c), was different because the N-terminal of the yeast Hsp90 crystallised as a dimer, where the C-
terminal of the domain form continuous hydrogen bond. The dimer forms a cylindrical channel which can 
accommodate a peptide binding between them. 
1-17 
from binding to the Hsp90 [80, 91], thus resulting in the inhibition of p23 binding [34, 
70, 77]. 
GA was shown to be resistant to the homolog of Hsp90 in C.elegans (daf-21). In 
the studies [24], the soil-dwelling nematode Caenorhabditis elegans was exposed to GA 
under a series of conditions designed to optimize the drug uptake. However, exposure of 
worms to GA produced no discernable phenotypes. In agreement, solid phase-
immobilized GA failed to bind worm Hsp90 from worm protein extracts. Further study 
was carried out by expressing plasmid constructs encoding either unmodified chick and 
worm protein or chimeric proteins by using transcription-translation reactions in 
reticulocyte lysate. The chimeric proteins consist of either chick N-terminus fused to 
worm C-terminus (c/w) or worm N-terminus fused to chick C-terminus (w/c). GA 
affinity precipitation was carried out with these proteins. The c/w chimeric protein was 
able to bind to GA beads as the unmodified chick Hsp90. Similarly, the w/c chimeric 
protein was unable to bind to GA beads as the unmodified worm Hsp90. This, suggests 
that the inability of worm Hsp90 to bind GA was unlikely to be a result of 
intramolecular interference by the worm's C-terminal domain [25]. These chimeric 
proteins produce were also still able to bind to adenosine triphosphate. Heterologous 
expression of worm Hsp90 in tumor cells, however, were still susceptible to GA. 
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1.2.3. p23 binds to N-terminal domain of Hsp90 
As mentioned before, the N-terminal domain consists of the site for 
binding and hydrolysis of ATP. The regulation of the Hsp90 ATPase cycle was assisted 
by p23 or its yeast homolog Sbal and several other proteins [3, 53, 77{Chen, 1998 #18]. 
p23 was shown to have a preference to bind to the ATP bound form of Hsp90 [41, 43, 
89, 1011 and the binding of p23 reduces the rate of ATPase activity. Therefore, more 
time is available for the client proteins to bind to Hsp90, thus allowing Hsp90 to carry 
out its structural functions. However, there is evidence that p23 can bind to the ATP 
free form of Hsp90 but less tightly than with ATP bound form of Hsp90 [53, 89]. p23  
binds to Hsp90 with the stoichiometry of one dimer Hsp90 to two p23  [53 {Ali, 2006 
#1042, 89]. In the complex crystal structure of yeast Hsp90, p23 and ATP analogue 
(Figure 1.10), the p23 /Sbal is symmetrically attached on each site of the Hsp90 
monomer. The N-domain connects to the middle segment by antiparallel 0 strands 
involving residues 206-213 and 262-269.The monomers of Hsp90 have a parallel 
arrangement with the N-terminal domains at one end of the dimer and the C-terminal 
domains at the other. This is achieved when the Hsp90 molecule makes a left handed 
twist. As a result of the twist, 
the amphiphatic loop (residues 329-339) projects from the inner surface of the large 






I N-terminal domain 
C 
} Middle domain 




Figure 1.10. The crystal structure of yeast-p23/SbaI complex. a) Backbone tracing of the complex. 
Hsp90; purple and red. p23/Sbal; blue and green. The yellow colour indicates the location of amphipathic 
loop. b) Molecular surface representations of the complex but 900 twisted along the dimer vertical axis. 
The colour codes are the same as a). c) Orthogonal view of the Hsp90 monomer showing the N to C-
terminal domains. Amphipathic loop was represented by blue colour. 
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1.3. Middle domain of Hsp90 
The middle domain of Hsp90 is a highly charged region. The middle region 
varies between species and is not well conserved. The region is almost missing in 
prokaryotic cells [12]. The region is involved in the association of Hsp90 with steroid 
receptor [23]. It binds to Ahal [45] and is also involved in the binding of ASK1 or Akt. 
Furthermore, the domain holds both of the proteins in close proximity thus initiating the 
formation of complexes between Akt and ASK1 [110]. As mentioned before, the middle 
domain binds to Ahal as well as its homolog Hchl. However, Hchl was only found in 
Candida albicans and was not conserved between species [45, 55] The binding of Hsp90 
with these proteins increases the rate of ATPase activity up tol2-fold [50]. Ahal was 
shown to be stage independent when binding to Hsp90 and does not interfere with the 
binding of co-chaperones. In the presence of Ahal, p23 can still inhibit the hydrolysis of 
ATP [50, 72]. 
The middle domain of yeast Hsp90 and E.coli Hsp90 (htpG) were crystallised 
and the structures have also been solved [3, 40, 54]. In the yeast Hsp90 middle domain, 
it can divided into three regions that form a-j3-a sandwich (Figure 1.11). The sandwich 
consists of a five stranded f3 sheet, a three turn a helix and irregular loops on the convex 
surface and a six turn a helix nestling in the concavity of the opposite face [3, 54]. Three 
features were identified in the middle domain that play a vital roles in catalysing ATP 
hydrolysis. A catalytic loop (Gin 335-11e388) was identified to help the ATPase 
hydrolysis by sensing the 7-phosphate of ATP when it is bound to the N-terminal. This 
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event will then activate the attacking water molecule in the ATPase hydrolysis reaction. 
There is also a hydrophobic surface patch centred on Phe 349 which is near the tip of the 
loop formed by residues 342-352. This hydrophobic patch is suggested to be involved in 
the interdomain communication and positioning of the catalytic groups from the N-
domain and middle segments. Another hydrophobic patch which is exposed and consists 
of Trp 300, and Phe 329, Leu 331 and Phe 332 formed one side and the tip of a 
conformationally flexible loop, have been identified which could be involved in protein-
protein interactions [54.. The flexible loop was cantilevered out from the body of the 
main structure. This solvent-exposed loop has an unusual sequence (327-A P F D L F E 
S K K K K N N-340) generating an amphipathic structure, with one hydrophobic side 
and one positively charged side {Meyer, 2003 #368, 561. The amphipathic loop was 
observed to project from the inner face of the large domain towards its equivalent in the 
other monomer when bound to p23 (Figure 1.10 c). The middle domain is also shown to 
stabilise the closed formation of llsp90 when it binds to ATP by coming closer to each 





Figure 1.11. Middle domain structure of .yeast Hsp90. The structure consists of sandwiches of c43a. 
The PDB id of is I HK7. The picture was modified by using PyMol. 
1.4. The C-terminal domain of Hsp90 
The C-terminal domain of Hsp90 also plays a number of vital roles in the 
function of Hsp90. This domain has been shown to bind client proteins such as the TPR 
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containing proteins [11, 21, 39, 85] and immunophilins [20, 27, 105] as well as inhibitor 
such as novobiocin and coumarin [44, 109]. 
1.4.1. Hsp90 forms a dimer 
Hsp90 exists in solution as a homodimer. Dimerization occurs through the C-
terminal domain of Hsp90 [57, 87, 90, 103]. The dimerisation of Hsp90 is important for 
the function of the protein. Studies on Hsp90 human a and J3 revealed that the C-terminal 
domain contains the site for dimer formation, deletion of this region of the protein 
resulted in the loss of dimer formation. Hsp90 human a requires at least 50 residues of 
the C-terminal domain to enable dimer formation [57]. A C-terminal construct of Hsp90 
human a containing residues 542-732 was sufficient to form a dimer [67]. The 
dimerisation constants of wild type Hsp90 was shown to be around 60 nm as determined 
by gel filtration studies [87]. A model of the mechanism of dimerisation was proposed 
which suggested that the dimer formed in an antiparallel fashion [66, 68]. The study was 
carried out using limited proteolysis of the protein coupled with two dimensional page. 
From this study, the protein could be delineated into three domains designated A,B and 
C. The C domains bind to each other in anti parallel fashion to form the dimer. Further 
studies were carried out on htpG and revealed similar domain structure, however 
domain B consists of two sub-domains designated BI and BIl [68]. This extended model 
showed that 16 residues of BIT were also involved in the dimerisation of Hsp90. 
In the carboxy terminal structure of htpG, the dimerisation domain was identified 
to be located on the two helices at the end of the proteins (Figure 1.12). The two helices 
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(1-14 and 1-15) were formed by the residues 587 to 624 of htpG. The two helices interact 
with their equivalent counterparts from the second monomer and formed a four helix 
bundle [36]. The same observation was made with the yeast Hsp90 structure. In 
addition, a helix strand segment (residues 587-610) projects from the core of the C 
domain towards the N-terminal end of the dimer and is involved in the dimer interaction 
(Figure 1.12). The helix strand segment become disordered when ATP binds to the 
Hsp90 [3]. Dimerisation through the C-terminus of Hsp90 was vital for effective 
hydrolysis of ATP. In the absence of the dimeric form of the protein, the rate of ATP 





Figure 1.12. Dimerisation model of Hsp90. a) Overlay of the C-terminal structures of htpG (green 
colour) and yeast Hsp90 (light blue). The dimerisation motif was labelled with red colour. b) and c) ribbon 
view of the dimer formation in htpG (b) and yeast Hsp90 (c). The dimerisation motif of yeast Hsp90 also 
involved extra residues in yeast Hsp90. The residues can be seen in red in c). 
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1.4.2. The C-terminal domain is important for binding to client 
proteins 
Hsp90 binds to several clients proteins especially those that contain a TPR 
domain [82] such as Hsp90 Organiser Protein (Hop), Cyp40 [15], FKBP 52 [20] and 
many others through its C-terminal domain. TPR domains contain between one and 16 
tandem repeats of the basic 34 residue motif. Most commonly, three tandem TPRs are 
found, suggesting that this is the usual length of a functional TPR domain and that 
longer sequences of repeats contain several such functional units [21]. The C-terminus 
of Hsp90 ends with the following residues MEEVD. This sequence of residues at the 
end of the protein is generally well conserved between species. However, htpG the E. 
coli homolog of Hsp90 lacks this C-terminal motif. The MEEVD motif of Hsp90 has 
been shown to interact with the TPR containing proteins via one of the TPR domains 
[21, 82, 107]. Hop consist of three TPR domains, one of which binds to the C-terminal 
of Hsp70 and another one binds to the C-terminal of Hsp90 [19]. Protein phosphatase 5 
(PP5) is a serine/threonine protein phosphatase consists of TPR domain N-terminal to 
its phosphatase domain. PP5 is involved in signalling pathways that control cellular 
responses to stress, glucocorticoids and DNA damage [106]. PP5 also binds to Hsp90 
through its N-terminal TPR domain [17]. Even though the TPR domain proteins bind to 
Hsp90 using the same motif, they have distinctive Hsp90 binding properties. The 
Hsp90/steroid receptor complexes are amongst the best characterised interactions, the 
sequential nature of the interaction has been studied in some detail [20]. The different 
proteins have distinctive properties was shown in the study of interactions between 
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FKBP 51 and 52 to Hsp90. Both of the proteins consists of a core TPR domain 
necessary to bind Hsp90 but not sufficient to result in 'full' binding. This study proposed 
that in addition to the TPR domain, a conserved region called the charged Y region, 
located downstream of the core TPR domain contributed to the distinctive binding seen 
with different TPR binding proteins. The conserved region can also be observed in other 
Hsp90-TPR binding proteins (Figure 1.13). The charged Y motif consists of 11-amino 
acids motif, was identified with the consensus organization —+—+X$YXXMF, where - 
represents Glu or Asp, + represents Lys or Arg, $ represents a hydrophobic amino acid, 
and X represents any amino acid 20]. The binding of both the core TPR domain and the 
charge Y motif was observed to give a higher binding affinity of FKBP 51 when 
compared to FKBP 52. Therefore the difference in the binding to I-Isp90 might be caused 
by the involvement of the charge Y region. 
-+-+ $Y MF 
B OVIN cyp 40 AELLKVKQKIKAQKDKEKAAIA1MFA---------------- 
CHIP 	 QEQLIPIILA!IXEVIDAFISENGWVEDI--------------- 
AlP RELRALEARIRQKDEEDKARFRGIF SH--------------- 
FKBP 52 	T QLAVC Q QRIRRQLAREKKLYAIIMFERLAEEENIcAKAEAS S 
FKBP 51 L QI SMC QKKAKEH!IERDRRIYAIIMFKKFAE QDAKEEA11IAM 
Figure 1.13. The charge V motif. Sequence alignment of several TPR containing proteins shows the 
existence of the charge Y motif. The consensus sequence of the Charge Y motif is depicted above the 
sequences alignment. 
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The binding of the client proteins to the C-terminal also involved the cooperation 
of other Hsp90 domains. Further studies on the interaction of Stil with Hsp90 showed 
that Stil exist as a dimer and can bind to both of the TPR sites in the Hsp90 dimer [82]. 
Stil is the yeast homolog of Hop [102]. The binding of Stil inhibited the ATPase 
activity of Hsp90. The ATPase activity was restored when Sti 1 is replaced with Cpr6 or 
the TPR domain of PP5. Cpr6 is the yeast homolog of Cyp40 [28, 30]. From this finding 
[82], it was proposed that in the intermediate stage of the interaction of Hsp90 with 
client proteins, Stil/Hop will bind to the Hsp90 dimer and inhibit the binding of f ATP. 
In the maturation stage of the interaction, Stil/Hop was replaced by other 
immunophilins that subsequently allowed the binding of ATP and p23 at the N-terminus. 
ATP hydrolysis occurs and promotes the release of p23 and the client proteins. Stil 
binds to Hsp90 and triggers the release of ADP. The proposed mechanism was 
illustrated in figure 1.14 and suggests that the binding of TPR client proteins act as 
regulators for the ATP binding and consequently hydrolysis. Thus, it also suggests that 
cooperation between the N and C terminal domains of is required in the interaction with 
co-chaperone. Hsp90 binds to the TPR domains with a various binding affinity. Hsp90 
bind to Cpr6 with a Kd of 0.24 ± 0.005 jiM . In addition, Hsp90 binds to Stil with a Kd 
of 0.33 ± 0.03 jiM, these interactions were determined by using ITC [82]. 
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Figure 1.14. Schematic diagrams showing the composition of, and transition between intermediate 
and mature complexes. The diagram was modified from, and based on the study of [82]. In the 
intermediate state, Still hsp70 complex binds to the C-terminal and makes contact with the N-terminal, 
thus inhibiting ATP binding. In the mature stage, immunophilinslPP5 replaces the Stil complexes and 
permits the binding of ATP and p23 at the N-terminal. ATP was then hydrolysed to release the 
immunophilins/PP5 as well as other client proteins [82]. 
1.4.3. The C-terminal domain is important for interaction with Cyp40 
The majority of the studies described in this thesis involve the binding of Hsp90 
to the immunophilins Cyp40. Cyp40 is the members of large immunophilin family 
together along side with FKBP52 and FKBP 51. Cyp40 has three TPR domains which 
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are involved in the binding to Hsp90 [100]. The substitution of the EEVD motif to 
AAVD motif reduced the binding affinity of Hsp90 to other TPR proteins but disrupt the 
binding of Cyp40 and Hop to Hsp90 [14, 18]. The deletion of 24 amino acids from 
residues 700 to 724 of human Hsp90 0 also abolished the interaction between these two 
proteins. Even though the MEEVD motif is important to the binding with Cyp40, a 
study of a number of Hsp90 mutants showed that 124 residues outwith the COOH 
terminal domain of Hsp90 contain the recognition site for Cyp40 and could be shown to 
stabilise the interaction [14]. 
Two different crystal structures of Cyp40 have been solved [100], in both 
monoclinic and tetragonal forms. The TPR domain of the monoclinic crystal structure of 
Cyp40 comprises of seven helices labelled P, Q, R, S, T, U, and V. The helices form a 
helix turn helix pattern (Figure 1.15). In the tetragonal crystal, only helix P and Q are 
retained, the second helix R and S helices were found to spring out and form one 
elongated helix (the other helices were not visible in the electron density) (Figure 1.15). 
Therefore, the tetragonal form of the crystal is regarded as a trapped intermediate in the 
folding pathway of the helix domain. The structure was used to model the interaction of 
Cyp40 with the Hsp90 C-terminal MEEVD sequence. The model showed the 
requirement of the MEEVD to run in opposite direction from the direction found in the 
Hop-peptide complex [94]. Both models however suggest that the binding groove of the 






Figure 1.15. The two structures of bovine Cyclophilin 40 (Cyp40). a) Tetragonal form of cyp40 
structure. The TPR domain helices were disordered. Helix R and S sprung together to be just one 
elongated helix. The other helices were not visible in the density map. b) Monoclinic form of cyp40 
structure. Seven helices of the TPR domain were labelled from P to V. The structures were taken from 
PDB files id IIHG and hIP respectively. 
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1.4.4. The C-terminal domain binds to novobiocin and A TP 
Heat shock protein 90 (Hsp90) is a molecular chaperone whose association is 
required for stability and function of multiple mutated, chimeric, and over-expressed 
signalling proteins that promote cancer cell growth and/or survival. Therefore, it is the 
ideal target for anti-tumor drugs [33, 58, 64, 65]. Drugs such as geldanamycin, radicicol 
and 17-AAG are known to bind at the N-terminus of Hsp90 [1, 25, 29, 46, 59, 76, 92, 
93, 111]. There is also evidence of the binding of novobiocin to Hsp90 [4, 44, 47, 48]. 
The binding was observed to inhibit the autophosphorylation of Hsp90 [44]. Plant Hsp90 
and rat Hsp90 were shown to autophosphorylate or phosphorylate other protein 
substrates in vitro but only in the presence of Mn 
2+  or Ca2 . Thus, suggesting the 
existence of Hsp90-associated kinase activity in the presence of specific divalent cations 
[44]. This Hsp90-associated kinase activity may be essential for proper functioning of 
Hsp90 in both protein folding processes and signal transduction pathways [44]. The 
binding of novobiocin was observed to occur at a different site from the 
geldanamycin/radicicol-binding site. Furthermore, novobiocin is able to interfere with 
chaperone function of Hsp90 and to deplete tumor cells. Thus, in SKBR3 breast cancer 
cells, a 16-hour exposure to novobiocin reduced 
185erbB2  mutated p53, and Raf-1 
protein levels in a dose-dependent fashion [48]. 
Further study of the binding between novobiocin and Hsp90 revealed that the 
binding site is in the C-terminal of Hsp90 [47]. In this study, several mutants of 




novobiocin. The deletion of amino acid 657-677 markedly reduced the binding of 
novobiocin suggesting that novobiocin bind to these sites. A peptide of sequence 
dCD H 
c i—i 3c 
C I—I 3cD 	 I 7) 
1 
Id 	v-ri 'y' I ri 
Novobiocin 
Figure 1.16. Structure of the Hsp90 inhibitors. Radicicol and geldanamycin were known to bind to 
the N-terminal of Hsp90. Novobiocin was observed to bind to the C-terminal of Hsp90. 
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YETALLSSGFSLED, corresponding to amino acids 663-676 of Hsp90 was synthesized 
and showed to be able to compete with the C-terminal chicken Hsp90 mutants from 
binding to the immobilized novobiocin.[47]. 
The binding of novobiocin inhibits Hsp90-dependent maturation of newly 
synthesized client target such as the maturation and activation of the Hsp90/Cdc37-
dependent kinase HRI. Furthermore, the binding of novobiocin was observed to decrease 
the interaction of Hsp90 to TPR client proteins [109]. In additions, the binding of 
novobiocin also protects the C-terminal from trypsin cleavage which suggested that the 
conformation of the protein was changed on binding [109]. Recently, it is has been 
shown that novobiocin in concentrations up to 1 mM can interfere with the dimerisation 
of C-terminal Hsp90. However, up to 10 mM of novobiocin was needed to completely 
inhibit the binding of immunophilins to the protein, provided that novobiocin was 
incubated with Hsp90 prior to addition of the immunophilins [4]. This finding suggests 
that the disruption of the dimerisation may be part of the reason for reduction in 
chaperones binding. 
As mentioned before, the binding of the C-terminal mutants of chicken Hsp90 to 
novobiocin sepharose were inhibited when the proteins were incubated with ATP before 
running them on to the column. The same result was obtained when the proteins were 
incubated with novobiocin before running the complex on ATP Sepharose which 
suggested novobiocin can inhibit the binding of ATP [47]. The ATP binding site was 
observed by Gamier et. a!, (2002) using ITC and circular dichroism (CD) [32]. 
However, the binding of C-terminal of chicken Hsp90 with ITC can only be analysed in 
the present of Mg 2+.  Mg2 was shown to promote the oligomerization of Hsp90 but in 
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the presence of ATP, Mg2 inhibits the oligomerization process. When GA is applied, 
the oligomerization induced by Mg2 is retained suggesting that the effects are not 
caused by the binding of GA/ATP to the N-terminal. A likely explanation is that, the 
effects are caused by the binding of ATP to the other ATP sites in the C-terminal 
domain [32]. The C-terminal Hsp90 ATP binding site can also bind to other nucleotide 
such as GTP and UTP but not NAD. Furthermore, the site is said to be hidden and can 
only be accessed if the N-terminal binding site was occupied [97]. 
Based on the study of the C-terminal Hsp90 domain, it was shown that the C-
terminal site probably plays a vital role in the function of Hsp90 but the true mechanism 
and function still remains unclear. There are two structures of the C-terminal domain 
now available, C-terminal of E. coli htpG [36] which is just 50% identical to other 
Hsp90 and more recently, the structure of the full length yeast Hsp90 [3]. The C-
terminal domain of yeast structure was not very much different from htpG. However, the 
structure of the extreme end of the yeast Hsp90 containing the MEEVD motif was still 
unsolved. In the crystal structure, these amino acids were disordered. 
1.4.4. Crystal structure of the carboxy terminal of htpG E. coil and 
yeast Hsp90 
The crystal structure of htpG consists of five helices and three 0 sheets (Figure 
1.17). The carboxy terminal starts with a short a helix (Hi) that leads to three anti-






The 3- sheet is followed by helices H3, H4 and H5. In the crystal structure, H4 and H5 
interact with their equivalent counterparts from a second molecule around 2-fold 
symmetry axes to form a dimer via the four helix bundle [36]. 
Figure 1.17. The carboxyl-terminal structure of htpG and yeast Hsp90. a) Monomeric structure of 
htpG carboxyl terminal (light purple) overlaid with the yeast Hsp90 C-terminal (green). The helices of C-
terminal of htpG were labelled with capital letters and the helices for C-terminal Hsp90 were labelled with 
small letters. The blue colour helix (h2) was longer than Hi. The light blue helix hi) indicates the extra 
helix in the yeast Hsp90 C-terminal structure. b) The same pictures as a) but in ribbon view. c) and d) The 
dimeric structure of htpG and yeast Hsp90 C-terminal domains. The red colour indicates the dimerisation 
motifs. 
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The C-terminal of yeast the Hsp90 consists of six helices and three 3 sheets 
(Figure 1.17). The yeast structure consists of one extra helix (hi) (before Hi of htpG) 
that contributes extra residues to the C-terminal domain (not present in htpG). 
Furthermore, helix 2 (h2) of the yeast structure which corresponds to Hi in htpG was 
longer. In addition, residues 587-610 (h3) of the yeast C-terminal are also involved in 
the dimer interaction. Even though H2 in htpG correspond to h3 in yeast Hsp90, it is not 
involved in the dimerisation motif of htpG [36]. 
1.5. Function of Hsp90 
The Hsp90 orthlogues are essential and ubiquitous molecular chaperones that 
play important roles in folding, activation and assembly of a range of clients proteins 
which are involved in signal transduction, cell cycle control or transcriptional regulation 
[73, 78]. Hsp90 was observed to help the folding of citrate synthase [42]. Denatured 
citrate synthase in the absence of added chaperones aggregates when diluted into 
renaturation buffer. In the presence of Hsp90, aggregation is significantly suppressed, 
suggesting that Hsp90 binds to these aggregation sensitive folding intermediates and 
leads them to follow the correct folding pathway, thus allowing a higher number of 
molecules to reach the active, native state. Hsp90 influences the folding and activity of a 
number of different non-native proteins, suggesting that Hsp90 functions in vivo as a 
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Figure 1.18. Mechanism of Hsp90 in steroid receptor cycle. The Hsp90/Hsp7O-based chaperone 
machine or foldosome, converts the glucocorticoid receptor (GR) from unfolded conformations to a folded 
conformation that will be accessible to bind with steroid hormone. Hop binds to Hsp90 and hsp70 through 
the TPR domain to form the foldosome. In the presence of ATP, Hsp90 is converted to ATP bound 
conformation which permits the binding of unfolded GR. p23 also binds to Hsp90 and the hsp70 
complex was released. As the TPR binding site is empty, immunophilins (LP) can bind to it. During the 
final stage, the GR is already folded and ready to be released to bind to the steroid hormone. 
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Hsp90 is also involved in the signalling pathway inside the cell. The best 
characterized example is that of the steroid hormone receptor [22, 1081. In this pathway, 
monomeric glucocorticoid receptor binds to Hsp90 via a Hsp90/Hop dependent 
mechanism or foldosome. The mechanism up to the binding of glucocorticoid receptor 
was illustrated in Figure 1.18. In this scheme, the glucocorticoid receptors attain their 
hormone binding conformation after binding Hsp90. When the folded monomeric 
receptor is released, it either binds the appropriate steroid hormone resulting in 
dimerisation and activation, or remains unstable and is recognized again by the 
chaperone machinery [22, 781. 
Hsp90 is also involved in stabilizing the catalytic domains of kinases such as v-
src before assembly of the kinases into the final signalling complex. Similarly, Hsp90 
stabilizes kinases such as the integrin link kinase (ILK). ILK has been shown to induce 
the phosphorylation of Akt and GSK-3 3 that leads to cell survival and proliferation. It 
also phosphorylates transcriptional factor aNAC and promotes the invasion by 
upregulating matrix metalloproteinase 9 expression through AP-1. activation [5]. 
Therefore, ILK indirectly involves the participation of Hsp90 in the pathway. By 
inhibiting Hsp90, ILK expression was suppressed [5] and because ILK overexpression 
and hyperactivity is involved in tumor development [6-8, 35, it will be an excellent 
target in cancer treatment. Hsp90 is also involved in other kinase cycles that can lead to 
the control of cancer. This makes Hsp90 an interesting target for the development of 
novel anti cancer drugs {Arlander, 2003 #408]. 
Therefore, the thesis described the work carried out to Hsp90 proteins and the aims 
were: 
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To characterise the interactions of the C-terminal and full length Hsp90 with 
TPR containing proteins including Cyp40 by biochemical and biophysical 
methods. 
To characterise the interactions of C-terminal and full length Hsp90 with small 
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Chapter 2: Materials and Methods 
In Chapter 2 the general materials and methods used throughout the study are 
outlined. The general methods include any well established technique or protocol 
widely used such as those utilised in cloning, protein purification and biochemical 
assays. This chapter also covers the use of commercial kits for a number of 
methods/techniques, in general the protocols as outlined by the manufacturer of the 
kits were followed. More details of a particular technique or when a standard 
protocol was modified in specific experiments are described in the relevant chapters. 
2.1. Source of chemicals and biochemicals 
The chemicals were of analytical or laboratory reagent grade. Specialized 
chemicals and biochemical components and their sources are listed in the appropriate 
section of the protocols. 
2.2. General methods used in cloning experiments 
2.2.1. Polymerase chain reaction (PCR) 
The PCR was utilised to obtain the gene of interest for cloning. The template 
for the reaction was C. elegans Hsp90 DNA cloned in pQE30 plasmid by Dr. Antony 
Page. 0.5 jil of plasmid was used in the PCR reaction. PCR was carried out in a 
reaction mixture containing 200 M of dNTPs, 1 X reaction buffer [200 mM Tris- 
2-1 
HC1 (pH 8.8 at 25°C), 100 mM KC1, 100 mM (NH4)2SO4, 20 mM MgSO4, 1% Triton 
X-100 and 1 mg/ml nuclease-free BSA], 0.5 M forward primers, 0.5 tM of the 
reverse primer and 5U of Pfu DNA polymerase (Stratagene). The mixture was made 
up to the desire volume using sterile distilled H20. The reaction was then carried out 
in the thermal cycler (Biometra) under the following conditions {95°C 2 mm, (95°C 
1 mm, 55°C 1 mm, 72°C 1 mm) for 30 cycles, 72°C forlO min}. At the completion 
of the reaction, the PCR products were analysed on 1.0% (w/v) agarose gel using 
Tris-Acetate-EDTA (TAE; 90 mM Tris, 90 mM Acetic acid and 2 mM EDTA). The 
agarose gel was stained with ethidium bromide (0.5 tg/ml) and observed over ultra 
violet light (260 nm). 
For screening purposes, Taq polymerase (Roche) was used instead of Pfu 
DNA polymerase (Stratagene).The DNA template used was a single colony from the 
transformation plate. Furthermore, the PCR was carried out under following 
conditions {95°C 10 mill, (95°C 1 mm, 55°C 1 mm, 72°C 1 mm) for 30 cycles, 72°C 
forlO mm). 
2.2.2. Plasmid extraction 
Plasmid extraction was carried out using the Qiaprep Miniprep kit (Qiagen), 
following the manufacturer's protocol [17]. Basically, the DNA plasmid extraction 
was carried out in microcentrifuge tube. 10 ml of bacterial culture was spun down in 
a 50 ml Falcon (10 min at 3000 rpm) and the pellet resuspend in 250 Itl of buffer P1 
(50 mM TrisCl, 10 mM EDTA, pH 8.0; 100 jtg/ml RNase A). The re-suspended 
pellet was transferred into a microcentrifuge tube. 250 jil buffer P2 (200 mM NaOH, 
2-2 
1% SDS (w/v)) was added to the mixture which was then thoroughly mixed by 
inverting the tube 4-6 times. 350 /Ll of buffer P3 (3.0 M potassium acetate, pH5.5) 
was added and immediately mixed as above. The sample was spun down at 13,000 
rpm for 10 min in a table top centrifuge. The supernatant was harvested and applied 
to a Qiaprep spin column. The column was spun down for 60s at 13000 rpm, the 
flow through discarded. The column was then washed with 750 itl of buffer PE by 
spinning it for 60s. The flow through was discarded and the column was spun down 
to remove residual PE buffer from the column which column was then placed into a 
1.5 ml microcentrifuge tube. The plasmid was eluted by adding sterile distilled H20 
to the center of the column followed by spinning at 13000 rpm for 60s. 
2.2.3. Digestion of DNA with restriction enzymes 
Digestion of DNA was achieved using appropriate restriction enzymes in a 
total volume of 50 itl containing an appropriate buffer (lx), 2ig acetylated BSA, 
IOU of each of the restriction enzymes (NEB) and 200 ng DNA. The mixtures were 
incubated at 37°C for 4-8 hrs and analysed immediately on a DNA agarose gel. The 
band of interest was excised and purified. 
2.2.4. DNA purification by using QIA quick gel extraction kit 
(Qiagen) 
The DNA purification was carried out following the manufacturer protocol 
[15]. Basically, the digested product was run out on a DNA agarose gel. The band of 
interest was then excised with a clean, sharp scalpel. The excised gel piece was 
2-3 
weighed and 3 volumes of buffer QG added to 1 volume of gel (100mg- 100/Li). The 
sample was incubated at 50°C for 10 min with vortexing every 2 mm. After the gel 
piece had completely dissolved, 1 volume of isopropanol was added followed by 
mixing. The sample was then applied to a QLkquick column and centrifuged for 60s 
13000 rpm. The column was washed using 750 /Ll of buffer PE followed by another 
60s centrifugation step. The flow through was discarded and the sample centrifuged 
for another 60s. After that, the column was placed into 1.5 ml microcentrifuge tube. 
The DNA was eluted by adding 50 /Ll of water to the centre of the column followed 
by centrifugation at 13000 rpm for 60s. 
22.5. DNA ligation and transformation 
The ligation step was carried out to ligate the genes of interest into the 
expression vector after the DNA had been purified using the gel extraction kit [15]. 
Ligation was carried out using a Rapid DNA ligation kit (Roche). Basically, 50 jig of 
vector and 150 ng of insert were mixed together in a microcentrifuge tube. lx T4 
DNA ligation buffer and 5U of the T4 DNA iigase were added to the mixture. The 
ligation mixture was incubated at room temperature for 1 hr. After incubation, the 
ligation mixture was immediately used to transform appropriate competent cells. 
Transformation was carried out using standard methods described elsewhere 
in the literature [16]. The transformation method described here was also used 
throughout the study to transform any plasmid into an appropriate competent cell and 
does not only refer to the method used in the ligation mixture. 3-5 /Ll of plasmid 
DNA was added to 50 /Ll of competent cells and the mixture incubated on ice for 30 
mm. After the incubation, the mixture was heat shocked at 420C for 45s, followed by 
2-4 
a 2 min incubation on ice. After the incubation period, 300 Itl of LB/SOC was added 
and the mixture incubated for 1 hr at 37°C with shaking. 80d of the culture was 
spread onto an LB plate containing the appropriate antibiotics. 
22.6. Topo TA cloning (Invitrogen) 
This particular cloning technique was used to clone PCR products into either 
a pEntr or a pCR2. 1 shuttle vector before the genes of interest were transferred to the 
final expression vector either pDest, pQe30 or pET. The kit used for these cloning 
experiments was supplied by Invitrogen, the manufacturer's protocol was followed. 
Basically, 4 pd of fresh PCR product was mixed with 1 jil of vector. 1 Al of the salt 
solution (200 mM NaCl, 10 MM MgCl2) was added to the mixture, which was then 
incubated for 30 min at room temperature. After incubation, 3 Itl of the mixture was 
used to transform 504ul Top 10 competent cells (Invitrogen). Transformation was 
carried out as described earlier in this chapter (Section 2.2.5). The transformation 
mixture was spread onto LB plate containing 50 ig ampicillin, the plate was then 
incubated overnight at 37°C. Transformants that appeared on the plate were screened 
by PCR, plasmids from colonies of interest were extracted and sent for DNA 
sequencing. 
2.2.7. Test for protein expression 
Before the protein was expressed in large volume, pilot test expression was 
carried out to determine the optimal conditions for production of each of the proteins. 
The plasmid containing the gene of interest was transformed to appopriate expression 
2-5 
cells following transformation steps in section 2.2.5. One transformant was picked 
and inoculated into 10 ml of broth with appropriate antibiotic and incubated at 37°C 
overnight with shaking. The next day, 10 ml of new LB broth containing appropriate 
antibiotic was inoculated with 100 itl of overnight culture. The culture was then 
grown in a shaking w incubator at 37 °C, shake at 200 rpm. 0D600 of the culture was 
measured every hour by taking a imi sample and measured with spectrophotometer. 
The culture was induced when the 0D600 reached 0.6 by the addition of IPTG to a 
final concentration of 1 mM. The culture was incubated for a further 5 hrs with a 
sample for SDS PAGE analysis being taken every hour. All the samples were spun 
down, the supernatant discarded, 50 itl of SDS loading buffer was added to each 
sample and the cell pellet resuspended and boiled for 10 mm. The samples were then 
analysed on an SDS polyacrylamide gel. Based on the results of the test expression, 
the optimal conditions such as the length of time to get reasonable protein was 
determined and were used for larger scale protein production. The optimization was 
carried out as a standard for all the proteins and if the protein productions were not 
satisfied under this condition, further optimisation was carried out. The further 
optimisation of the protein production was mentioned to for the relevant protein in 
Chapter 3. 
2.2.8. Western blot analysis 
The cell extracts or purified protein was run on a 13-15% SDS 
polyacrylamide gel using standard conditions as outlined earlier. The protein was 
transferred onto a nitrocellulose membrane using a semidry transfer unit (BioRad). 
Briefly, a sheet of thick filter paper was saturated with transfer buffer (25 mM Tris- 
Wo 
HC1, 190 mM glycine, 20% (v/v) methanol) and placed on the anode (lower 
electrode), followed by pre-soaked nitrocellulose membrane, the gel and finally 
another sheet of buffer saturated filter paper. The cathode was placed carefully on 
top of the "blotting sandwich", the transfer was carried out for 1 hr at a constant 
voltage of 15 V. 
After transfer, the nitrocellulose membrane was blocked with a 10% (wlv) 
solution of skimmed milk in PBS-T (PBS containing 0.002% Tween 20) for 1 hour. 
Skimmed milk was used for blocking to prevent the unspecific binding of the 
primary and secondary antibody to the membrane. The blocking solution was 
discarded and the membrane washed with lOmi PBS-T. Anti-Hsp90 antibodies 
(Stressgen) or anti-His antibodies (Qiagen) were diluted (1:1000) in PBS-T and 
incubated with the blocked membrane. After 1 hr incubation with the primary 
antibody, the antibody solution was discarded and the blot washed. A secondary 
alkaline phosphatase conjugated antibody at a dilution of 1:3000 in PBST was added 
and incubated. The nitrocellulose membrane was washed after every step at least 
three times with 20 ml of PBS-T. Finally, substrate containing 0.05 mg/ml of NBT 
(Nitro Blue tetrazolium) and 0.1 mg/ml BCIP (5-bromo-4-chloro-3-indoyiphosphate) 
(Promega) in alkaline phosphatase buffer (50 mM Tris , 3 mM M902,  pH 9.8) was 
added to the membrane which was incubated until the colour from the reaction 
developed. 
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2.3. Protein expression and purification 
2.3.1. Scale up of protein expression 
Cultures of E. coli cells harbouring the recombinants plasmids were grown 
overnight in 100 ml LB broth containing an appropriate antibiotic. On the next day, 
the overnight culture was spun down at 3000 rpm for 10 mm, the supernatant 
discarded and the pellet resuspended in 40 ml of fresh LB with antibiotic. 10 ml of 
the resuspended overnight culture was used to inoculate IL of LB broth containing 
an appropriate antibiotic followed by shaking incubation at 370C until the OD600 
reached 0.6. Normally 4L of LB was used in each of the scale up experiments. The 
cultures were induced by adding IPTG (isopropyl-B-D-thiogalactopyranoside) to a 
final concentration of 1 mM and incubated for an additional 5hrs. Cells were pelleted 
by centrifugation at 8000 rpm for 15 min in a Beckman JLA9 100 rotor. The pellet 
was resuspended in lysis buffer (50 mM NaH2PO4,, 300 mM NaCl, 5mM Imidazole, 
20 mM f3-mercaptoethanol; pH 8.0) containing 1 mg/mi lysozyme (Sigma). The 
resulting cell lysate was incubated with the lysozyme for 30 minutes before it was 
sonicated (5 times at 30s bursts). After sonication, the cells lysate was spun down at 
22000 rpm in Beckman JA 25.50 for 1 hr. The pellet was discarded and the 
supernatant filtered with 0.45 am syringe filter. At this point the supernatant could 
be frozen at -20°C if required. 
2.3.2. Ni-NTA or Talon purification 
The purifications were carried out using an AKTA Prime system (Amersham 
Pharmacia). Ni-NTA or Talon resin was packed into an appropriate column 
following the manufacturer's protocol. The column containing (either Ni-NTA 
(Qiagen) or Talon (BD Biosciences) resin was equilibrated with 5 volumes of buffer 
A (50 mlvi NaH2PO4, 300 mM NaCl, 5 mM Imidazole; pH 8.0) or until a stable 
baseline was reached. The flow rate of the machine was 1 mL'min. Filtered cell lysate 
was applied to the column which was then washed with buffer A until the baseline 
was reached. The column was then washed with 10 % buffer B (50 mM NaH2PO4, 
300 mlvi NaCl , 250 mM Imidazole; pH 8.0). This step was used to wash off the 
proteins bound non-specifically to the resin. A slow gradient elution from 10 to 
100% buffer B was carried out oven 0 column volumes. 10 or 5 ml fractions were 
collected at this stage. The column was then washed with 3 column volumes of 100% 
buffer B. Finally, the column was re-equilibrated with 5 column volumes of Buffer 
A. The fractions from the elution were analysed on an SDS polyacrylamide gel to 
visualise the proteins. 
2.3.3. Gel filtration 
Gel filtration was used as a polishing step in the purification and also to 
analyse proteins and protein complexes. The columns used were Sephacryl 200 and 
Superdex 200 or 75 (Amersham). The purification was carried out using an AKTA 
FPLC system (Amersham). The column was equilibrated with one column volume of 
appropriate buffer until a stable baseline was reached. The flow rate for the 
experiments was 0.5 ml/min. The filtered solution containing the target protein was 
2-9 
concentrated to an appropriate volume and loaded onto the column. The volume of 
sample loaded was dependent on the manufacturer's suggestion for each specific 
column, however as a general guideline no more than 1 %( v/v) of the column 
volume should be applied to maximise resolution of the desired protein(s). The 
elution was carried with one column volume of buffer and 0.5 or 1 ml fractions were 
collected over the elution period. The fractions were then analysed on a 12-15% SDS 
polyacrylamide gel. 
2.3.4. Anion exchange column (Mono-Q) 
This column was used to increase the purity of the C-terminal domain of 
human Hsp90 a during a trial purification. 10 ml of 30 Q resin was packed into an 
XK16 (Amersham) column according to manufacturer's protocol. The purification 
was carried out using an AKTA Prime system. The column was equilibrated with 5 
column volumes of buffer A (50 mM Tris; pH 7.5) at a flow rate of 1 ml/min. The 
sample after dialysis overnight in buffer A, was loaded onto the column which was 
washed with buffer A until baseline was reached. The protein was eluted using buffer 
B (Buffer A + 0.5M NaCl). A gradient over 10 column volumes from 0 to 50 % 
buffer B was used, 10 ml fractions were collected over the gradient. The gradient 
was then increased from 51 to 100 % over another 5 column volumes and 10 ml 
fractions collected. Another 5 column volumes of 100% were carried to clean the 
column. The column was the re-equilibrated with buffer A for 3 column volumes and 
kept for further use. 
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2.4. Methods for characterizing Hsp90 
2.4.1. Intrinsic tryptophan fluorescence 
The experiments were carried out using Flouromax-3 (Jobin Yvon, Hariba). 
The experiment was carried out by using either a 200 jtl or a 3 ml cuvette having 
path lengths of 0.1 and 0.5 cm respectively. The 3 ml cuvette was used in the 
experiment where ligands were titrated into a protein solution. The rationale behind 
carrying out the experiments in this way is as follows: ligands can be prepared at 
very high concentrations and can therefore be titrated into the protein. The protein 
samples are not amenable to being maintained at such high concentrations, a further 
potential problem of conducting the experiments in this way would be the very large 
amount of protein required. Furthermore, the total volume added during the titration 
ideally must not be more than 4% of the initial volume. Adhering to this goal makes 
the resulting dilution factor negligible and minimizes change in the initial 
concentration of the protein. Therefore, in the protein-protein interactions studied 
using fluorescence or when the availability of one component was limiting, the 
samples were prepared separately in a total volume of 200 Itl and the 200 Itl cuvette 
was used to measure the emission. 
Preliminary experiments were carried out using the 200il cuvette. The aim of 
the experiment was to determine if an interaction occurred between the 
proteins/ligands by carrying out an emission scan using the data acquisition program 
on the fluorimeter machine. Briefly, 1M protein was excited at 295 nm and the 
emission was scanned at a range of wavelengths between 310 to 460 nm. The scan 
was repeated with the complex mixture and also with a 50 AM solution of the other 
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proteins or ligands. The profiles from the emission scans were compared to 
determine if either quench or enhancement was observed in the complex when 
compared to both of the components alone. The scan was also monitored for the 
existence of blue or red shift of the emission profile. Based on this the emission 
wavelength of the peak during the complex scan was taken and used later for further 
experiments. 
The experiment was repeated using a time based acquisition program 
supplied with the machine. The temperature of the machine was adjusted to an 
appropriate temperature for the experiment, usually 250C which is the RT. The 
excitation wavelength was set at 295 nm but the emission wavelength was based 
upon data from the emission scan and in the experiments was either 350 or 355 nm. 
The emission was measured for 60s. The measurements were then averaged and 
corrected against inner filter effects, background fluorescence and also dilution 
factor. In the experiments, the slits were usually set at 2.5 mm for excitation and 2.5 
mm or 5.0 mm for emission. There are two slits in the machine that control excitation 
and emission. The wider the slits, the more light during excitation or emission was 
permitted to reach the sample or release from the sample. The slits can not be too 
wide as error of measurements can occur. Therefore, the slits were dependent on the 
initial emission of the sample and were used for all of the experiments. In the 
titration experiments, 1 pM protein in 3 ml buffer solution was titrated into the 
ligands under test using a Hamilton syringe The solutions were mixed gently and left 
for 5 mill before the measurement was taken. In the other experiment, a separate 
reaction was prepared in a total volume of 200 l in a micro-centrifuge tube. The 
mixture was then incubated for the desired time before the measurement was taken. 
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The data was treated for correction of inner filter effects as well as background but 
not for the effect of the dilution factor. The details of the specific experiments 
utilising Trp fluorescence are more fully described in a later chapter (Chapter 4, 
section 4.2.3.2). 
2.4.2. Sensor chips preparation for Surface Plasmon Resonance 
(SPR) 
SPR is is an evanescent wave biosensor technology that monitors the 
interaction of two or more molecules in real-time. The technique detects the change 
in refractive index of a sensor surface. For example, when ITC was used to study the 
interaction of two proteins, which are A and B. Protein B was immobilised on the 
surface of a sensor chip whereas potential binding partner A was carried in a flow of 
buffer solution through a miniature flow cell (Figure 2.1). In the event of binding of 
the protein A and B, the changes in the refractive index of the sensor chip was 
captured by the detector. The refractive index changes over time were recorded on 
the sensorgram (Figure 2.1). Then, the sensorgrams can be analysed to give the 
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Figure 2.1. Illustration of SPR reaction. a) Protein A was immobilised onto a sensor chip. The chip 
was selected dependent on the type of coupling suitable to the protein. In this experiment, hHsp90-a 
521 was coupled to the NTA chip via the histidine tag on the protein. On the other hand, the ceHsp90-
492 was coupled to the CM5 chip via primary amine. In the experiment, the potential binding partner 
such as Cyp40 was passed over the surface. If the interaction occurs, the density of the surface was 
changed and when polarized light shines on it, the refractive index will also changes. The changes of 
refractive index over time were interpreted into sensorgrams b). The sensorgram can be analysed to 
give strength of binding and also kinetics of the interaction. The picture was taken and modified from 
M. 
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The experiments were carried out using a Biacore 3000/T1000 instrument 
(Biacore). The experiments were designed to investigate the binding of Hsp90 
protein to the immunophilin Cyp40. In order to carry out the experiment; two types 
of sensor chip were prepared. The hHsp90-a521 was coupled via its histidine tag to 
the Ni-NTA chip, whereas the ceHsp90-492 was coupled covalently to CM5 chip. 
For coupling via the His-tag, the NTA sensor was preloaded with Ni2 according to 
Biacore protocols. Briefly, the NTA sensor was charged with NiC12 by running 5 ml 
of 500 jiM NiC12 in Hepes-buffered saline (HBS) (10 mM Hepes 0.15 M NaCl, 
0.005% surfactant P20, pH 7.4) over the surface of an the chip at a flow rate of 20 
,41/min. Loading the chip with nickel in this way should give a baseline rise of only 
40 RU [14], The chip was washed with the same buffer to discharge unbound Ni2 . 
The His-tagged protein (100 to 500 nm) in Running buffer (10 mM HEPES, pH 7.4; 
150 mM NaCl; 0.005% surfactant P20) was passed over the sensor surface for 60s at 
a flow rate of 5 jil min-', The change in response unit seen for each of the runs was 
monitored to obtain the optimal conditions producing a saturation response. The 
optimal conditions determined were then used to bind the His-tagged protein to the 
Ni- NTA sensor chip. The chip was washed with running buffer to clear the unbound 
protein [14, 23]. The NTA sensor chip with protein bound was now ready to be used 
in the binding experiments with Cyp40. This step was regenerated between each 
injection of a new concentration of the partner protein. The experiments were each 
repeated three times. The data was analysed using software supplied by Biacore. 
Specific details of the experiments are described in greater details in chapter 4, 
section 4.2.3.3. as well as the results. 
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The ceHsp90-492 was coupled to the CM5 chip via the protein primary 
amine. In order to do this, the surface was first activated by running 1:1 mixture of 
0.4 M 1 -ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and 0.1 M N-
ydroxysuccinimide (NHS) in water at 5 4al min-1 for 3 mm. After the surface 
activation, 200 nM of ceHsp90-492 was passed over the surface to start the coupling 
reaction. The coupling process was carried at 5 p1 min-' for 10 min until the response 
deposited reach 6000 RU. The sensor was then washed with 1 M ethanolamine, pH 
8.5 to deactivate the excess carboxyl group on the sensor surface. The chip was now 
ready to be used in the interaction with Cyp40. The details of the SPR experiment of 
ceHsp90-492 are described in Chapter 5. 
2.4.3. Isothermal titration calorimetry (ITC) 
ITC is known to be a useful technique in the study of protein and small 
inhibitor interactions [7, 9, 181.The study used a VP-ITC machine (Microcal, U.K). 
In principal, the machine contains two cells, known as the reference and sample 
cells. The reference cell contains just the buffer used throughout the experiment. The 
sample cell is filled with a protein (B) whereas the ligand (A) is taken up in the 
syringe supplied with the ITC machine. The sample and the reference cells are kept 
within the same temperature between them. The ligand A is injected into the sample 
cell and is free to interact with protein B. After each injection, the heat released or 
absorbed in the sample cell was measured by comparison to the reference cell 
(Figure 2.2) [2, 11]. The heat released or absorbed gives several peaks which then 
converted over time to give apparent heat change. If the molar ratio of A to protein B 
was low at the beginning of titration, all of A will bind to the protein and the peak 
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areas are similar. As the molar ratio increase, protein B becomes saturated and the 
heat changes gradually decreased. The small heat change still occurring at the end of 
the titration was caused by the dilution of A and other non-specific effects [10]. 
The experiment was started by thoroughly cleaning the reference, sample 
cells and the syringe with sterile distilled water and then with buffer (100 mM Tris; 
pH 7.5, 50 mM NaCl). The ligand, buffer and the protein solutions were then 
degassed. 1.4 ml of degassed buffer was placed inside the reference cell. The sample 
cell was usually filled with protein, but the ligand used in this experiments 
precipitated at high concentration. Therefore, it was used in the sample cell in low 
concentration and titrated with the protein. Ligand (50 -100 jzM) in a total volume of 
1.4 ml was placed inside the sample cell. The syringe was filled with protein (300 - 
500 /zM) to a final volume of 280 jzl. The temperature of the experiment was set to 
either 18 or 30 T. The sample was stirred at 300 rpm. The protein was titrated in to 
the fixed ligand solution. The titration was carried out by setting the program on the 
machine. The initial volume injection was 5 ltl. Subsequent injection volumes were 
either held at 5il or increased to 10 pd, dependent upon the signal of the heat 
different between injections. The number of injections per experiment was either 50 
or 25 and was dependent upon the volume used per injection as the total volume that 
can be taken up by the syringe is 280 j1. Following careful setup of the experiment, 
the data aquisition program was started and the data obtained were analyzed using 
the analysis package supplied with the Origin software. More details of the 
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Figure 2.2. Illustration of the ITC reaction. a) Sample cells were filled with binding partner B 
(usually a protein). In the experiments described in this thesis, binding partner B was ligand. Binding 
partner A was usually a ligand but in that experiment carried out it was filled with protein. b) When 
binding partner A was injected into the cell, an interaction occurred. If the interaction is exothermic, 
less energy is needed to be supplied to the sample cell when compared to the reference cell to re-
equilibrate the temperatures. If the interaction is endothermic more energy needed to return the 
temperature of the sample cell to that of the reference cell. The difference in the amount of energy 
required to re-establish an equilibrium temperature between the two cells was monitored and 
interpreted to analyse the interactions. 
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2.4.4. Malachite green assay standard curve 
Malachite green was used to study the ATPase activity of the C-terminal 
Hsp90 in this thesis. The assay was straight forward. The malachite green solution 
was obtained from Upstate, UK. The solution contains (0.0812%, (w/v)) malachite 
green dye, polyvinyl alcohol (2.32%, (w/v)); dissolves with difficulty and requires 
heating), ammonium molybdate (5.72%, (w/v), in 6 M HC1), and water, mixed in the 
ratio 2:1:1:2 [19]. During ATPase activity, phosphate was released and bound to 
molybdate ion to form phosphomolybdate. The compound was then reacted with the 
malachite green dye and formed a green colour that can be measured at 620 M. The 
malachite green solution also functions to stop the ATPase activity because it 
contains a high concentration of HC1 (6M) in the solution. 34% sodium citrate was 
added to the mixture after adding malachite green solution to stabilise the signal and 
reduce background due to unspecific phosphate release from the reaction [19]. 
The standard curve for this assay utilises phosphate and was obtained by 
following the manufacturer's protocol (Upstate, UK). Briefly, 10 ji! of 1% Tween 20 
solution (Sigma) was mixed with lml of malachite green solution. The malachite 
green solution containing the Tween 20 was used in one experiment. A 1 MM stock 
of KH2PO4 was made and diluted to 0.1 mlvi prior to use. The 0.1 mM phosphate 
solution was further diluted as listed in Table 2.1. 
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Volume of diluted 
stock (0.1 mM) 
Volume of distilled water 
or diluent 
Phosphate concentration 
per 100 Itl 
50 200 2000 pmoles 
45 205 1800 
35 215 1400 
30 220 1200 
25 225 1000 
15 235 600 
10 240 400 
5 245 200 
0 250 0 
Table 2.1. Phosphate dilution series used to produce the standard curve for phosphate used in 
the malachite green ATPase assays. The total volume of each of the reactions was 250ji1. The 
dilutions were then used to carry out the malachite green assay as described below. 
100 Al of each of the dilution series was aliquoted into individual 
microcentrifuge tubes. 320 Itl of malachite green solution containing 1% Tween was 
added to each tube followed by gentle mixing. 50 lil of a 34% sodium citrate solution 
in water was added immediately and mixed thoroughly. The reactions were left for 
15 mm. After 15 mm, the absorbance at 620 nm was taken. From the absorbance, a 
standard curve was plotted and used to measure the amount of phosphate released in 
ATPase assay. 
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2.5. Methods for crystallization trials 
2.5.1. Hanging drop vapour diffusion 
All the purified proteins were subjected to crystallization trials. The trials 
were carried out using the hanging drops vapour diffusion method. This method is 
most widely used for crystallization trials due to its relative ease of use and 
simplicity [3, 4, 6]. The method utilises 24-well Linbro plates (Molecular Dimension 
Limited). The lip surrounding each of the wells was greased using soft paraffin wax. 
The Siliconized glass cover slips (Molecular dimension limited) were thoroughly 
cleaned by wiping them with a soft lens tissue to remove any fibres or dust. The 
wells were filled with lml of each of the required reservoir solutions containing a 
variety of precipitants. 2 Al of protein was pipetted into the center of the siliconised 
cover slip. Then, 2 Itl of each of the well solutions was added to the appropriate 
protein drop. The cover slip was inverted immediately but carefully and placed onto 
the rim of the appropriate well of the Linbro plate (Figure 2.3). The coverslip was 
then gently pressed down into the paraffin wax, making a seal between the coverslip 
and the plate beneath. The above steps were repeated for all wells. 
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Figure 2.3. Illustration of the set up of the hanging drop vapour diffusion technique. The drop 
containing 2 il of protein solution and 2 ltl of reservoir solution was placed in the center of a 
siliconised cover slip. The cover slip was then inverted and placed on top of the grease at the mouth of 
the well. 
2.5.2. Crystal soaking and co-crystallisation experiments 
Crystal soaking experiments were a useful tool for the project described in 
Appendix A. Crystal soaking can be used to study the interaction of protein with a 
ligand or inhibitor [13, 20 21, 22]. Crystals were grown following standard methods 
as outlined above. A plate was set up using conditions very similar to those that 
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produce native crystals. Separate reservoirs containing a range of concentrations of 
ligands were made. 2 iil of each of the reservoir solutions containing the ligands 
were placed in the center of a cover slip (one per ligand concentration). One or more 
native crystal was picked and put into the droplet containing ligand. The steps were 
repeated for all other concentrations of the ligands. In the experiment (appendix A), 
Cyp3 crystals were soaked in an increasing concentration of 1.5 to 120 mM of 
dipeptide Gly-Pro. The crystal was soaked for 20, 60 and 120 minutes for each of the 
dipeptide concentrations. The crystals were then flash frozen and stored in liquid 
nitrogen before X-ray data was collected using either the home source or station 14.1 
at the SRS, Daresbury. 
Besides crystal soaking, co-crystallization can also be utilised to study the 
interaction of protein with ligands [5, 8, 12, 20, 24]. This technique can also be 
helpful in obtaining crystals from a "new" previously structurally uncharacterised 
protein by utilising a protein partner which has already been crystallised. Therefore, 
co-crystallization experiments were used for the C-terminal domain of Hsp90. The 
partner proteins/ligands used with the Hsp90 constructs were Cyp40, ATP and 
novobiocin. Basically, the protein(s) were incubated together before the complex 
mixture was placed onto the cover slip. The protein mixture was set up and incubated 
at RT or 40C for 30 mm. The mixture was mixed with the ratio of 1 concentration of 
protein to 10 times of the ligand dissociation constant (Kd) plus the protein 
concentration. The mixture was set up based on the assumption that the occupancy of 
a binding site is independent of the protein concentration and only determined by the 
actual concentration of the ligand. For example, 300 M (10mg/mi) of h}Isp90-a521 
was used to in the co-crystallisation. In order to get the occupancy of hHsp90-a521 
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near saturation, 10 times the Kd of the interaction (Kd 701iM) was needed in the co-
crystallisation. Therefore the concentration of ligand needed was 1mM (10 *Kd + 
[protein] = 10 (70) +300 =1mM). The mixture was then used to set up crystallisation 
trials with various precipitant and commercial screening kits. 
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Chapter 3: Cloning and purification of Hsp90 
3.1. Introduction 
Chapter 3 describes the cloning and purification of both the N and C-terminal 
domains of C. elegans Hsp90. Clones for human Hsp90 a were supplied by Thomas 
Ratacjzak from Department of Pharmacology, University of Western Australia. The 
individual protein purification protocol developed for each of the target proteins are 
also outlined in this chapter. 
3.2. Materials and Methods 
3.2.1. Cloning the N and C-terminal domains of C. elegans Hsp90 
The C-terminal domain of C. elegans can be used as a comparison with the 
C-terminal of human Hsp90. Cloning was carried out with the help of Dr. Antony 
Page from Wellcome Centre for Molecular Parasitology, The Anderson College, 
University of Glasgow. The cloning experiments were carried out in his lab as well 
in-house. Cloning of the C-terminal domain of C. elegans Hsp90 was carried out to 
enable the production of an analogous region of the protein from a different species, 
allowing parallel characterization and crystallization trials with those of the C- 
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terminal domain of Hsp90 human. Basically, the regions to be cloned were selected 
by sequence analysis and secondary structure prediction to be as directly comparable 
Gene name DNA 	fragment Protein name Protein size 
length (bp) (kDa) 
CIF 386 C. elegans 12.5 
Hsp90575-702 
(ceHsp90-575) 
C2F 545 C. elegans 17.5 
Hsp90525-702 
(ceHsp90-525) 
OF 635 C. elegans 21 
1 Hsp90492-702 
(ceHsp90-492) 
N-terminal 660 C. elegans 24 
Hsp906-219 
(ceHsp90-6) 
Table 3.1. List of the genes and their sizes that were cloned to obtain the target 
proteins. The target protein was as named based on where the protein fragments started 
and ended. The calculated sizes of the proteins without any linker are shown. 
as possible to the cloned peptide sequences available for human Hsp90. Cloning 
experiments produced a number of target proteins as listed in Table 3.1. 
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The N-terminal domain of C. elegans Hsp90 (ceHsp90-6) was cloned in order 
to investigate reports that, despite high sequence identity with human Hsp90, the C. 
elegans Hsp90 is resistant to the ansamycin antibiotic geldanamycin. A clone of full 
length C. elegans Hsp90 was available, however the resultant protein was not very 
stable and to date despite extensive efforts no crystals have as yet been obtained. It 
was hoped that the N-terminus alone would produce more stable protein and 
therefore be more amenable to experiments investigating the characteristics of the C. 
elegans Hsp90 interaction with ligands such as ATP and geldanamycin. 
3.2.1.1. Polymerase chain reaction (PCR) 
The PCRs were carried out as described in Chapter 2 (Section 2.2.1). The 
primers used for the reactions were listed in Table3.2 and the regions where the 
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Primer Primer type Vector for cloning Primer sequences 
Hsp90bamc if 5 '-cgggat ccggatggtccgctaa 
catggagcgc-3' 
Forward pQE-30(Qiagen) Hsp90bamc2f 5' -cgggatccaccgaggaggagaa 
gaagaaga-3' 
Hap90bamc3f 5' -cgggatcctgcgacccaa 
ttgatgagtactgc-3' 
Hsp90pstr Reverse 5'-gcctgcagttagtcgacctcctc 
catgcg-3' 
GWC1F forward r-caccggatggtccgctaacatg-3' 
Forward GWC2F forward pEntr 	T0P0 5'.-caccgaggagaagaagaagttc-3' 
gateway 





Hsp90C3 fNdel Forward 5' -gaagtcctccatatgtgcgac 
ccaattgatgag-3' 
Hsp90BamHI Reverse pET 28a 5'-ggcttaaggatccttagtcgacctcctc 
catgcg-3' 
NtermF6Ndel Forward 5' -atgtccgagcatatggaaaccttcgca-3' 
Nterm2 1 9BamHI Reverse 5 '-gacagcctcggatccttaaa 
cctccttctc-3' 
Table 3.2. List of the primers used in the cloning experiments. The primers were designed to 
produce the same region, however, there are sequence differences because the cloning sites for each of 




N4 t 1 
NtxmF6NdI atgtc 	at at  
&gtc qge gee gaaae ettegettccaggcgattgctcagttgatggctt 9 
NI EN AET F A F 	At I AQL NI L 
at cat cc  act ttctacagtcggatctcttgc99tt gat CtCoC9CC 
I I NT FRI NKE I? L RE L 	IN A 
tccgagctctt gacaagattcqctaccOpgCCt CACCgagC ctccgagctgacact 
ID AL D X I K? Q ALT E PIE LA T 
AR EL FIX IT PRXE E K T L T I N 
gat ac cggatcggoatgar caaggccgatctgt cacaccttggaacc attgccag 
AT Al ANT ERA LVNNL AT I AX 
tc9gaaccoggccttcat ggaggctcttcaagctggagctg at tttCC atgAtggt 
I A I K ARME AL Q A RADII MI A 
cagt cggaqtc ggattctactctgctttcctt9tcgccgat9gtt9tc gtcocao cc 
F AS) Ar? IA r L V AD KSJVVT I 
aagaaccgt gatgac agctatcaat gggagcttccpcggaggAtctAtcgcgtt 
K!! ND DII ?Q U 	IDA A A I F V V 
C9tCC attcaat gacccgag9caccc gtggaacg attgtCtgcc atcaggag 
RP FNAPE VT RAT K I VI!!! I K E 
g 








gagggg:t9tc gaggctaagtgggaggagagggtc gag &Ic9tc9ct 
E AVE AK It EKEE A EVE NV A 
gacgacgctgacaagaagaagaccaagaaaatcaaggagaagtacttcgaagacgaig.ig 
ID AD KKKTKK I K E ER FE D E E 
cttaacaagaccaagccaatctggaccagaaacccagacgatatctccaacgaagaatat 
LNET KR I VT R N P DII INEE V 
9Ct9a9ttCtC aggctt gtccaotgcAggggatCtcttgccgtcagCattc 
AE F?KIL IN D V 	DIlL AUKI! F 
bccgttggpgccttgttccgtgctcttct cttcgtccccaagagcvccttt 
153 E A Q LE FR ALL Fl/P Q 	AR F 
cgctctcgttcgA cgtgtctc 
DL FENKK IKNI I K 	?SJRRSJ F 
atcatgggctgcgaggctctgc cagaAtoccttcttcatcggggtcgtc 
INEN C E E LIIPE?LN F 1K AS/V 
gtvctgggt cttccctt ctcv ctcgtgaatpctcc gcotcc agtcttg 
DIED LPL NI IRE ML I Q 1K! L 
agrc cctaagtcttgtcga9tgct99agcttatcgcgggAtgcc9a9 
KS) IRKNLVKECNEL I D E VAt 
gaaagcgttcggttcc9a9Catt C99 gatctcgctcggaatc 
DKDN FKK F?t IF &ENLKL A I 
ccg2pgctCtCaaCC9CaaggCtttCCgJtttCCttC9Ct2CtCt CctccgCt 
NED I TNR EKL ID FL R?I TI A 
ADEPT IL Kt VS/I RMKEN II 
gt 
I?? IT At IKDVV AR I AFVt K 
l!SP95C3ldeI agtc ctccatstqtgcgacccaattqatag 




VKSRGFEVLYISCD P I D E Y C V 
caacaactcaAgagtatgatggsaaga&gcttgtctCCçtCac csaggasggsctcgag 
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ceHsp 525-702 
A2I' forward 	cAcclaggaqasgaagaalttc 
BairifE 
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eagcgcatcat9assgctcaagct.c ttcgtgattcctctactatglgatacatggccgc C 
EPIMKAQALRD SR TB GYI!AA 
aagaagcatctc9Ravtcaaccca9accacgctatcatgaagacaCttC gtgetcgtgtc 
KEN LE INPDHAIBKT L R D R V 
gaggtcgataagaatgscasgsccgttaaggatttqgttgttCttCttttCgsgsCt9C t 
EVDKNDKTVI(D L V V L L F E T A 
cttctcgcttccgattctcccttgoggagcCacaatctcaCgC ttccC gcstctacaga 
LLASGFS LEEPQSMASRIYR 
at9atcsagc ttggtctcgatstCggaqatgaCg800tt9aagattCtgCtgttCCatCa 












Figure 3.1. The locations of primer binding sequences in C. elegans Hsp90 genes. Forward 
arrows indicate the start of the four protein constructs. The backward arrows show the location of 
reverse primer binding sequences. The red highlighted sequences indicate the restriction sites in each 
primer. The blue highlighted sequences show the common sequences in the forward primer for every 
region. 
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primers bound was shown in figure 3.1. The primers were slightly different, being 
dependent upon the cloning vector. 
The PCR products obtained from all the reactions were confirmed by running 
them on 1% agarose gels containing ethidium bromide followed by visualization 
using UV light. 
3.2.1.2. Cloning strategies 
3.2.1.2.3. Cloning into shuttle vectors (pCR®2.1-T0P0® and pENTRTr4'SD/D 
TOPO®) 
After all the gene products had been sequenced to confirm they contained the 
correct DNA, they were cloned into either the pCR92.1-TOPO® vector or the 
pENTRTM/SDID-TOPO® vector. However, the PCR products were first concentrated 
and cleaned up by using PCR cleaning kit (Qiagen). Then, 4 pd of the PCR products 
were added to the mixture containing salt solutions (1.2 M NaCl, 0.06 MgCl2)  and 
pCR02. 1 -TOPO®. The mixture was incubated for 5 min at RT. 3 jzl of the mixture 
was used to transform DH5u competent cells. The transformation protocol followed 
was as described in Chapter 2. The transformation mixtures were spread onto LB 
plates containing 50jig/ml of both ampicillin and kanamycin followed by overnight 
incubation at 370C. The transformants were then screened directly by PCR using the 
method of direct colony PCR. The positive transformants were grown up overnight 
in 10 ml LB broth containing 50 ig of ampicillin. On the next day, plasmid 
extraction was carried out from the overnight culture. These plasmids were used for 
cloning into the desired expression vector. 
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3.2.1.2.4. Cloning into the expression vectors (Gateway system, pQE30 and 
pET28a) 
The next steps of the cloning experiments were largely vector dependant. In 
the Gateway cloning system, the genes of interest previously cloned into the 
pENTRTM/SDID-TOPO® vector can be transferred into an expression vector without 
having to digest the genes out from the pENTRTM/SD/D-TOPO® vector. After the 
PCR products had been shown to be correctly cloned into the pENTRTM/SD/D-
TOPO® vector, the genes were transferred to pDest 17 (His-Tag containing vector) 
or pDestl5 (GST-Tag containing vector) by the LR recombination reaction. The LR 
recombination reaction was performed as followed: A mixture of 4 itl of 
pENTRTM/SD/D-TOPO® containing the gene of interest, 1z1 of pDestl7/15 were 
mixed and made up to a volume of 8 jl with TE buffer. 2 Itl of LR Clonase II 
Enzyme was added up to the reaction. The LR clonase reaction was incubated at 
250C for an hour. Then, 1 Itl of Proteinase K was added and the reaction was 
incubated at 370C for 10 mm. Finally, the mixture of reaction was transformed into 
the DH5ct competent cells. The transformation mixture was spread onto LB agar 
plates containing 50 Itg/ml of kanamycin. 
Transformants appearing on the plate were screened by direct colony PCR. 
Positive transformants were used to inoculate a 10 ml culture of LB broth, followed 
by growth of the culture overnight at 37'C, The plasmid was extracted from the 
overnight culture and transformed into the expression host BL21 Al cells. The 
plasmids were also sent for sequencing. Several transformants on the plate were 
picked and a pilot test expression (as outlined in Chapter 2) was carried out. 
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In order to clone the genes of interest into the pET 28a (Novagen) and pQE30 
(Qiagen) vectors, a different approach compared to that for the Gateway system was 
taken. Digestion of the TOPO vector was used during the cloning procedures for 
Pet28a and pQE30. The TOPO plasmids that contain the genes and the vectors were 
digested using the same restriction sites used to clone the genes. The vector was 
treated with Antartic phosphatase (NEB) to prevent self-ligation. Both the digested 
vector and the TOPO plasmid were run on DNA gels. Bands corresponding to the 
digested vectors and the gene fragments were excised and recovered using a gel 
extraction kit (Qiagen). The purified vector and the gene fragments were ligated 
using a Rapid DNA ligation kit (Roche), the ligation mixture was transformed into 
DH5a competent cells. The transformation mixture was spread on LB agar 
containing antibiotics as appropriate to the vector used. 
Direct colony PCR was used to screen for positive transformants. The colony 
that gave positive results from the PCR screen was grown overnight in 10 ml LB 
broth containing the appropriate antibiotic. The plasmid was extracted as before. The 
plasmid was then transformed into appropriate competent cells for large scale protein 
expression. Various competent cells were used to in attempts to maximise protein 
expression. The plasmid was also sent to School of Biological Sciences (Edinburgh 
University) Sequencing Service (SBSSS) for DNA sequencing. 
3.2.2. Purification of C-terminal human Hsp90 a and C. elegans 
Hsp9O 
In order to purify the proteins, the bacterial cells containing the recombinant 
plasmid were grown up in a large volume of LB and prepared for purification as 
described in Chapter 2. The lysate was filtered with 0.45 ItM syringe filter. 
3.2.2.1 .Ni-NTAITalon affinity column 
The column was equilibrated with Buffer A (50 mM NaHPO4, 300 mM Tris, 
5 mM Irnidazole, pH 8.0). After a stable baseline was observed, the filtered lysate 
was loaded and the column washed with Buffer A until the absorbance at 280 nm 
returned to baseline. The column was then washed with 50 mM imidazole to remove 
contaminating proteins. After the baseline was reached, a gradient of buffer B (50 
mlvi NaHPO4, 300 mM Tris, 250 mM imidazole, pH 8.0) was applied to the column 
(from 50 mM to 250 mM Imidazole over 5 column volumes). 5 ml fractions were 
collected over the gradient. The fractions were analysed on 12% SDS 
polyacrylamide gel to confirm a protein of the correct size had been purified. 
3.2.2.2. Gel filtration 
Gel filtration was used as the second purification step using an S200 
(Amersham) column. The column was equilibrated with 1 column volume of buffer 
(50mM Tris, 100 mM NaCl, pH 7.7 1 mM DTT). The sample (1 ml after 
concentration), was loaded onto the column followed by elution using one column 
volume of buffer (50mM Tris, 100 mM NaCl, pH 7.7 1 mM DTT). 1 ml fractions 
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were collected throughout the experiment. The fractions were run on SDS 
polyacrylamide gels. The fractions corresponding to the peak of the protein of 
interest were pooled. 
3.2.3. Native purification of the N-terminal Hsp90 of C. elegans 
CeHsp90-6 was purified using ion exchange and gel filtration. The first step 
of the purification utilises anion exchange chromatography. A 10 ml column of Q 
Sepharose resin was prepared and equilibrated over 3 column volumes with buffer A 
(50 mM Tris, pH 8.0). The protein lysate was loaded onto the column followed by 
washing with buffer A until the baseline was reached. Elution of the protein was 
achieved by increasing the concentration of NaCl from 0 to 500 mM over 10 column 
volumes. The fractions collected (10 ml) were run on 12% SDS polyacrylamide gels 
(Figure 3.4). The fractions containing the protein were pooled and concentrated to 1 
ml using a 10, 000 Da Vivaspin concentrator. 
The second step of purification utilised Sephacryl 200(S200) gel filtration 
column. The gel filtration column was run on AKTA FPLC(Amersham) as described 
in chapter 2, section 2.3.3. Buffer A contained 50 mM Tris, pH 7.5 and 100 mM 
NaCl and was used for the gel filtration experiments. 1 ml fractions were collected 
and checked by SDS PAGE as before running on the Mono-Q anion exchange 
column. 
Mono-Q column was equilibrated for three column volumes with buffer A 
(50 mM Hepes, pH 7.0). The protein was filtered with 0.45 IM syringe filter and 
loaded onto the column. The column was washed with buffer A after loading until 
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the baseline was reached. Elution was started by increasing the NaCl concentration in 
buffer B (Buffer A + 0.5 M NaCl) from 0 to 0.5 M. lOmi fractions were collected 
and analysed by SDS-Page. 
3.2.4. Denatured purification and refolding of the N-terminal Hsp90 
of C. elegans 
CeHsp90-6 was also purified under denaturing condition. In this method, the 
pellet was lysed in the lysis buffer containing 100 mM NaH2PO4, 10 mM Tris, 6M 
GuHC1 pH 8.0. The pellets were stirred gently at 40C for 30 mm. The lysate was then 
centrifuged at 22000 rpm for 1 hour. The supernatant was taken and filtered with 
0.45 iM syringe filter. The lysate was purified by using Ni-NTA column. The 
column was attached to AKTA Prime (Amersham). The column was first 
equilibrated with 3 column volumes of buffer 1 (100 mM NaH2PO4, 100 mM Tris, 
8M urea); pH 8.0. The protein was loaded into the column at 1 ml min-'. The column 
was washed with buffer 1; pH 8.0 until the stable baseline was reached. The column 
was washed with three column volumes of buffer A; pH 6.3 at lml min 1 to remove 
unspecific bound proteins. The protein was eluted then by using 10 column volumes 
buffer 1; pH 5.9. 10 ml fractions were collected at this elution stage. The fractions 
were run on 12% SDS-PAGE to visualise the protein. 
In order to refold the protein two methods were tried. The rapid dilution 
method was carried out by injecting the protein slowly into cold stirred buffer 
(100mM Hepes, 100 mM NaCl, 100 mM, 3-(l-Pyridinio)-1-propanesulfonate; pH 
7.5) in the ratio of 1 protein volume to 10 volume of the refolding buffer. The protein 
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was then left in the cold stirred buffer for 2 hrs before centrifuged at 22000 rpm for 1 
hour. The supernatant was then dialysed overnight in buffer containing 100 mM Tris 
and 50 mM NaCl ; pH 7.5. The next day, the protein was concentrated to 1 ml and 
run on Superdex 200 gel filtration column. The second method to refold the protein 
was by carrying out the refolding step on the Ni-NTA column. In this method, the 
protein was loaded onto the column at 1 ml mind. The column was then washed by 
using buffer A as in native Ni-NTA purification (section 3.2.2.1) until stable baseline 
was reached. The column was then washed with three column volumes of 10% 
buffer B to remove the unspecific proteins. The column was loaded with the 
refolding buffer at 0.5 ml min-' for 20 column volumes. The protein was then eluted 
by running 100% of buffer B. 10 ml fractions were collected upon elution. The 
fractions were run on 12 % SDS gel and the fractions containing the protein were 
pooled and later on concentrated to 1 ml. The concentrated protein was then analysed 
by running on Superdex 200 gel filtration column. 
3.2.5. Protein verification and confirmation 
All the proteins were verified to be the correct proteins by Western blot with 
anti-Hsp90 antibodies. The Western blot was carried out as described in Chapter 2 
(section 2.2.8). 
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3.3. Results and discussion 
3.3.1. Polymerase chain reaction of genes encoding the N and C-
terminal domains of C. elegans Hsp9O 
All the DNA fragments needed for cloning were successfully amplified (Figure 3.2) 
from cDNA of C. elegans and showed roughly the correct fragment sizes based on the 
agarose gel. As mentioned before, Cl F, CH, OF and the N-terminal domain were around 
386, 545, 635 and 660 bp respectively. The sequences of the regions were as shown in figure 
3.1 
3.3.2. Cloning of the C. elegans genes into shuttle vectors 
All the genes were successfully cloned into the shuttle vectors. The colonies 
were amenable to blue/white screening as the shuttle vector contained LacZ genes at 
the cloning site. The LacZ genes were interrupted and hence not expressed if the 
DNA fragments were inserted between the genes. As a result of the interruption of 
the LacZ 
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1 	2 	 3 	4 
a) 
Figure 3.2. Agarose gel photos of the PCR products. a) PCR products of the DNA fragments that 
were used for cloning in the shuttle vectors. Lane 1: 1 kb DNA markers. Lane 2: Cl F; Lane 3: C217; 
and lane 3: OF. The products were all of the expected size. b) PCR products obtained from the direct 
colony PCR screening. The primers used for screening were combinations of M13 forward primer 
and the genes reverse primer. The inserts were slightly bigger as the PCR products contained extra 
sequences of the vector. Lane 1:1 kb DNA marker. Lanes 2-4: OF, C2F and CIF respectively. The 
inserts were confirmed by DNA sequencing. 
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expression, the cells were unable to utilize the X-gal on the LB plate; therefore the 
colonies appeared as white and not blue. The white colonies were picked and 
subjected to direct colony PCR screening (Figure 3.2).The positive transformants 
were grown up in lOmi LB broth containing the appropriate antibiotic. The next day, 
plasmid was extracted from the cells and sent for sequencing. Sequencing data 
confirmed the identity of the inserted fragment to be correct. 
3.3.3. Cloning, expression and purification of the N and C-terminal 
domains of C. elegans Hsp90 
DNA fragments encoding the C-terminal of C. elegans Hsp90 were cloned 
into three different vectors. However, the N-terminal genes were only cloned into the 
pET28a vector. The plasmid containing the genes was transformed into various 
expression hosts. The cells containing the plasmid were subjected to test expressions 
using 1 mM of IPTG in 10 ml of LB broth containing appropriate antibiotics as a 
standard screen. Table 3.3 summarises the successful cloning and over-expression of 
the C. elegans Hsp90 constructs. 
All the C-terminal C. elegans Hsp90 DNA fragments were trialed in the three 
systems (pQE30, pET28a and Gateway), however only the successful experiments 
are listed in Table 3.3. All the trials using pQE30 as the cloning/expression vector 
were unsuccessful. All the DNA fragments were cloned into the Gateway system 
successfully. However, not all of the constructs could be over-expressed. For 
example, construct CIF (ceHsp90-525) may not have been expressed as this system 
has not been optimised for the expression of relatively small proteins. To try and 
overcome this problem, pDestl 5 with a GST tag of around 20 kDa was used to test if 
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Construct Protein Protein Vectors Tag Hosts Notes 
name name sequences 
N-terminal CeHsp90-6 6-219 of pET28a His BL21(D Protein was 
C.elegans E3) expressed, good 
C.elegans 
Hsp90 pLysS yield but tag not 
Hsp90 functional 
CeHsp90- 575-702 of pDestl7 His BL21 No protein 
C.elegans (DE3) expressed 
575 Hsp9O BL21 
CIF Al 
CeHsp90- 575-702 of pDestl5 GST BL21 Protein is 
C.elegans Al expressed but has 
575 Hsp90 non-cleavable tag 
CeHsp9O- 525-702 of C. pDestl7 His BL21 ( Protein is 
C2F elegans Hsp90 DE3) expressed but in 525 
low yield. Does 
not purify well 
with NiNTA 
resin 
CeHsp90- 492-702 of C. pDest His BL21 Protein expressed 
elegans Hsp90 17 Al in high yield but 
492 insoluble 
C3F 
CeHsp90- 492-702 of C. pET 28a His BL21 Protein is 
elegans Hsp90 (DE3) produced in good 
492 pLysS yield and is 
soluble 
Table 3.3. Summary of the cloning and expression of C-terminal C. elegans Hsp90. Only 
successful cloning experiments are listed in the table. The table also lists the various expression hosts 
used and also the quality of the protein yielded by these hosts. 
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Figure 3.3. SDS polyacrylamide gels and a Western blot of the C-terminal C. elegans Hsp90 
proteins, a) The expression of the CIF genes encoded for ceHsp90-575 in GST tag vector. Lane 1: 
Non-induced sample. Lane 2: Protein Markers. Lanes 3 and 4: ceHsp90-575. Arrows indicate the 
bands corresponding to the proteins. b) Western blot of CH genes encoded for ceHsp90-525 using 
anti-Hsp90 antibodies. Lane 1: Protein markers. Lane 2: ceHsp90-525 Lane 3: Non induced sample. 
Arrow indicates the band corresponds to the protein. c) The over-expression of OF genes encoding 
for ceHsp90-492 in pDestl7 vector. Lane 1: Proteins marker. Lane 2: Non induced sample. Lane 3-5: 
CeHsp90-492. Arrows indicate the bands correspond to the protein of interest. d) SDS polyacrylamide 
gel of the ceHsp90-525 fractions collected over the course of the Ni-NTA purification. Arrows 
indicates the band of interest. The protein is neither hugely over-expressed. 
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the protein can be expressed with a larger protein acting like a carrier protein. The 
GST construct did express some protein, however the protein did not readily purify 
on a GST affinity column (Figure 3.3). Even if the protein had purified well, the 
construct did not contain a cleavage site to remove the GST therefore it would have 
been of limited use in crystallisation trials. 
For C2F, the genes were successfully cloned into the pDestl7 vector. The 
protein could also be expressed in BL21 DE3 competent cells (Novagen), but the 
yield from these cells was very low. The protein was further characterised by 
Western blot using anti-Hsp90 antibodies (refer Chapter 2; Section 2.2.8) (Figure 
3.3). This protein also did not purify very well with the nickel column. The purity 
was only 40% (Figure 3.3). The attempt to clone the gene into pET28a was 
unsuccessful. 
The gene product designated OF encoding for the C-terminal region of C. 
elegans Hsp90 492-702 was successfully cloned into both pDestl7 and pET 28a 
vectors. The OF was first cloned into the pDestl7 vector. The protein was over 
expressed to a very high level in this vector (Figure 3.3). Unfortunately, the protein 
was totally insoluble. In order to make it soluble, several approaches were tried. The 
first approach was to use different temperatures after induction. The cells were 
grown at 370C until 0D600 -0.6 was reached. The cells were induced with 1 ml\4 
TIPTG at either 25/150C and grown for 6 hrs post induction at these temperatures. The 
protein was once again highly over-expressed but still mostly insoluble if it was 
grown at 250C. The protein yield was not very good when the cells were grown at 
150C and was still mostly in the insoluble fraction. The next approach tried was to 
add sorbitol and also betaine to the growth medium. The aggregation of protein in the 
bacterial cells can be reduced by adding polyols such as sorbitol and betaine. It has 
been shown that addition of these agents during the expression phase can help 
stabilise the protein as it is expressed [3]. By adding these chemicals to the growth 
media, it is hoped that the protein will not form any aggregates and will therefore be 
both more stable and soluble. Therefore, LB broth containing 2.5 mM glycine 
betaine and 1 M D-sorbitol were used to grow the bacterial cells at 25°C [1]. The 
protein was expressed really well in this media but was still insoluble (Figure 3.4). 
The genes encoding the proteins were cloned into the pET28a vector. The protein 
over-expressed well and was soluble (Figure 3.4), the reasons why the protein 
become soluble in this vector are unknown. In order to purify a large quantity of the 
the ceHsp90-492 protein, a 4L culture of LB broth containing 50jig/ml of 
kanamycin. The cells were harvested and lysed. The protein was purified using a 
Talon affinity column (refer Chapter 2; Section 2.3.2. The protein was approximately 
80% pure after this first affinity step and could be further purified (>95% pure) on a 
S200 column.(Figure 3.4). 
The N-terminal domain of ceHsp90-6 was successfully cloned into the 
pET28a vector. The genes can be expressed very well and the protein was soluble 
However, the problem arises as the protein can not bind to Ni-NTA affinity column 
through its N-terminal His-tag under native conditions. The protein can be purified 
very well under denatured purification condition (Figure 3.5). However, attempts to 
refold the protein in solution and on the column were not successful as the protein 
was over 20kDa. So far most of the protein that successfully refolded was having 
size less than 20kDa. Furthermore, the protein also consist several flexible loops 
which make it not easy to refold due to instability of the loops. 
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Figure 3.4. SDS polyacrylamide gel of cHsp90-492. Arrows show the band corresponded to 
ceHsp90-492. a) Different temperatures were used to try and increase the solubility of the protein. 
Lane 1: Protein markers. Lanes 2-4 and 8-10: Insoluble fraction' at 25°C and 15°C respectively. Lanes 
5-7 and 11-13: Soluble portions at 25( C respectively. The protein was not expressed very well at 
15°C for 6 hrs. b) and c) show the expression at 37°C of ceHsp90-492 in pDestl7(b) and pET28a (c). 
Lanes 2(b), 3 (b) and 4(c): Soluble portions of the lysate. Lanes 4(b), 5(b) and 5(c): Insoluble portions 
of the lysate. Lane 1(c): Non-induced sample. Lane 3(c): Induced sample. d) Fractions collected from 
S200 purification. Lane 1: Protein markers. Lanes 2-4: ceHsp90-492. 
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The probable reason for the non functional tag is that the His-tag was buried 
and therefore was not accessible to bind to the Ni 2+  Therefore, the protein was 
natively purified using a three step purification protocol. This involved two ion 
exchange columns and a gel filtration step between them. The first step of the 
purification used Q-sepharose anion exchange column (refer Chapter 2: Section 
2.3.4). The fractions containing the protein were pooled. At this step the protein was 
only 50% pure (Figure 3.5).The second step of the purification was by using S200 
gel filtration. At this time, the protein was only 70% pure (Figure 3.5). The fractions 
containing the "cleanest" protein were pooled and loaded onto the Mono-Q column 
as the final purification step. The fractions containing the protein were pooled and 
concentrated again. The purity at this stage was about 80% (Figure 3.5). There are 
still several bands present in the purified sample. No further purification steps were 
tried to purify the proteins, as the total proteins especially the protein of interest were 
lost throughout the purification and the three purification steps was already time 




tiuuon vouumo mi 







__. 25kda-j + 
	
25kda.1J 	_ 




Figure 3.5. Purification of ceHsp90-6 under native and denatured conditions. a) CeHsp90-6 was 
natively purified by three steps purification that utilised Q-sepharose resin, S200 gel filtration and 
mono-Q resin. The fractions after mono-Q still contained unwanted proteins. Arrows showed the 
protein of interest. b) The purification of ceHsp90-6 under denatured condition by using Ni-NTA 
column. The protein was very pure after the purification. However, the protein can not be refolded. c) 
Elution profile of the protein on Superdex 200 after refolding step. The protein was eluted at the void 
volume indicated that the protein formed aggregates and was not refolded. 
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3.3.4. Expression and Purification of the C-terminal domain of 
human Hsp90 
The plasmid encoding the C-terminal of human Hsp90 was transformed into 
appropriate competent cells. All the proteins involved in the expression and 
purification were listed in Table 3.4. Figure 3.7 shows the location of the C-terminal 
domains of human Hsp90 a purified in this chapter. The All the proteins were 
successfully expressed (Figure 3.6) by growing them in LB broth containing 50 
ig/ml of kanamycin. The cells were induced at OD600-0.6 and incubated for another 
4 hrs. 1 mM IPTG was used to induced the cells. The proteins were confirmed by 
Western blot with anti-His (Sigma) or anti Hsp90 (Stressgen). The proteins were 
showed to be the proteins of interest by using anti-Hsp90. However, hHsp90-a604 
was not recognised by the anti-His reagent. 
3-23 
	
123456789 	 1 2 3 4 5 6 
a) 	 b) 	 _ 
Aw 	 4:i 
25kDa- 
25kDa— IJIIIIU 
1 6kDa—g $ 
 







25kDa— 	 16kDa- 
16kDa 
Figure 3.6. Sds polyacrylamide gel and Western blot of the expression of the C-terminal 
domain of human Elsp90 a. Arrows show the protein bands mentioned in the legends at each of the 
panel. a) SDS gel showed the expression of hHsp90-a52 I and hHsp90-a604. Lane 1: Prestained broad 
range protein marker. Lanes 2- 5: hHsp9O-a52lwith size around 28kDa. Lanes 6-9: hHsp90-a604 
with the size around I 8kDa. b) SDS gel of the expression of hHsp90-a596and hHsp90-a63 1. Lane 1: 
Prestained broad range protein marker. Lanes 2 and 3: hHsp90-a596 with size around 24 kDa. Lanes 
4-6: hHsp90-(x63 Iwith the size around 12 kDa. c) Western blot with anti-His antibodies of hHsp90-
a52 1 and hHsp90-a604. Lane I: Prestained broad range protein marker. Lanes 2 and 3: hHsp90-a52 1. 
Lanes 4 and 5: hHsp90-(x604 but no bands correspond to the expected size were observed. d) Western 
blot of hl-lsp90-a63 1 and hHsp90-a596 with anti-His antibodies. Lane 1 Prestained broad range 
protein marker. Lane 2: hHsp90-ct63 1. Lanes 3 and 4: hHsp90-a596. 
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Protein names Sequences Vector Expression host 
hHsp90-a521 Residues 521-732 pET28a BL21 DE3 
hHsp90-ct596 	---JResidues 596-73 r 8a BL21 DE3 
hHsp90-a604 [Residues 604-732 pET28a BL21 DE3 
hHsp90-ct631 Residues 631-732 [FET28a BL21 DE3 
Table 3.4. Lists of the constructs of the C-terminal of human Hsp90 a. The lists showed the 
vector used to clone the genes and the expression cells used to express the proteins. The constructs 
were supplied by Thomas Ratacjzak. 
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human Hsp90 alpha 
521-732 
Precj. 	 c-. 
Pred: CCCCIInnCCCEEEECCCCCCCCCCm 
A? 	I EPIDEYCVQQLKBFE13KTLV3VTKEGLRLPEDEEKKKQ 




Fred: H HEiHI1HHHHHCCCEEEEEEECCCCCCCCCEEC 
EEKIQTKPHNLCKIMXDI LEKKVEICSTVVSNRLVTS PCC EV'T 
570 	580 	590 	600 
human Hsp90 	 human Hsp9O 
alpha 604-732 alpha 631-732 
Pred 
Preci CCCCC iliHCCCCCCCCCCCCCCCEEEECCCH 
AA: 5TYGwANMRITKAQAI.RDNSTMYMAAxKHL. INPDHS 
63.0 	620 	630 	640 
Pred HJ1ImHCCCCBHInIEIrnIEThUmEHHCCCcHm1H 
A2 	II ETLRQKAE.DKDXVKDLVILL.YETALLSSF2LHDP 
650 	660 	670 	680 
Pred: 
Preci }HHBHHHHCCCCCCCCCCCCCCCCCCCCCCCCCC 
QTHANR][YRHI KI.c•LGI DBDDPTADflTSAEMPP]1,E 




Figure 3.7. Amino acid sequences of human Hsp90 a show the location of protein constructs. 
Arrows mark the beginning of each of the C-terminal Hsp90 human a constructs overexpressed and 
purified in this chapter. 
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The cells were grown in 4L of LB broth containing 50zg/ml kanamycin. The 
cells were harvested and lysed by adding 1 mg/ml of lysozyme and sonication. The 
proteins were purified using an affinity column. hHsp90-a521, hHsp90-a596and 
hHsp90- a631were purified using a column of Ni-NTA. HHsp90-a604 did not bind 
to the nickel affinity column. No further investigations were carried out to determine 
the reason the protein did not bind to the nickel column. Even though the other 
proteins bound to the nickel affinity column, they were not really pure following this 
step (Figure 3.6). The purification was optimized by adding 20 mM 3-
mercaptoethanol and 1mM of PMSF. Only hRsp90-a521 gave 80% pure proteins 
using these conditions (Figure 3.8). The other two protein constructs were still not 
very pure. In order to overcome the problem, Talon resin (BD Biosciences) was used 
to try and purify both hHsp90-a596 and hHsp90-a63 1. The resin was working very 
well to purify hHsp90-ct63 1 but not hHsp90-a596. Mono-Q resin (Pharmacia) which 
is an anion-exchange resin was used as the second step in the purification of hT4sp90-
a596, however this was not very successful. For hHsp90-a521 and hHsp90-u631, an 
S200 gel filtration column was used as the second purification step to get rid off the 
other contaminating proteins and to get the proteins as homogenous as possible prior 
to crystallisation and characterisation experiments. 
In the purification steps with the nickel affinity column, a reducing agent was 
added to the buffer to get purer proteins. The reducing agent was needed to break any 
non-specific interactions between the proteins of interest as well as any potential 
disulphide bonds formed between the protein of interest and any contaminating 








protein quickly. The addition of the reducing agent was successful in helping in the 
purification of hHsp90-(x52 1. However, h}Isp90-a631 needs to be purified by using 
Figure 3.8. SDS polyacrylamide gel of the C-terminal domain of human Hsp90 a after 
purification, a) After purification with Ni-NTA affinity column following basic purification 
protocols. Most of the proteins still are not very pure. b) The same proteins after optimization and gel 
filtration column. 11) Final purity of hHsp90-a521 after optimization of Ni-NTA column and S200 gel 
filtration. 2) Final purity of hHsp90-a63 I after Talon and S200 gel filtration column. 3) Final purity of 
hHsp90-a596 after Talon and Mono-Q. The proteins were still not pure as the other two proteins. 
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Talon affinity column (BD sciences). Talon resin is a cobalt charged resin with a 
higher affinity for hexa-histidine tagged proteins than that seen with the nickel resin 
[4]. Therefore it binds more specifically to hHsp90-a63 1 rather than other protein in 
the preparation that contains one or two nearby histidine residues. By using these 
optimisation steps, two of the proteins (hHsp90-a521 and h}{sp90-a631) were 80% 
pure. The use of a gel filtration column after this step was to get the proteins to a 
purity of 90% and to make sure the protein were homogenous (Figure 3.8). 
3.4. Conclusion 
A number of C-terminal human Hsp90 a constructs have been successfully 
over-expressed. However, the purification of these proteins demands multiple 
conditions and techniques. Based on the purity, the proteins were chosen and further 
used for crystallization trials and other biophysical assays. The ability of these pure 
proteins provided the basis for analysing the results obtained later in a systematic 
way. The cloning, expression and purification of the C. elegans proteins gave a 
protein construct to explore and reveal more about the unique properties of the C-
terminal Hsp90. In summary, the proteins that were purified well are liHsp90-a521, 
hHsp90- a631 and ceHsp90-492. Most of the work described in this thesis was 
focused on these three proteins. 
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Chapter 4: Characterisation of the C-terminal domain of human 
Hsp90 alpha 
4.1. Introduction 
In this chapter, the results of the biochemical and biophysical characterization of 
the C-terminal domain of human I-Isp90 a are reported. Several constructs of different 
lengths were made and expressed in E. coli, the purification was discussed in Chapter 3. 
Only two of the constructs gave very pure protein, hHsp90-a52 I and hHsp90-a63 1. 
Both of the proteins contain the MEEVD sequence that is essential for binding to the 
TPR client proteins. The proteins were characterized using several different techniques 
such as fluorescence, gel filtration, and surface plasmon resonance. The characterization 
was carried out to study the proteins alone as well as their interactions with other 
compounds/partner proteins. 
As mentioned earlier, the residues at the C-terminal end of the protein (MEEVD) 
are important in interactions with partner proteins (Figure 4.1). This sequence motif is 
able to bind to the TPR client proteins such as Hop, PP5 [33]and Cyp40 [5]. Interaction 
of the C-terminal domain of human Hsp90 3 with Cyp40 was shown by conventional 
pull-down assays between the two proteins [33], site directed mutagenesis to the Cyp40 
TPR domain allowed identification of residues key to the interaction to be determined. 
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In this study, a number of constructs of the C-terminal domain of human Hsp90 a (an 
isoform of human Hsp90 3) were provided by Thomas Ratacjzak, Department of 
Pharmacology, University of Western Australia. The proteins were used to further 
characterize the interaction with Cyp40 with the techniques available in house. 
Hsp90 has also been shown to bind to drugs such as geldanamycin (GA) [3, 16, 
18, 24, 26]. GA was shown to bind to the ATP binding site on the N-terminus of Hsp90. 
The binding inhibits the hydrolyzation of ATP which is important for in vivo function of 
Hsp90 [21, 22] and without Hsp90 function, the cell will be dead. GA is a very potent 
inhibitor; however it is unsuitable for clinical use due to its marked hepatotoxicity and 
narrow therapeutic window [28].The C-terminal domain of Hsp90 contains the binding 
site for novobiocin [15, 35, 36]. Interestingly, the same site also recognizes ATP. 
Therefore, it is of interest to study the binding of the C-terminus of human Hsp90 alpha 
to novobiocin and ATP as they can provide more understanding towards Hsp90 function 
as well as structure. 
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N-terminal domain I 	Charged Middle region C4enmnaJ domain MEEVD 
ATP/GA binding sites linker 
Full length human 
1-Isp90 alpha 
1 	 732 




521 	 732 
6-His 	I C- 	MEEVD 	 human Hsp90 alpha 
terminal 
domain 	 631-732 
631 	 732 
Figure 4.1. A cartoon representation of the C-terminal domains of the human l-Isp90 a constructs 
used in this study. Full length human Hsp90 a is also shown for comparison. Both of the 
constructs contained a histidine tag at the N-terminus. The MEEVD motif was also present in all 
of the constructs. The MEEVD motif is essential for the protein to bind to the TPR client 
proteins. 
4.2. Materials and methods 
4.2.1. Determination of the oligomeric forms of human Hsp9O a C-terminal 
domain 
4.2.1.1. Gel filtration 
The experiment was carried out using a Superdex S200 column. First, the 
column was calibrated using an Amersham calibration kit. The experimental protocol 
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was from the kit manual and was described in chapter 2. In order to determine the 
protein molecular mass, 100 M (250 jzL) of the sample was load onto the Superdex 200 
column attached to an AKTA FPLC (Amersham Bioscience). The Ve was noted and the 
Kay was calculated. The molecular size was estimated from calibration curve. 
4.2.1.2. Mass spectroscopy 
The experiment was carried out by Andrew Cronshaw as part of the Edinburgh 
Protein Interaction Centre (EPIC). Basically, the protein was run on a polyacrylamide 
gel. The gel was stained by using Gelcode (Pierce) for an hour. The band of interest was 
cut out from the gel and the sample was sent to EPIC. The band was subjected to trypsin 
digest. Basically, the slice gel was incubated in solution containing 300 Al of Buffer 1 
(200 mM NH4HCO3 and 50% acetonitrile) at RT for 30 min to remove SDS. The step 
was repeated twice. Then, the gel sliced was incubated with the Buffer 1 but with the 
addition of 20 mM DTT. The incubation was carried at 320C for 1 hour. The mixture 
was then washed three times with Buffer 1. The mixture was incubated with alkylate 
cysteines made up with iodoacetamide and Buffer 1 at RT in dark for 20 mm. After the 
incubation the mixture was washed twice with 500 il of buffer 1. The band was cut to 
small pieces and spun down at 13000 rpm for 2 mm. The gel slices were then covered 
with 200 jl of 50% acetonitrile in a microcentrifuge tube for 2 mm. The supernatant was 
decanted and the gel was left to dry. Trypsin stock was prepared in 50 mM NH4HCO3 at 
40C. The gel pieces were swelled by adding the trypsin stock. The mixture was kept at 
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40C until the gel pieces were swollen and incubated at 320C for 16-24hrs. The sample 
was then analysed using a Maldi —Tof spectrometer. 
4.2.2. Determination of the dimerisation constant of protein 
The dimerisation constant of the proteins were determined by gel filtration. A 
series of protein concentrations were prepared in buffer containing 50 mM Tris, 100 mM 
NaCl, pH 7.7. The proteins were run through a Superdex 200 column as above. The 
elution volumes of the peaks were recorded and dissociation curves based on the elution 
volume plotted. The analysis of the curve was based on the assumption that at any given 
time the monomeric and dimeric species were in equilibrium [27]. Data were fitted by 
using Kaleidagraph based on the equation 1 
EVEVmono_(EVmono EVdimer)x([Proteifl]/([Protein]+I(d(app))) (eq. 1) 
where EV represent the elution time, EVmono is the elution volume of the monomeric 
species, and EVdimer is the elution volume of the dimeric species. The dissociation 
constant (Kcj) obtained is an apparent Kd since the proteins were diluted several fold 
during the course of the experiment. Therefore, the real K4jjmer was obtained by dividing 
the Kd(app) by the dilution factor. 
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4.2.3. Study of the interaction of the C-terminal domain of human 
Hsp90 a with Cyclophilin 40 (Cyp40) 
4.2.3.1. Gel filtration 
This method was used to investigate the binding interaction between Hsp90 C-
terminal domains and a TPR containing protein Cyp40. Firstly the proteins were 
analysed individually using an Superdex 200 (Amersham) column attached to an AKTA 
FPLC (Amersham Biosciences) run as described in Section 2.3.3 in Chapter 2. This 
allowed the elution volume of the individual components of the complex to be 
determined. The protein concentrations used were 100 jtM and 50 jtM for Hsp90 and 
Cyp40 respectively. Secondly, the Hsp90 C-terminal domain proteins and Cyp40 were 
mixed together in the same concentration as their individual protein gel filtration (50iiM 
Hsp90: 100 /LM Cyp40) assuming that the stoichiometry of the interactions will be one 
dimer of Hsp90 that binds to two monomeric Cyp40 molecule. The mixture in a total 
volume of 250 jL was incubated at 10°C for 30 min and run through the Superdex 200 
gel filtration column. 0.5 ml fractions were collected throughout the run. A difference in 
the elution volume of the peaks between that of the proteins alone and the complex 
mixture indicates that a complex had indeed formed. In order to visualise the complexes 
formed, 30 jzl samples of the fractions collected over the peaks from all the experiments 
were analysed by SDS-PAGE. 
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4.2.3.2. Intrinsic Tryptophan fluorescence 
4.2.3.2.1. Human Hsp90 a 521-732 (hHsp90-a521) 
A number of reaction mixtures with a final volume of 200 jil were set up in 1.5 
ml eppendorf tubes as described in Chapter 2; section 2.4.1. Each reaction consisted of a 
fixed concentration (1 M) of hHsp90-ct52 1. However, the final concentration of Cyp40 
was varied in each tube and ranged from 1 to 50 /LM. Measurements were also carried 
out for the same concentrations of Cyp40 alone. The reaction was incubated at 20 °C for 
30 minutes before the measurement was taken using a Flouromax-3 (Jobin Yvon, 
Hariba). The Trp fluorescence measurement was obtained by excitation at 295 nm and 
emission at 350 nm, data was aquired using time base data acquisition over 60 seconds. 
The slits were set at 2.5 mm for both excitation and emission. The emission values for 
each of the concentrations were averaged. 
4.2.3.2.2. Human Hsp90 a631- 73(hHsp9O-a631) 
Several reaction mixtures of 200 j.l were set up as before. However, in this series 
of experiments the concentration of Cyp40 was kept constant while that of hHsp90-ci63 1 
was varied. The rationale behind this approach was to use hHsp90-ct63 1 (which has no 
Trp residues) to monitor changes in the environment of the Cyp 40 Trp residues by 
changing the concentration of the Hsp90. The concentration of hHsp90-a63 1 used in this 
experiment ranged from 1 to 150 jiM. The reaction was incubated at 20 °C for 30 
minutes before measurements were taken as above. The same concentrations of the 
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proteins alone were also measured for Tip fluorescence using excitation at 295 nm, 
emission at 350 nm and time base acquisition of data over 60 seconds. The slits were 2.0 
mm for excitation and 5.0 mm for emission. The emission values for each concentration 
were averaged. 
For both of the proteins, F0b is the observed emission at 350 nm minus both the 
buffer signal and the emission of the individual proteins at the same concentrations. The 
Fobs was corrected against the inner filter effect using equation 2 
F01-,. = Fobs! ea( with a= -2.303 x E x L x c) - equation 2 
where Fcorr is the corrected emission in the experiment. c is the extinction coefficient in 
M' cm'. L is the path length of the cuvette used for measurement. c is the molarity 
concentration of the various proteins used. Fcoj-r  was then added to the emission values 
of the proteins alone. The values obtained were plotted against the different 
concentrations of the proteins used in the experiment, the data was fitted to equation 4 
using Kaleidagraph 3.5 (Synergy). 
The corrected fluorescence signal , F-r can be defined as 
Fcorr = Ff+ (Ff - Fb )- Equation 3 
where Ff is the fluorescence of free protein and Fb is the fluorescence of the protein A 
protein B complex at infinite concentration of protein B. At any total concentration of 
protein A [A], F depends on the total protein B [B] concentration and on the equilibrium 
constant for the complex (IKd)  according to equation 4. 
F 0 =Ff +(Fb—Ff ) x  {(Kd +[A]+[B])-i((Kd+[A]+[B])2 
- (4 x  [A] x  [B]))/2 x [B]} - equation 4 
4.2.3.3. Surface Plasmon Resonance (SPR) 
SPR measurements were performed on a Biacore 3000 instrument (Biacore 
Instruments Limited). hHsp90-a521 was immobilized on the NTA sensor chip as 
described in Chapter 2: section 2.4.2. The sensor was loaded with Ni2 . His-tagged 
hHsp90-a521 at concentration of 200 nM in running buffer (10 mM HEPES pH 7.4; 150 
mM NaCl; 0.005% surfactant P20) was passed over the sensor surface for 60s at a flow 
rate of 5 AL min-1 to get a saturation of response units of approximately 550 RU. The 
injection of the protein was stopped followed by a wash with running buffer for 100 
seconds. Various concentrations of Cyp40 (2 to 300 M) were passed over the 
immobilized protein at a flow rate of 30 Al min t for 180s. The complex dissociated 
when running buffer was passed over the surface for 300s at 30 Al min- . The surface 
was regenerated with 5 mM EDTA in running buffer between applications of different 
concentrations of Cyp40. The NTA-chip recharged with Nil, and the cycle repeated as 
before. The data was analyzed with the software supplied by Biacore. 
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4.2.4. Study of the interaction of the C-terminal domain of human 
Hsp90 a with small ligands 
This part of the study aimed to investigate potential interactions of the C-
terminal domain of human Hsp90 a with both ATP and novobiocin. Interaction of the 
protein with the ligands was interesting in a number of ways, including as a tool to 
further characterise the protein biochemically and biophysically and also to help with 
crystallisation trials as the protein could be more stable with a ligand bound. The 
techniques used to study the interactions were Hummel-Dreyer gel filtration, Isothermal 
Titration Calorimetry (ITC), Tryptophan fluorescence and ATPase assay. 
4.2.4.1. Hummel-Dreyer gel filtration 
The experiment follows the method established by Hummel and Dreyer in the 
1960's [4]. This experiment utilizes the principles of a gel filtration experiment to study 
interactions between the C-terminal human Hsp90 a and ATP by monitoring the 
peak/trough that is formed by ATP. The appropriate gel filtration column was 
equilibrated with buffer containing ATP. A stable and straight baseline should be 
observed. Then, a sample containing fixed concentration of protein and the same 
concentration of ATP was run on the column. A trough should be observed if there is a 
complex as some of the ATP in the sample involved in the complex formation and the 
concentration of free ATP eluted was less than the equilibrated buffer. The area under 
the trough was calculated. The same concentration of ATP was used to form the 
complex every time because the concentration of the protein is constant. Therefore, as 
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the ATP concentration was increased in the sample, more free ATP was available and 
eluted at the same elution volume. A peak will then form if the concentration of free 
ATP in the sample is more than the concentration in the equilibrated buffer. The areas 
under the peaks were calculated as well. The graph of areas under the peak/trough were 
plotted against ATP concentrations in the samples. When there is no peak or trough 
observed, the free ATP concentration is the same concentration as that of ATP in the 
buffer. Therefore, the concentration of the complex and also free protein can be 
calculated. 
The experiment used a Superdex 75 gel filtration column, equilibrated with 
running buffer (50 mM Tris; pH 7.5, 100 mM NaCl) containing 75 tM ATP. A sample 
containing 75 iiM ATP (no protein) was loaded onto the column and run with the same 
running buffer. A straight and stable baseline was observed during the run. A sample 
containing 80 jtM protein with 75 M ATP was run onto the column. Samples 
containing a constant 80 AM of protein mixed with increasing concentrations of ATP 
(75 to 200 M) were applied to the column. The areas under the trough/peak were 
calculated. A graph of the areas under the troughs/peaks against the ATP concentration 
was plotted. The concentration of ATP when the area is zero was determined. The Kd 
was calculated. The graph of bound ATP over free ATP against bound ATP was also 
plotted. From this graph both the Kd and the stoichiometry of the interaction were 
obtained and explained further in the results section. 
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4.2.4.2. Trp fluorescence 
The binding of increasing concentration of ATP (0-1 200MM) or Novobiocin (0-
50 tM) to C-terminal domain of human Hsp90 a (IM) or N-acetyl tryptophan was 
monitored by fluorescence spectroscopy, with excitation at 295 nm and emission at 355 
nm in a 0.5 cm path length cuvette. The final titration volume was only 1% of the initial 
volume. The fluorescence values observed were corrected against dilution factors and 
inner filter effects using the equation below. 
-2.3O3xExLxc 
F01- = dilution factor x Fobs / e 	 —equation 5 
where Fob,  is the observed fluorescence. c is the extinction coefficient in M'cm'. L is 
the path length of the cuvette used for measurement. c is the variable concentrations of 
the proteins in moles U'. The corrected fluorescence was fitted with the equation below 
and plotted using Kaleidagraph. 
F = Ff +[( Fb— Ff ) x { (K + [A] + [ATP] )- I((K + [A] + [ATP])2 -(4 
[A] x  [ATP]))/2 x  [A]}]—equation 6a 
where Ff is the fluorescence of free un-complexed protein and Fb is the fluorescence of 
compound A:ATP complex at infinite concentration of ATP. At any total concentration 
of compound A [A] concentration, F depends on the total ATP [ATP] concentrations 
and the equilibrium constant for the complex (Kd). 
For the novobiocin experiment, a "two binding sites equation" (equation 6b) was 
used instead of equation 6a above. 
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Fobs  = F -[((F)/2) X  ({ (K11 + [AJ2] + [novobiocin] )- i((K 1 + [A/2] + 
[novobiocin])2 -(4 x  [Al2] x [novobiocin]))/2 x [Al2]})+ {(Fb x [novobiocin])! 
Kj 0 + [novobiocin])}]—equation 6b 
where Ff is the fluorescence of free un-complexed protein and Fc is the fluorescence of 
protein A:novobiocin complex at certain concentration of novobiocin on the first binding 
site. Fb is the fluorescence of compound A:novobiocin complex at infinite concentration 
of novobiocin on the second binding site. At any total concentration of compound A [A] 
concentration, F0b5  depends on the total novobiocin[novobiocin] concentrations and the 
equilibrium constants of both the binding sites (Kdl5t and K1 2nd)  for the complex. 
4.2.4.3. Malachite green ATPase assays 
The assays were performed in Eppendorf tubes incubated at 370C in a 
temperature controlled heat block. 5 /LM of either the C-terminal domain of human 
Hsp90 a, human CypA or 1 nM Phosphofructokinase (PFK) was mixed with a series of 
ATP concentrations ( 0.15, 0.25, 0.5, 0.6, 0.7, 1, 1.25, 1.5, 2 mM) for 90 minutes for C-
terminal human Hsp90 a and CypA, 3 minutes for PFK). The reactions were stopped by 
adding 320 ItL of Malachite green solution at RT (Upstate, UK) and mixing well. 50 JtL 
of a 34% (w/v) of sodium citrate was added to the mixture, which was left for 15 min at 
RT. All samples were transferred to a 1 ml cuvette and the absorbance at 620 nm 
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measured using a spectrophotometer. A standard curve of the absorbance of phosphate 
alone was also made following the protocol supplied by the manufacturer as described in 
Chapter 2 section 2.4.4. Based on the standard phosphate curve, the amount of 
phosphate release was obtained and used to calculate the rates of ATP hydrolysis. 
4.2.4.4. ATPase inhibition assays 
C-terminal human Hsp90 a or PFK were mixed with a series of concentrations of 
novobiocin and incubated at 370C for 30 mm. ATP was added to the mixture and 
incubated for an additional 60 minutes or 3 minutes for PFK. The final concentrations of 
protein and ATP are 5 jM and 1 mM respectively. The final concentrations of 
novobiocin used ranged from 1-100 AM. The reactions were stopped by adding 320 AL 
of Malachite green solution (Upstate, UK) and mixing well at RT. 50 jL of 34% (wlv) 
of sodium citrate was added to the mixture left for 15 min at RT. The absorbances of the 
samples at 620 nm were then measured. The experiment was repeated with PFK 
although different protein and ATP concentrations were used (1 nM and 5 mM 
respectively). The final concentrations of novobiocin were from 1- 300 ItM. 
4.2.4.5. Isothermal Titration Calorimetry (ITC) 
ITC was carried out to study the interaction of novobiocin an hHsp90-a521. 
Preliminary trials with ITC show that novobiocin precipitated in the ITC syringe at high 
concentrations. Therefore, as a solution to this problem, novobiocin was placed in the 
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sample cell. 100 ItM novobiocin dissolved in 100 mM Tris, 50 mM NaCl pH 7.5 was 
degassed and 1.4m1 of the solution was put inside the sample cell. The reference cell was 
filled up with 1.4 ml of buffer only. The ITC syringe was filled with 280 Itl of hHsp90-
a521 (460 AM). The jacket temperature of both cells was set up to 200C. The syringe 
was placed inside the sample cells. The sample was stirred at 300 rpm. The injection 
profile (injecting protein into the ligand solution in the sample cell) was programmed as 
follows:- The initial injection volume was 5 ItI, with 3 minutes between injections. 
Subsequent injection volumes were either held at 5l or increased to 10 al, dependent 
upon the signal of the heat change between injections. The number of injections per 
experiment was either 50 or 25 and was dependent upon the volume used per injection 
as the total volume that can be taken up by the syringe is 280 jzl. The reaction was left to 
run and later on the data was analysed by using the Origin software supplied with the 
machine. 
4.3. Results 
4.3.1. Native forms of the C-terminal domains of human Hsp90 a 
The native form of the C-terminal domain was studied by using gel filtration. 
The study aimed to obtain the approximate size of the C-terminal proteins and the 
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Standard proteins Size(kDa) Elution 	volume 
(Ve)(ml) 
Kay 
Ferritin 440 10.51 0.16 
Catalase 232 12.1 0.26 

















Table 4.1. Proteins standards used to calibrate the Superdex 200 gel filtration column. The elution 
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Figure 4.2. Calibration curve of Superdex 200 plotted based on the Kay of the standard proteins. 
The data was obtained by running standard proteins through the column according to Amersham manual. 
The elution volume of each protein was noted and the Kay calculated. The graph can be used to estimate 
the molecular weight of unknown proteins applied to the column. 
oligomeric state of the proteins in solution. The aim can only be achieved by monitoring 
the size and profile of the protein eluted from the gel filtration column. In order to get 
the information needed, the column has to be calibrated with known or standard 
proteins. The column used was Superdex 200 (Amersham). Based on the protocol from 
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the Amersham High and Low MWT gel filtration Calibration kits, the protein standards 
were loaded in two batches. The first run consisted of ribonuclease A, ovalbumin, 
aldolase and ferritin. The second run of the column consisted of chymotrypsinogen A, 
albumin and catalase. The elution volume of each of the proteins was noted, from the 
elution volume the Kay of each of the reference proteins was calculated (Table 4.1).A 
graph of the log of size against the Kay value was plotted (Figure 4.2). The graph was 
used to estimate the size of unknown individual proteins and also that of the complexes 
formed. 
All the C-terminal domain proteins of human Hsp90 a were analysed by gel 
filtration on the S200 column. The Ye from each run was obtained and the Kay 
calculated (Table 4.2). Based upon the gel filtration results, hHsp9O-a52lcontains two 
distinct peaks, A and B of approximately 148 and 296 kDa respectively (Figure 4.3). 
Peak A corresponding to 148 kDa, was the dominant peak, comprising approximately 90 
% of the sample which correspond to the dimer form of hHsp90-a521. Peak B which 
corresponds to 296 kDa, was shown to be reduced upon time and diminish in size over 
three days, suggesting some sort of aggregation which degraded to form dimer or small 
portion of the proteins. 
hHsp90-a63 1 produced a single peak when run on the Superdex 200 gel filtration 
column. The molecular mass of the protein as obtained from its elution volume was 
estimated at 135 kDa. However, the elution volume was dependent upon the protein 
concentration applied to the column (Figure 4.3). The apparent size of the protein 
reduced as the protein concentration decreased. It is believed that this illustrates the 
protein changing from a dimeric form present at higher concentrations to a monomer at 
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low concentrations. This will be explained in greater detail later in this chapter in section 
4.3.2. 
Proteins Column Ve (ml) Kay Molecular 
weight (kDa) 
hHsp90-a521 Superdex 200 A:12.7; A :0.31; A :148; 
B: 11.4 B: 0.21 B: 296 
hHsp90-a631 Superdex 200 13 0.31 135 
Table 4.2. Lists of the information obtained by running 100 AM of each proteins through Superdex 
200 
As described above, using the elution volumes obtained from the gel filtration 
experiments, the sizes of the proteins were estimated and the oligomeric state of the 
native proteins predicted. However, the estimated sizes of the entire human Hsp90 C-
terminal domains were very big compared to what was expected from the sequence. The 
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Figure 4.3. Chromatogram of the proteins eluted from Superdex 200 (Amersham Biosciences) gel 
filtration column. a) hHsp90-a521 as eluted from the column consisted of two peaks (A, B), shown in 
blue. (b)HHsp90-a63 I eluted from the column. However the elution volume of peak C and D was 
dependent upon protein concentration. For example, the elution volume for C which is 100 1iM protein 




sizes of the proteins were bigger than those predicted from polyacrylamide gel 
electrophoresis results. The proteins were expected to be either monomer or dimer in 
their native forms, therefore the expected sizes were about 28 or 56 kDa for either 
monomer or dimer for hHsp90-a521. HHsp90-ct631 was expected to be either 
monomeric or dimeric with an estimated size of 12 or 24 kDa respectively. However, the 
apparent molecular weights of the proteins are significantly larger than expected. The 
different sizes as obtained are likely to be due to the shape of the protein. As mentioned 
before, gel filtration is very useful in determining the molecular size of spherical 
symmetrical proteins [27], however it is likely that the Hsp90 proteins are not present in 
a compact, globular spherical form amenable to easy interpretation using gel filtration 
data. 
4.32. Dimerisation constants of the C-terminal human Hsp90 a 
A series of concentrations ofhHsp9O-ct631 (3, 5, 25, 50, 100, 150, 250 [LM) were 
run on Superdex 200 column. The elution volumes of the peak for each concentration 
were noted (Figure 4.4) and fitted using the equation 1. From the fit of the curve, the 
K.iimer obtained was an apparent dimerisation (K jimer(app)) constant. In order to obtained 
the real Kciimer,  the Kdimer(app)  has to be divided by the dilution factor. The dilution factor 
was obtained by dividing the elution volume of the peak with the volume of sample 
loaded onto the column. All the proteins were diluted 16 fold during the experiments. 
Therefore, the real Kciimer  from the experiment is 4.98 ± 2.12 jLM. 
However, it was not possible to determine the Kiimer  of hHsp90-a52 1 because of 
technical limitations imposed by the available equipment. Protein concentrations lower 
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than I ltM were not detectable and the elution profiles seen at any concentration above 
that of IjiM showed no differences. 
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Figure 4.4. HHsp90-a631 dimer formation, a) Graph of the various concentrations of protein run on the 
Superdex200. The elution peaks shifted from A to E as the concentration increased from 3 to 250 .tM. The 
shift in the elution peaks was used to calculate a dimerisation constant. b) Plot of the elution volume of the 
peaks against the protein concentration. Based on this graph the apparent Kd was calculated by fitting 
equation 1. The kd on the graph is the real Kd of dimerisation. 
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4.3.3. Interaction of the C-terminal domain of human Hsp90 a with 
Cyclophilin 40 (Cyp40) 
Several methods were used to study the binding of the C-terminal domain of 
human Hsp90 a with Cyp40, including gel filtration, intrinsic tryptophan fluorescence, 
near UV circular dichroism and surface plasmon resonance. However not all the 
techniques a promising results. Therefore only convincing positive or negative results 
are presented here. 
4.3.3.1. C-terminal human Hsp90 a binds to the bovine Cyp40 as shown by gel 
filtration 
Gel filtration was used to investigate the interaction of the C-terminal domains of 
human Hsp90 a with Cyp40. The mixture of proteins was run through a Superdex S200. 
The elution peaks of the protein mixture were compared with those of the individual 
proteins applied to the same column. Any shift in elution volume was then analysed by 
SDS PAGE to determine the constituent proteins present in any given peak.The profile 
of the a63 1-Cyp4O complex on Superdex S200 was shown to be different from that of 
the proteins alone (Figure 4.5). Peak A from the gel filtration ofhHsp9O-a631 alone was 
shifted to peak C when the complex was run on the same column. Besides, most of peak 
B from gel filtration of Cyp40 alone disappeared. The total area under peak C was the 
same as that of peaks A and B combined. The size of the complex based upon the 
elution volume of peak C also showed an increase of 50 kDa (which corresponds well 
to the size of Cyp40 calculated from peak B).The fractions collected from gel filtration 
experiments were loaded on SDS PAGE gels (Figure 4.5). Based on the gel, bands 
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Figure 4.5. Gel filtration studies of complex formation using hHsp90-a631and bovine Cyp40. a) Plot 
of the gel filtration profiles from all Superdex 200 runs. A, B and C peaks were observed in each of the 
independent runs. Peak C was the peak that corresponded to the formation of a complex while A and B 
were observed when the proteins were analysed individually. A shift from peak A or B to peak C indicated 
complex formation. Panels b and c and d show the SDS polyacrylamide gel analysis of all the fractions 
obtained over the runs. The fractions were numbered based on their elution volume with 0.5 ml each. b) 
Fractions collected from the gel filtration run of the complex. c) and d) Fractions collected from the 
individual runs of Cyp40 and hHsp90-a631 respectively. 
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corresponding to Cyp40 were shifted from fraction no. 14.5 to fractions no. 11.5 upon 
complex formation. 
Similarly, the complex of hHsp90-a52 1 and Cyp40 also showed a different 
elution profile from that of its individual protein components following gel filtration on 
a Superdex 200 column (Figure 4.6). Peak A from hHsp90-a521 alone was shifted to 
peak C. Peak B from the individual Cyp40 gel filtration run almost disappeared. The 
area under peak C was corresponded to that of A and B together. SDS polyacrylamide 
gel (Figure 4.6) of the fractions collected showed that Cyp40 was detectable in earlier 
fractions. The band corresponding to hHsp90-a52 1 was also detectable in earlier 
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Figure 4.6. Gel filtration studies of the formation of complex between hHsp90-a521 and 
bovine Cyp40. a) Graph showing the gel filtration profiles from each run on the Superdex 200. 
Peaks A and B (hHsp90-a521 and Cyp 40 respectively) were shifted to peak C indicating the 
formation of a complex. b) and c) show the SDS polyacrylamide gel of the fractions collected from 
over the complex and Cyp40 peaks respectively. In gel b) breakdown products of hHsp90-a521 
can also be seen in addition to both of the target proteins. 
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4.3.3.2. The dissociation constant (Kd) of the interaction between Cyp40 and C-
terminal human Hsp90 a obtained from Trp fluorescence 
Trp fluorescence is one of the tools widely used to monitor the changes in 
protein. The technique monitors the changes that happen to the Trp residues or their 
environment when the protein makes a contact to other compounds or proteins. These 
changes can be monitored by looking at the fluorescence intensity, maximum 
wavelength, anisotropy, fluorescence lifetimes and energy transfer [32] .In this series of 
experiments, changes in Trp intensity were used to monitor the changes that occurred to 
the Trp residues of the proteins when complex was formed. The study was carried out to 
investigate the binding of the C-terminal domain of human Hsp90 a with Cyp40. From 
the study of the Trp fluorescence, the dissociation constant (Kd) can be calculated. 
In the first experiment, various concentrations of h}{sp90-a631 (1 to 160MM) 
were added to a fixed amount of Cyp40 (1 AM) and the changes in fluorescence were 
monitored. The excitation wavelength of the complex was 295 nm; the emission 
fluorescence was taken at 350 nm. The observed fluorescence was corrected against 
inner filter effects and background. The observed fluorescence from the experiment was 
subtracted with the fluorescence of Cyp40 alone at the same concentration used in the 
experiment. The background subtracted fluorescence was corrected against the inner 
filter effects. A graph of the corrected fluorescence against concentration (JIM) was 
plotted (Figure 4.7). Based upon the graph, equation 4 was fitted to get the Kd. The Kd 
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Figure 4.7. Graphs showing Trp fluorescence measurements of the interaction between the C-
terminal domain of human Hsp90 a with bovine Cyp40. a) Various concentrations of bovine Cyp40 
were added to I uM of hHsp90-a52 1. The emission at 350 nm at each concentration of Cyp40 was 
monitored. The Kd for the interaction is 66 ± 17 tM and was obtained by fitting the curve with Equation 
4. b) Increasing concentrations of hHsp90-a631 were added to a solution of 1tM Cyp40. The emission 
was also monitored at 350 nm and the Kd was obtained by fitting the curve with equation 6. The Kd of the 
interaction is 39 + 7.4[LM. 
The same experiment was carried out to study the binding of hHsp90-
ct521 to Cyp40. In this experiment, a fixed concentration of hHsp90-a521 was used and 
mixed with various concentrations of Cyp40. The fluorescence values were corrected 
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against both the inner filter effects and the background. Based on the graph, the Kd for 
the interaction is 66 ± 17 iiM  (Figure 4.7). 
4.3.3.3. Surface Plasmon Resonance (SPR) also supports the binding of the C-
terminal human Hsp90 a with bovine Cyp40 
The SPR experiments were carried out with the assistance of Dr John Butler 
from BIACORE. The experiment used the NTA chip to study the interaction between 
hHsp90-a521 and Cyp40. The NTA chip was charged with Ni2 by following 
manufacturer's protocols. Figure 4.8 indicates one single cycle of SPR carried out to 
study the interaction of the proteins. The cycle of SPR was started by coupling the 
hHsp90-a52 1 onto the surface of a Ni-NTA chip via the His-tag on the protein to nickel 
ions bound on the surface of the sensor. The on-rate for the binding of the protein to the 
sensor is 0.1 tM 1s 1 which gives a Li  of 1 JLM and the dissociation rate is 0.05s 1 . The 
respond signal was decreased around 0.2 RU s 1 . Cyp 40 (at the concentration of 37.5 
/LM in the figure 4.8) was passed over the chip at a flow rate of 30 Itl min-'. Cyp40 binds 
to the hHsp90-u52 1 on the surface and dissociated by itself over 180s. Dissociation of 
hHsp90-a521 from the surface was carried out by washing with running buffer. 5 mM 
EDTA was used to completely remove the protein and the Ni2 from the surface as well 
as regenerating surface. The surface was recharged with the Ni2 . The cycle was then 
repeated for other concentration of Cyp40. The binding of increasing concentrations of 
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Figure 4.8. Generation of an NTA-hHsp90-a521 sensor surface. The reference corrected SPR 
sensorgram from a Biacore3000 machine to the capture (phase a), of 200 nM Hexa- hHsp90-a521, in 
Running Buffer (10 mM HEPES, pH 7.4; 150 m NaCI; 0.005% surfactant P20), for 60 sec at 5 d.min', 
over an Ni2tNTA sensor surface. Following injection ofhHsp90-a521 (the capture signal response in this 
experiment 550 RU. The mean value was 531 + 28 RU; + SE, n = 30) the injection of protein was 
stopped and the lines washed with Running Buffer (phase b). The response signal drops steadily due to 
hHsp90-a521 dissociating from the surface (phases b - d). The off-rate for this dissociation is 0.05 s', 
corresponding to a baseline drift of 0.2 RU.s', as seen in the Cyp40 binding-phase (phase c and Figure 
4.9). The on-rate for hHsp90-a521 binding is 0.1 jzM 1s', giving a Kd of— 1 M. Following washing of 
the injection lines, a 180 s injection at 30 uI mind, of (in this case 37.5 uM) Cyp40 in Running Buffer 
(phase c) was performed. Dissociation (phase d) was performed in Running Buffer for 300 s at 30 j1 min'. 
4-30 
Following this, the surface was regenerated with 5 mM EDTA in Running Buffer, the NTA-chip recharged 
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Figure 4.9. Binding of Cyp40 to Ni2+  -NTA immobilized hHsp90-u521 . (A) Reference corrected SPR 
binding curves (black) for various concentrations of Cyp40 monitored on a surface of Ni -NTA captured 
hHsp90-a521 . The data was globally fitted (red) using a kinetic model (with a drifting baseline of - 0.2 
RU s1) where a 1:1 complex is formed between hHsp90-u521 and Cyp40. From this experiment the 
apparent on-rate constant (k) is 0.018 tM 1 s', and the apparent off-rate constant (ic) is 1.3 
51  giving an 
equilibrium dissociation constant (KdK1) of 72.2 iM, for Cyp40 binding to hHsp90-cc521 .Running buffer 
was 10 mM HEPES, pH 7.4; 150 mM NaCl; 0.005% surfactant P20. Curve a, 2.35 PM Cyp40;  b, 4.7 jiM 
Cyp40; c, 9.4 jiM Cyp40; d, 18.8 jiM Cyp40; e, 37.5 jiM Cyp40; f, 75 jiM Cyp40; g, 150 jiM Cyp40; h, 
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300 ItM Cyp40. (B) Plot of steady-state response units, Req, verses the concentration of Cyp40 in /,LM. A 
least squares fit of the equation Req = (Reqsat x [Cyp40]) / ([Cyp40] + Kd), to data from three repeat 
experiments is shown in red. Req  is the equilibrium response (RU), Reqsat  is the saturated equilibrium 
response for the chip surface, [Cyp40] is the total Cyp40 concentration in M and K  is the equilibrium 
dissociation constant. The mean Kd Eq value = 95.7 ± 19.5 jM (± SE). 
seen were plotted against the concentration of Cyp40 (Figure 4.9). The graph was fitted 
with equation below. 
Req = (Reqsat x [Cyp40]) / ([Cyp40] + 
	-equation 7 
The experiments were repeated three times. Req  is the equilibrium response of the 
interaction in RU units, Reqsat is the saturated equilibrium response for the chip surface 
which is 500 RU, [Cyp40] is the total Cyp40 concentration in AM and Kd' is the 
equilibrium dissociation constant. The mean Kd Eq value = 95.7 + 19.5 AM (+ SE; n=3). 
From the experiment, the equilibrium dissociation constant (KdK)  is 76 ± 19.5 (± SE; 
n=3) with apparent on-rate contants, K+ (.tM 1s 1) and off-rate constants of, K (s') 
0.018 ± 0.002 and 1.3 10.3 respectively. 
4.3.4. Interaction of the C-terminal domain of human Hsp90 a with 
ATP and novobiocin 
Besides studying the interactions of C-terminal human Hsp90 a with bovine 
Cyp40, another area of interest of the project was to study the interaction of the proteins 
with ligands. The ligands that were studied were ATP and novobiocin. The interest in 
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both of these ligands arose mainly because they were shown to bind to the C-terminal 
domain of the Hsp90 proteins [8, 30]. However, these interactions are not particularly 
well documented, few groups have investigated the binding of the C-terminal domain 
Hsp90 with ATP (in contrast to the situation of the N-terminal ATP binding which has 
been well characterised). Therefore, the availability of relatively large quantities of these 
proteins presents an opportunity to study the interactions of the C-terminal domain with 
both ATP and novobiocin. Novobiocin has previously been shown to bind to the C-
terminus of Hsp90 [14, 15, 36]. Novobiocin also inhibits the binding of ATP to C-
terminal Hsp90 [14]. 
4.3.4.1. Trp fluorescence showed that ATP bind to hHsp90-a521 
Intrinsic Trp fluorescence was used to investigate the binding of ATP to hHsp90-
ct52 1. The experiments were carried out by titrating ATP into a solution of the proteins. 
The fluorescence signal of individual concentrations of ATP was also determined. ATP 
does not give any significant absorbance at 295 rim, it also does not fluoresce 
significantly under the experimental conditions used, therefore the background 
fluorescence was negligible and has been ignored when analysing the data from this 
series of experiments. The observed fluorescence was corrected against the dilution 
factor resulting from the titrations only. The final volume added was only a maximum of 
1% of the total initial volume. The values for the corrected fluorescence were plotted 
and the curve was fitted with the equation (equation 6b) mentioned before in section 
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4.4.2 using Kaleidagraph 3.5 (Figure 4.10).The Kd obtained for the interaction of 
hHsp90-a 521 is 101 ± 15 jiM. 
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Figure 4.10. Intrinsic Trp fluorescence of hHsp90-a521 titrated with an increasing concentration of 
ATP. The fluorescence experiment was carried out with excitation at 295 nm, emissions were measured at 
355 nm. The observed emissions were corrected against the inner filter effects as well as the background. 
The curve was fitted using Kaleidagraph 3.5. Based from the fit, the Kd observed is 101 ± 15 jLM 
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As a control, the experiment was also carried out with cyclophilin A that does 
not bind to ATP. The results of this experiment showed that the graph is linear with a 
negative slope. The result indicated that, as predicted, there is no interaction between 
ATP and cyclophilin A. 
4.3.4.2. Hummel-Dreyer gel filtration showed ATP binds to hHsp90-a521 but not 
hHsp90- a631 
The interaction of hHsp90-a52 1 with ATP was also shown by the Hummel-Dreyer 
experiment (Figure 4.11). In this experiment, 75 ItM ATP was added to the running 
buffer used to equilibrate the gel filtration column. Samples containing hHsp90-u521 
with various concentrations of ATP were applied to the column. The initial 
concentration of ATP in the sample was the same as in the running buffer. The change 
from trough to peak as the ATP concentration increased indicates interaction between 
protein and ATP. The trough to peak changes was caused by the differences in 
concentration of ATP eluted from the sample with the concentration of ATP in buffer 
that equilibated the column as mentioned in section 4.2.4.1. In these experiments, the 
concentrations of ATP used varied from 75 to 200 [IM, the concentration of protein was 
fixed at 80 jtM. The change from trough to peak was observed when the concentration 
of ATP was increased (Figure 4.11). The areas under the trough or peak were calculated 
and the graph of the area versus ATP concentration was plotted. From the graph, the 
value of the ATP concentration when neither peak nor trough was determined. The 
concentration of ATP at this point indicated that the free ATP concentration was the 
same as that in the running buffer. The ATP concentration in the sample is 
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approximately 1 00tM when neither a trough nor a peak were observed. From this value, 
free hHsp90-a52 1 can be calculated as a well as the concentration of complex. These 
values were then used to calculate the Kd based on the equation below. 
Kd = [ui52 I f,,,] [ATPtree] /[a52 1 :ATP]- equation 8 
The Kd of the interaction of ATP and hHsp90-a521 from the Hummel-Dryer 
experiment is 300 ± 90 AM (mean ± S.E, n = 3) (Fig 4.11). The stoichoimetry of the 
interaction is 1: 0.75 (hHsp90-a52 1: ATP). The stoichiometry was obtained by plotting a 
Scatchard graph of [ATPbond]/ [ATPfree] against [ATPb0 d] (Figure 4.11). The slope of 
the graph is equal to -1/Kd and the intersection of the plot with the abscissa give the 
potential concentration of protein occupy the binding site (in this case 60 AM). The Kd 
obtained from this graph is 277 AM which is very similar to the Kd obtain from other 
experiments. The experiment was repeated with hHsp90-u63 1 but showed that the 
protein did not bind to ATP 
4.3.4.3. ATPase activity of hHIsp90-a521 detected by malachite green assay 
The ATPase activity of the proteins was measured using an assay system based 
on malachite green. The assay was performed using 5M hHsp90-a521-732. The linear 
phase of the ATPase activity against time was determined first prior to any experiments 
using different amount of ATP (Figure 4.12b (insert)). The experiments were then 
carried out to determine the rate of ATPase activity by measuring the concentration of 
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phosphate release caused by a fixed concentration of protein over a fixed time with a 
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Figure 4.11. Hummel- dryer experiment of hHsp90-a521 and ATP. a) The graph of the change from 
trough to peak as the ATP concentration in the sample loaded was increased from 75 AM to 200 saM. b) 
The graph of the areas under the peak/ trough again sts the concentration of ATP. The value of the ATP 
concentration when the area is zero was determined to be approximately 100 jM.The value indicates the 
concentration of free ATP was equal to that in the running buffer. From this value all other parameters 
were determined and fitted to equation 8 to obtain the Kd. The Kd shown above was obtained from 3 
experiments. c) The graph of ATP bound over free ATP against bound ATP was plotted. The Kd is 
determined by the negative inversion of the slope. The stoichiometry of the interaction was determined by 
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dividing the concentration of ATP at abcissa with the amount of protein in the sample loaded. The Kds 
determined by both of these plots were very similar, the stoichiometry of the interaction is 1: 0.76 which is 
close to 1:1. 
The background amount of phosphate released due to self hydrolyzing ATP was 
also measured and subtracted from the results obtained. The concentration of phosphate 
released (M min) was plotted against the concentration of ATP using Kaleidagraph 3.5. 
The graph was fitted with equation below. 
Rates (M min) = (KcatX [ii521] )( [ATP]/ Km + [ATP])- equation 9 
From the graph (Figure 4.12), the kcat is 0.021 + 0.002 min 1andthe KmS 377± 101 jiM. 
The malachite green ATPase assay experiment showed that hHsp90-a63lhas no 
significant activity above that of the background (Figure 4.12). The assay was also 
carried out using Phosphofructokinase (PFK) (a well characterised protein that has well 
known ATPase activity) as a positive control. The results (Figure 4.12) show the Keat of 
the reaction is 116 ± 25 s 1  with a Km of 770 ± 5 jiM. The assay was also carried out 
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Figure 4.12. ATPase activity of C-terminal human Hsp90 a using the malachite green assay system. 
a) ATPase activity of hHsp90-a52lwith increasing concentrations of ATP. The rate of the phosphate 
release was monitored over 60 min by measuring the absorbance of the phosphomolybdate compound at 
620 nm. b) Rate of phosphate release from the initial substrate 2mM ATP against time from 0 to 120 mm. 
Based on this graph the time required to measure the ATPase activity was determined to be 60 minutes. c) 
Graph of ATPase activity of the control protein PFK and hHsp90-a631, plotted on two different x-axes 
scales for clarity. The ATPase activity of hHsp90-a63 1 is negligible and is considered as a background 
suggesting as no ATPase activity. 
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4.3.4.4. Novobiocin binds to the C-terminal human Hsp90 a determined by Trp 
fluorescence and ITC 
The interaction of novobiocin with the C-terminal domain of human Hsp90 a 
was also investigated using Tryptophan fluorescence studies. The binding of novobiocin 
to the C-terminal Hsp90 was not well documented in literature compared to 
geldanamycin. Therefore, it will be useful if more information can be obtained from this 
study. However, only hHsp90- a521 was amenable to studies with this technique as 
hHsp90-a63 1 does not contain any Trp residues. Attempts to study the interactions by 
Hummel-Dreyer were unsuccessful as novobiocin itself stuck to the gel filtration 
column. The novobiocin was also found to be sticky and stacked to each other especially 
at high concentrations. In the fluorescence experiments, increasing concentration of 
novobiocin were titrated into 1 uM protein in a 3 ml cuvette. The protein was excited at 
295 nm and the emission collected at a wavelength of 355 nm over a 60 second time 
period. The data from increasing concentrations of novobiocin without the protein were 
also measured to determine the background fluorescence. Novobiocin itself exhibits 
background fluorescence, the fluorescence emission of the complexes were corrected 
againsts both background and the inner filter effects using equation 5. The corrected 
emission data were plotted and fitted with two binding sites equation 6b. The Kd 
obtained from the experiment is 1.26 ±0.46 jtM (Figure 4.13). However, the second Kd 
was large and with huge error showed that the second binding was unspecific and due to 
the novobiocin which is sticky. In order to determine if the binding of novobiocin to 
hHsp90-a521 is genuine, the experiment was repeated using N-acetyl tryptophan as a 
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Figure 4.13. Study of the interactions of hHsp90-a521 and N-acetyl tryptophan with 
novobiocin. The study was done by using intrinsic Trp fluorescence and isothermal titration 
calotimetry (ITC). a) The graph shows the changes in emission caused by the titration of an 
increasing concentration of novobiocin into a fixed amount ofhHsp90-a521. The graph was then 
fitted with equation 6b to obtain the Kd which is 1.26 ± 0.46 1iM.b) A Stern-Volmer plot of the 
fluorescence data from both of the experiments. From the Stern-Volmer plot, the bimolecular 
quenching constant of free Trp and novobiocin was determined to be 900 tM. The Stern-Volmer 
plot of hHp90 021 was also displayed. The plot shows the interaction deviated from linearity 
and indicates specific interaction. The facts were explained further in discussion. C) ITC data of 
the interaction between hHsp90-a52lwith novobiocin. The Kd determined from the experiments 
was 3.7 ± 0.04 jtM. 
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control. The emission fluorescence were corrected and plotted using the Stem —Volmer 
equation, F0/F = 1+KD[Novobiocin]. From the KD,  the bimolecular quenching constants 
can be calculated by using KD= kqto [Novobiocin] where kq is the bimolecular quenching 
constants and the to is the half life of Trp which is 3.6 s. 
From available data the bimolecular quenching contants for the N-acetyl- Trp is 
about 900M, which indicates the binding is non-specific. The interaction of the protein 
with novobiocin was also determined by using ITC. The ITC data was fitted by using 
two binding sites equation provided by manufacturer. From the fitted curved, the Kd for 
the specific interaction was 3.7 ± 0.04 jtM whereas the unspecific Kd was about 150 
iiM. The reaction was entropically favourable with a AG = -6.6.kcal moF', AH= -2.14 
X 10-1 kcal mol and AS= 2.41x102  kcal mof'K'. 
4.3.4.5. The inhibition of ATPase activity by novobiocin 
The next experiment is to investigate if novobiocin was able to inhibit the 
ATPase activity of hHsp90-a521as novobiocin was showed [14, 15] to compete with 
ATP at the C-terminal. The experiment was carried out as described. Absorbance at 620 
nm was converted to the amount of phosphate released against time (pmoles 	and 
the graph of rate versus concentration of novobiocin was plotted. The IC50 was obtained 
by fitting the curve with equation 10 as below. 
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Figure 4.14. Inhibition of ATPase activity by novobiocin using the Malachite green assay. a) The 
inhibition graph ofhHsp90-a52land PFK. The assay was carried out using either 5uM ofhHsp9O-a521 or 
1 nm PFK. Increasing concentrations of novobiocin were incubated with the proteins at 370C for 30 mm. 
The ATPase assay was carried out as described in chapter 5, section 4.2.4.4. The IC50 of hHsp90-
a52 1 inhibition was obtained by fitting equation 10. The IC50 (10.8 tM) and the Km  ( 377GM) were fitted 
to equation 11 to get the Ki which is 2.79 ± 2.02 j.tM. The inhibition of ATPase assay was also carried 
out using PFK. Even though up to 300 1tM of novobiocin was added to the 1 nM protein, no inhibition of 
the ATPase activity was detectable. b) ATPase activity of both of the C-terminal human Hsp90 czjust as a 
comparison to the inhibition. 
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where rates, is the rate of ATPase activity at infinite concentration of novobocin. 
RateSinit is the initial rate of ATPase activity in the absence of novobiocin. From the 
graph, the 1050 is 10.8 ± 6.8 ItM. The inhibition constant (Ks) was calculated using 
equation 11. 
Ki = IC50 /( 1 + ([ATP]/K,,,)) —equation 11 
Where the IC50 was obtained from the previous ATPase experiment. [ATP] is the 
concentration of ATP used (1000 jIM) and the Km  (377 M) was obtained from the 
ATPase assay, resulting in a calculated K1 of 2.79 ± 2.02 jiM. The inhibition of ATPase 
activity was also carried out using PFK at mM concentration as a control (Figure 4.14). 
No inhibition of the ATPase activity was observed even at a concentration of 300 saM. 
4.4. Crystallization trials 
Crystallisation trials have been setup using various kits and precipitants. The 
commercial kits which have been tried are Structure screens 1 and 2 (MDL Ltd), Peg/Ion 
screen (MDL Ltd), Crystal screens 1 and 2 (Hampton Research) and the Sodium 
malonate screen. Besides the kits, precipitants such as ammonium sulphate and various 
types of PEG were also tried. The proteins were also used in co-crystallization 
experiments with Cyp40, ATP and novobiocin, unfortunately to date no useful crystals 
have been obtained. The best lead so far was obtained from hHsp90-a521 from 
condition no. 4 of Structure Screen 1. The solution consists 3.4 M 1,6-hexanediol, 0.2M 
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; 
MgCl2.6H20 and 0.1M Tris pH 8.5. However the crystals obtained were very small and 
did not grow (Figure 4.15). Seeding was used in an attempt to encourage the crystals to 
grow but was unsuccessful. The crystals were screened but did not diffract. 
Figure 4.15. Crystals of hHsp90-a521. The crystals were tiny and formed a single needle-like shape 
(inset). The crystals were obtained from solution 4 of the Structure Screen I kit (MDL). Optimization 
experiments in an attempt to obtain better crystals were unsuccessful. The crystal did not diffract when 
screened on beamline 14.1 at CCLRC Daresbury. 
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4.5. Discussion 
4.5.1. The dimerisation of the C-terminal human Hsp9O a 
The study on hHsp90-a521 and hHsp90-ct631 showed that both of the proteins 
exist in solution as a dimer. The Kcjimer  of hHsp90-a63 1 can be measured using gel 
filtration. However, the dimerisation constant of hHsp90-a521 Kjjmer could not be 
determined as it was likely to be in the AM range and therefore below the available 
limits of detection for the in house system. A previous study had mapped the sites 
involved in the dimerisation of human Hsp90 0 to residues 548-567, 661-667 and 679-
728 [19, 27]. All of the sites or parts of them were present in the C-terminal of human 
Hsp90 a proteins. Therefore, it was likely that the proteins would exist as dimer. In the 
previous studies [34] showed that the site most important for dimer formation is 650-
732. However, the dimer only exists if the region is paired with another human Hsp90 a 
region containing the middle and the C-terminal domain (human Hsp90 a 400-732) [34]. 
Our hHsp90-a63 1 consists of only part of the sequences needed for dimer formation 
hence dimer formation was observed between the same proteins region (631-732) with a 
weaker Kjimer.  In agreement with [13], the dimer can still exist but a stronger dimer can 
be formed if the other monomer is longer. Therefore, the dimer of hHsp90-a63 1 is 
weaker with a Kiimer  of approximately 5 AM and dependent on concentration. 
Furthermore, in the HtpG structure, the dimerisation motif was formed by two long 
helices (1-14 and 1-15) comprised of residues 587-624. These helices interact with their 
equivalent counterparts from the second molecule and forming four helical bundles [12]. 
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The motif was also similar in the recently published yeast Hsp90 full-length crystal 
structure. In addition to this motif, a helix segment residues 587-610 is also involved in 
the dimer formation [2]. The residues 587-624 of htpG were equivalent with residues 
652-693 of human Hsp90 a whereas residues 587-610 of yeast Hsp90 were equivalent 
with 607 to 630 of human Hsp90 a. The lack of residues 607-630 in hHsp90-a631 was 
probably another reason for its weak dimer formation. hHsp90-a521 contains all of the 
residues important for dimer formation in addition to a number of residues from the 
middle domain. Therefore, it can be assumed that hHsp90-a52 1 forms a tight dimer and 
has a Kdimer  in the nM range. The assumption was made as the Kjimer  of the full length of 
yeast Hsp90 is 60nm [27] and if the dimerisation is only caused by the C-terminal, 
therefore the Kjjmer of hHsp90- a521 must also be in the nM range. 
4.5.2. Cyp40 bind to the C-terminal human Hsp90 a via MEEVD motif 
Based on all the experiments studying the binding of Cyp40 to C-terminal 
Hsp90, an interaction between these two molecules can clearly be established. The 
interaction was showed by gel filtration using Superdex 200. Cyp40 was also shown to 
interact with human Hsp90 P, the interaction being mediated through the MEEVD motif 
of Hsp90 [33]. In that experiment, 24 amino acids of the TPR domain were mutated by 
site directed mutagenesis. The mutants were then used in interaction studies with the C-
terminal domain of human Hsp90 3, using the yeast two hybrid f3-galactosidase filter 
assay. The interactions of the TPR domain mutants with Hsp90 was as shown by GST 
pull down experiments and an ELISA of the mutants of certain amino acid of Cyp40 to 
4-47 
the C-terminal of human Hsp90 P. Even though, the binding of Cyp40 to Hsp90 had 
been shown previously [5, 6, 23, 31], however little was known as to the specific affinity 
of the interaction. In this study, the dissociation constants of the interaction between the 
C-terminal of Hsp90 with Cyp40 were investigated. The Kd of the interactions between 
the C-terminal constructs of human Hsp90 a that we have, were between 39 to 95 fLM. 
The Kd was determined by intrinsic Trp fluorescence or SPR. Cyp40 was also shown to 
bind to the MEEVD peptide with a Kd of 34 ± 20 jiM which is very similar to the Kd of 
the interaction of Cyp40 with the larger C-terminal region of Hsp90. Based on the SPR 
results, it is also noteworthy that the dissociation of the complex was very rapid with an 
off-rate (K) of 1.3 s_I when compared to the on-rate of 0.018 ± 0.002 jiM. There is also 
agreement between the Kd El and the Kd Kin  which can be calculated from the apparent 
the off- and on-rate. Due to the rapid equilibrium of the complex, some of the techniques 
used in an attempt to characterize the interactions were unsuitable for this particular 
experimental system. Near UV Circular Dichroism (Near CD) is an example of such a 
technique, where the binding of the two proteins was very rapid that the change in the 
protein structure can not be detected (data not shown). 
From my experiments, it was also shown there is a difference in the dissociation 
constants between the C-terminal human Hsp90 a proteins analysed. The dissociation 
constant was lower for the hHsp90-a63 1 construct which indicated tighter binding than 
that seen with the hHsp90-a52 1 construct. As described earlier, the constructs differ in 
length, hHsp90-a63 1 lacks 110 amino acids from the N-terminus, secondary structure 
predictions show hHsp90- a631 to be missing 4 helices. In other Hsp90, TPR binding 
proteins such as Hop (Hsp90 Organiser Protein), the mammalian homolog of Sti 1, 
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partial deletion of the N-terminal domain of Hsp90 resulted in decreased binding 
affinity with Stil [33]. However, no similar effect was seen to occur with immunophilin 
binding when the N-terminal of Hsp90 was deleted [7, 25]. It has also been shown that 
the binding of the C-terminal domain of human Hsp90 13  to Cyp40 was similar to that 
seen with full length human Hsp90 l, indicating that this binding interaction is not 
influenced by the N-terminal domain [33]. Our results suggest that the shorter Hsp90 
hHsp90-a631 construct when compared with the hHsp90-a521 construct is more 
accessible for immunophilin binding and also shows a lower dissociation constant but is 
still not hugely different. Similarly, the binding of the MEEVD peptide to Cyp40 also a 
roughly the same dissociation constant. In contrast, ITC experiments using full length 
human Hsp90 and human Cyp40 exhibited dissociation constants of about 226 ± 61 nm 
[23], which is lower than the Kd of our truncated Hsp90 constructs providing evidence 
in support of the argument that binding interactions are influenced by not just the C-
terminal of Hsp90. Thus, even though the binding of the C-terminal of human Hsp90 
was different between them, the Kd of the interaction between the full length human 
Hsp90 a and Cyp40 was probably lower than their C-terminal proteins. However, it is 
difficult to determine the effect of the deletion of the N-terminal and the middle domains 
upon the interactions with partner proteins as we do not have the full length human 
Hsp90 protein 
Further support of the requirement for other Hsp90 domains has also been shown 
by ITC. Hsp90 binds both Stil and Cpr6, the dissociation constants (Kd) from these 
experiments are 330 nM and 240 nM respectively [25]. In this experiment, the binding 
of Stil was influenced by the N-terminal domain of Hsp90 [25]. Direct comparison of 
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the binding interactions between these TPR containing proteins and those described in 
this thesis is not possible as different Hsp90 constructs were used, however a previous 
ITC study suggests the interaction needs the presence of other Hsp90 domains for the 
interactions with the TPR domain. However, there was still a difference in their affinity 
to bind to Hsp90. The difference in affinity was probably because they function at 
different times in the cell as illustrated in figure 1.18, Chapter 1. In the intermediate 
folding complex, Stil/Hop was present and the inherent ATPase activity inhibited. The 
inhibition was later relieved when Sti 1 /Hop is replaced by other co-chaperones in the 
mature complex. In this complex, the C-terminal domain of Hsp90 was bound by an 
immunophilin co-chaperone such as Cyp40. 
45.3. The C-terminal domain contains a second A TP binding site and 
has low ATPase activity 
Apart from binding to TPR containing proteins, Hsp90 also binds to ATP. 
Binding to ATP/ADP is mediated through the N-terminal domain. The N-terminus of 
Hsp90 was shown by structural and biochemical studies to contain ADP/ATP binding 
sites [10, 24, 29]. It was also shown that Hsp90 can hydrolyse ATP [20, 22, 27] and that 
ATP hydrolysis is vital for its chaperone function in vitro [22]. An ATP binding site has 
also been suggested in the C-terminal region of Hsp90 [8, 14]. ATP binds to the C-
terminus of Hsp90 in the presence of Mg2 as shown by using ITC [8]. Several 
truncated C-terminal constructs of chicken Hsp90 were shown to bind to ATP Sepharose 
[14]. Based on our Trp fluorescence results, hHsp90- a521 binds to ATP with a K1  of 
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101 ± 15 tiM. Our result from the Hummel-Dreyer gel filtration experiment using 
running buffer containing ATP also showed ATP binding to the protein, with a higher 
Kd of approximately 250 to 300 ItM. Both of the assays were carried out without Mg 
2+ 
 
in the buffer. Trp fluorescence studies cannot be used with hHsp90-a63 1 as this region 
of the protein does not contain a tryptophan. Attempts to carry out Hummel-Dreyer 
experiment with this protein also failed as the breakdown products of the protein 
interfere with the ATP elution peak' trough analysis. Therefore, it is uncertain whether 
the deletion of amino acid acids 521-630 has any effect on the capability of the C-
terminus to bind ATP. 
As a result of the ability of hHsp90-a521 to bind to ATP, it is of interest to 
investigate if the C-terminal region itself can hydrolyse ATP. In order to do this, the 
malachite green assay described earlier was used. The assay was utilised as it is rapid 
and easy to use compared to the PFK enzyme coupled reactions. Malachite green has 
been used to detect ATPase activity in a number of proteins including Hsp90 [1, 9, 11, 
28]. In this assay, phosphate ions released are captured by free molybdate ions. The 
resulting phosphomolybdate compound reacts with the malachite green dye, the 
absorbance resulting from this reaction can be measured at 620 nm [28]. Based on the 
results, ATPase activity was observed in the hHsp90- a521 construct. However, the 
activity was only 30% of that for full length human Hsp90 a (0.092 min-' [16, 17]). The 
most active Hsp90 ATPase yet characterized is that of yeast hsp82 that has an ATPase 
activity of 0.47 mm' [16, 17,28]. 
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4.5.4. Novobiocin binds to the C-terminal domain and inhibits 
ATPase activity 
The C-terminal domain of Hsp90 was also shown to bind to novobiocin [14, 15, 
36]. Novobiocin (Chapterl; figure 1.16), is an antibiotic known to bind adjacent to the 
ATP binding site of bacterial gyrase B. There is evidence showed that native chicken 
Hsp90 and a number of its truncated C-terminal constructs were able to bind to 
novobiocin sepharose [14]. The binding of novobiocin at that site interferes with 
nucleotide binding where the truncated C-terminal constructs was inhibited to bind to 
ATP sepharose [14]. In agreement with these results, we showed novobiocin binds to 
hHsp90-a521 with a range of Kd of 1.26 to 3.77 pM. A further study carried out by [14, 
15] has also shown that a motif corresponding to region 657-677 of chicken Hsp90 was 
able to compete with the Hsp90 mutants for novobiocin binding to the novobiocin 
sepharose resin. Furthermore, deletion of this region reduced the binding of chicken 
Hsp90 mutants to novobiocin sepharose [14]. This region is conserved in human Hsp90 
a (residues 659 to 680).Therefore, this suggested that the same motif is also involved in 
the binding of novobiocin to our C-terminal constructs. 
In order to make sure the interaction of novobiocin to Hsp90 is specific, the 
experiment was repeated using N-acetyl- tryptophan as a control for Trp fluorescence 
experiment. From the Stern-Volmer plot (Figure 4.13), a linear relationship was 
observed when the concentration of novobiocin increased. This relationship is expected 
as novobiocin can bind to free Trp without any restriction. Both molecules can bind and 
disassociate rapidly, therefore a linear relationship was observed. The same plot was 
4-52 
used to analyse the binding of novobiocin to hHsp90-a52 1 (Figure 4.13). The graph 
shows a linear relationship at the beginning of the experiment which then plateaus as the 
novobiocin concentration is increased. This pattern would have been expected in the 
case where one Trp residue in the protein is inaccessible to the "quencher" and therefore 
the resulting fluorescence signal from this residue cannot be quenched. However, 
hHsp90-a521 contains a single Trp residue which can be "seen" by fluorescence studies 
in the early stages of the experiment. Therefore, the plateauing of the curve seen was 
caused by novobiocin binding specifically to the protein. Additionally, the bimolecular 
quenching constants (kq) of the free Trp bound to novobiocin can be inverted to become 
the dissociation constants of the interaction. The Kd for this interaction is 9001iM. The 
Kd of  the interaction between novobiocin and the protein is 900-fold more than that of the 
Kd of the interaction between novobiocin and free Trp indicating that binding of 
novobiocin to protein was more specific than to that of the free Trp. Further support for 
the suggestion that novobiocin binds to Hsp90. HHsp90-a521 came from ITC data 
which show the binding and give a Kd about 3.7 IM. All the Kds obtained were almost 
similar therefore suggesting genuine binding. 
As mentioned before, novobiocin was shown to inhibit binding between ATP 
and the C-terminal domain of Hsp90 [14, 15]. In this series of experiments, Hsp90 was 
inhibited from binding to novobicin Sepharose by ATP and vice-versa. Based on our 
results, the ATPase activity of hHsp90-a 521 can be inhibited by novobiocin. The IC50 of 
the inhibition is 10.8 ± 6.8 iiM  and the Ki is approximately 2.8 jtM. The Ki is in 
agreement with the Kd from the fluorescence experiments. As a control, the same 
experiment was carried out using PFK. The ATPase activity of PFK was not inhibited by 
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novobiocin even though the concentration of novobiocin used was 300 JtM to a 1 nM 
solution of PFK. This indicates that the inhibition seen with Hsp90 is specific to the 
protein. The fact that the ATPase activity of hHsp90-a521 can be inhibited by 
novobiocin also provides support for the results presented earlier that the ATPase 
activity and binding seen in the C-terminal domain is genuine. 
4.6. Conclusion 
Chapter 4 described the interactions of the C-terminal domain of human Hsp90 a 
with Cyp40 and also with small ligands such as ATP and novobiocin. The chapter also 
support the dimer formation of Hsp90 and identifies possible region for the dimer 
formation. The experiments also provide greater information on the binding strength 
between the proteins with the use of several biophysical techniques. In addition, more 
knowledge about the binding of C-terminal to ATP and novobiocin were revealed. Even 
though, some of the results are new and controversial, it does not mark the end of it. In 
future more study are needed to investigate the findings. Table 4.3 summarises the 
results obtained in this chapter. 
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Protein T Ligand or Methods Kd (riM) 1C50/Ki Km  kon k0ff (s) Kd kin kcat 1Qirner Figure 
(°C) inhibitor  (UM) (jiM) (M' s)  (j.tM) (min') (GM)  
4 ATP Hummel- 300±90 4.11 
Dreyer  
25 ATP Trp 101± 15 4.10 
fluorescence  
37 ATP Malachite 377± 0.021 4.12 
green ATPase 101 ±0.002 
assay  
25 Novobiocin Trp 1.26± 4.13 
flourescence 0.46  
hHsp90- 20 Novobiocin ITC 3.7± 4.13 
a521 0.04  
37 Novobiocin Malachite 10.8± 4.14 
green ATPase 6.8/ 
assay 2.79 






25 Cyp4O SPR 95.7 ± 0.018± 76 ± 19.5 49 
19.5  0.002 __  
4 Cyp40 Gel filtration 4.6 
4 ATP Hummel- No 
Dryer binding 
observed 
37 ATP Malachite No 
green ATPase ATPase 
hHsp9O-______  assay  activity  
a631 25 Cyp40 Trp 39±7.4 4.7 
fluorescence  
4 Cyp4O Gel filtration 4.5 
4 Gel filtration 4.98 ± 44 
2.12  
Table 4. 3. List of results obtained from all the human Hsp90 a experiments that were carried out in Chapter 4 
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Chapter 5: Characterization of C. elegans Hsp90 
5.1. Introduction 
All the work relating to the C. elegans Hsp90 part of the project is described in 
this chapter. In the series of experiments outlined, two different protein constructs were 
used in an attempt to compare and contrast the roles of the N and C-terminal domains in 
their interactions with potential partner proteins or ligands. The constructs were full 
length C. elegans Hsp90 (ceHsp90) and C-terminal Hsp90 (ceHsp90-492). The aims of 
the study were to explore the interaction of the proteins with immunophilins such as 
Cyp40 and also with a number of small ligands, including ATP, geldanamycin and 
novobiocin. One of the aims of this part of the project was to mirror some of the 
experiments described in Chapter 4, utilising full-length protein from a different species 
in an attempt to shed more light onto the nature of the interaction between Hsp90 
molecules and their partner proteins/ligands. The results of this study could potentially 
be very interesting and could help to unravel the properties of Hsp90. Such information 
could be useful in many ways including crystallization trials of the protein both free and 
with bound ligand. 
The C. elegans Hsp90 constructs were either made in-house or with the help of 
Dr Tony Page from Wellcome Centre for Molecular Parasitology, The Anderson 
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College, University of Glasgow who also kindly supplied the C. elegans cDNA. The 
constructs chosen are shown in Figure 3.1 and Table 3.1 displayed in Chapter 3. The full 
length was purified and supplied by Sandra Bruce which is in the same laboratory as the 
author. The cloning, expression and purification protocols for the C-terminal proteins 
were described in Chapter 3, section 3.2.1 and 3.2.2. C. elegans has provided many 
genetic insights into the highly conserved signalling pathways. The Hsp90 ortholog in C. 
elegans has been identified as daf-21. The protein is approximately 74% identical to 
human Hsp90 a [8]. As mentioned earlier, this chapter is focused on the results obtained 
from two different constructs of the C. elegans Hsp90, the C-terminal domains 
individually as well as full length C. elegans daf-21. 
5.2. Material and methods 
5.2.1. Gel filtration and mass spectroscopy to confirm the identities 
and oligomeric properties of the C.elegans Hsp90 proteins 
5.2.1.1. Gel filtration 
The oligomeric form of the proteins was investigated by running 50 jzM of the 
proteins through a Superdex 200 column (Amersham) using an AKTA FPLC. The 
elution volumes of the proteins were measured and the predicted size of the molecule 
was calculated from the calibration curve as outlined in Chapter 4. 
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5.2.1.2. Mass spectroscopy 
The proteins were also sent to EPIC for mass spectroscopy analysis to confirm 
the identity and the mass of the proteins. The method employed was the same as that 
described in Chapter 4 
5.2.2. Study of the interaction of C.e!egans Hsp90 with bovine Cyp40 
by intrinsic Trp fluorescence and Surface Plasmon Resonance (SPR) 
5.2.2.1. Trp fluorescence 
1 /LM of ceHsp90 or cellsp90-492 was mixed with an increasing concentration of 
Cyp40 to a total volume of 200 jil. The mixtures were incubated at room temperature for 
30 min prior to the fluorescence measurements being taken. The measurements were 
carried out with excitation at 295 nm and emission at 350 nm. The emissions from 
individual concentrations of Cyp40 alone were also measured. The emissions of the 
complex were corrected for both inner filter effects and the background fluorescence of 
Cyp40. The corrected emission data was plotted against the concentration of Cyp40. The 
curve was fitted with equations I and 2 and the Kd was estimated from the fitted curve. 
The emission, 	was corrected as below, 
F0- = F350/ e2303 
x Lx c x [C'r40} x [protein] - equation 1 
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where L is the path length of the cuvette which is 0.1 cm. c is the extension coefficient at 
295 nm for Cyp40 which is 6675 M' cm-1. [Cyp40] is the concentration of Cyp40 added 
during the measurement and [protein] is the concentration of C. elegans protein used in 
moles per litre. The curve was then fitted with equation 2 to estimate the Kd. 
FCO!T = Ff + ( Fb-  Ff ) x { (Kd + [A] + [Cyp40/ligand] )- J((K + [A] + [Cyp40])2 - (4 
x [A]  x [Cyp40]))/2 x [Cyp40/ligand]} - equation 2 
where Ff is the fluorescence of free uncomplexed protein and Fb is the fluorescence of 
the protein A: Cyp40/ligand complex at infinite concentration of Cyp40/ligand. At any 
total concentration of protein A [A], F depends on the total Cyp40/ligand [Cyp40/ligand] 
concentration and the equilibrium constant for the complex (Kd) according to equation 2. 
5.2.2.2. Surface plasmon resonance (SPR) 
SPR measurements were performed on a Biacore TWO instrument (Biacore 
Instruments Limited). ceHsp90-492 was immobilized on the CM5 sensor chip as 
described in Chapter 2: section 2.4.2. The sensor was loaded with the protein through the 
binding with primary amine. Various concentrations of Cyp40 (2 to 600 JLM) were 
passed over the immobilized protein at a flow rate of 30 Al min-' for 180s. The complex 
dissociated when running buffer (10 mM HEPES pH 7.4; 150 mM NaCl; 0.005% 
surfactant P20) was passed over the surface for 300s at 30 ItI min'. The surface was 
washed with running buffer between applications of different concentrations of Cyp40. 
The data was analyzed with the software supplied by Biacore. 
5-4 
£2.3. The study of the interaction of C. elegans Hsp90 with small 
ligands. 
It is also of great interest to study the interactions of the C. elegans Hsp90 with 
small ligands, to shed more light onto the nature of the interaction between the protein 
and some potentially inhibitory small molecules. The ligands that were involved are 
novobiocin, ATP and geldanamycin (GA). GA is known to bind and inhibit the function 
of Hsp90 in yeast and human [15, 16, 20, 21]. However, C. elegans is resistant to the 
drug, indicating that the C. elegans Hsp90 differs in some way from those species 
susceptible to GA[8]. Therefore, it is of great interest to investigate this property of the 
C. elegans Hsp90 using full-length C. elegans Hsp90 (ceHsp90) and also to further 
investigate the interaction with GA. Besides GA, novobiocin binds to the C-terminal 
Hsp90 and it is also of interest to characterize the binding of this drug to ceHsp90 and 
also to the ceHsp90-492. Interactions of ATP with a number of Hsp90 constructs have 
been reported in the literature, similar studies have been undertaken in this series of 
experiments using C. elegans Hsp90. The availability of a number of different lengths of 
constructs covering both the full length and C-terminal domains of the proteins has 
allowed further characterisation of the site of interaction of ATP with the ceHsp90. It is 
to be hoped that the results of such studies will provide an understanding of the 
interaction and may prove useful in attempts to crystallize the protein. The techniques 
used for these studies were intrinsic Trp fluorescence as well as ATPase activity assays 
using the malachite green method. 
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5.2.3.1. Intrinsic Trp fluorescence 
Increasing concentrations of the ligands were titrated into a 1 ItM solution of 
protein. The buffers for the experiments were dependent on the ligands used. Basically, 
the buffer consists of 100 mM Tris pH 7.5 and 50 mM NaCl. 0.1% DMSO was added to 
the buffer to increase the solubility of GA. The experiment was carried out using a 3 ml 
cuvette. The fluorescence was measured by using Flouromax-3 (Jobin Yvon, Hariba). 
The measurement was carried out by excitation at 295 nm and emission at 355 nm. The 
emission produced by the increasing ligand concentration alone was also measured. The 
emission fluorescence was corrected against the following: the dilution factor, inner 
filter effects and background fluorescence using equation 1 in section 5.2.2, with a few 
amendments. The amendments were as follows: L is 0.5 cm; E is the extinction 
coefficients of GA. For the ATP titration experiment; negligible background and no 
inner filter effect was observed, therefore no correction except for the dilution factor was 
required for the data. The graph was plotted and the curve was fitted with equation 2 in 
section 5.2.2. However, for the Trp fluorescence using Novobiocin, two binding sites 
equation (equation 3) was used instead of equation 2 above. 
Fobs = Ff  -[((F)/2) X  ({ (K 15 + [A/2] + [novobiocin] )- I((K1i5 + [AJ2] + 
[novobiocin])2 -(4 x  [A/2] x  [novobiocin]))/2 x  [Al2]})+ {(Fb X [novobiocin])/ 
Kd2nd+ [novobiocin])}J—equation 3 
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where Fç is the fluorescence of free un-complexed protein and Fc is the fluorescence of 
protein A:novobiocin complex at certain concentration of novobiocin on the first binding 
site. Fb is the fluorescence of compound A:novobiocin complex at infinite concentration 
of novobiocin on the second binding site. At any total concentration of compound A [A] 
concentration, F,bs  depends on the total novobiocin[novobiocin] concentrations and the 
equilibrium constants of both the binding sites (Kd1t and K1 2nd)  for the complex 
5.2.3.2. Malachite green ATPase activity assay 
The assays were performed in Eppendorf tubes at 370C. 5 to 10 ItM of the 
protein was mixed with a series of ATP concentrations (0.15 to 2mM) for 30min for 
ceHsp90 or 60 min for cellsp90-492. The reaction was also carried out using the same 
ATP concentrations in the absence of any protein to check for ATP self hydrolysis. The 
reaction time (30 or 60 mm) was determined from previous assays that measured the 
activity of a single concentration of ATP against a fixed concentration of protein over 15 
to 120 mm. The reactions were stopped by the addition of 320 jil of malachite green 
solution (Upstate, UK), mixed well and left at room temperature. 50 l of 34% (wlv) of 
sodium citrate was added to the mixture which was left for an additional 15 minutes. 
The absorbance of each of the samples at 620 nm were then measured. The amount of 
the phosphate released was obtained by using the phosphate standard curve derived 
earlier. The amount of phosphate released was subtracted from the amount of phosphate 
released by self hydrolysis of ATP (background). The rates of ATPase activity (in 
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Mmin 1) of the protein at individual ATP concentrations were calculated and a curve was 
plotted. The curve was fitted using equation 4. 
Rates (M mm') = (Kcat X [a521] )( [ATP]/ Km+ [ATP])- equation 4 
5.2.3.3. ATPase inhibition assays 
The C. elegans Hsp90 protein was mixed with a series of concentrations of 
novobiocin or geldanamycin followed by incubation at 370C for 30 mm. The ATPase 
assay was carried out using the mixtures after the incubation period. The final 
concentrations of protein and ATP used were 5 AM and 1 mM respectively. The final 
concentrations of novobiocin used varied from 1-100 JLM. GA concentrations used in the 
assay was only up to 200 M. The data was treated as in section 5.2.3.2 although the 
rates were expressed in relative percentage ATPase activity, assuming the rates of 
activity in the absence of the inhibitors as 100%. The graph of the relative percentage 
rates obtained against novobiocin/ geldanamycin concentrations was plotted. This graph 
was fitted with equation 5 to give the IC50. Based on the 1050, the inhibitor dissociation 
constant was calculated using equation 6. 
Rates (% ATPase activity) = (rates .+ (ratesm jt-rates))(1 + ([novobiocin]/1C50)') - equation 5 
K1 = IC50 /( 1 + ([ATP]/Km)) —equation 6 
5.2.3.4. Surface plasmon resonance (SPR) 
SPR measurements were performed on a Biacore TWO instrument (Biacore 
Instruments Limited). CeHsp90-492 was immobilized on the CM5 sensor chip as 
described in Chapter 2: section 2.4.2. The sensor was loaded with the protein through the 
binding with primary amine. Various concentrations of Cyp40 (50 to 800 AM) were 
passed over the immobilized protein at a flow rate of 30 Al min-' for 180s. The complex 
dissociated when running buffer (10 mM HEPES pH 7.4; 150 mM NaCl; 0.005% 
surfactant P20) was passed over the surface for 300s at 30 Al min- . The surface was 
washed with running buffer between applications of different concentrations of Cyp40. 
The data was analyzed with the software supplied by Biacore. 
5.3. Results 
5.3.1. CeHsp90-492 forms a dimer 
CeHsp90-492 was run through a Superdex 200 column. The protein was present 
as one major peak that eluted at 12.9 ml, which corresponded to 133 kfla (Figure 5.1). 
As shown with the C-terminal domain of Hsp90 human a, the apparent molecular weight 
of the protein is larger than might be expected from the sequence. This is likely to be 
due to the protein being elongated rather than globular in shape, therefore the apparent 










ceHsp90- 492 by carried out the trypsin digest and the profile of the digestion confirmed 
the identity of the protein. 
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Figure 5.1. Chromatogram of the gel filtration experiment of cehp90 492 applied to a 
Superdex 200 column (Amersham). The protein has one major peak which elutes at 12.9 ml. 
5.3.2. The interaction of C. elegans Hsp90 with bovine Cyp40 
The study of the interaction involved the use of a number of techniques that have 
been described previously in Chapter 4. The techniques used were Trp fluorescence and 
Surface Plasmon Resonance (SPR). 
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5.3.2.1. The dissociation constants (Kds) of the interaction between ceHsp90 and 
ceHsp90-492 with bovine Cyp40 determined by Trp fluorescence 
Similar to the previous experiments, the Trp fluorescence was used to obtain 
quantitative results of the interaction such as the dissociation constant (Kd). In the 
experiment, increasing concentrations of Cyp40 were mixed with a fixed concentration 
of either ceHsp90 or cellsp90-492. The mixtures were incubated at 250C for 30 minutes. 
The measurements were taken by exciting the samples at 295 nm, the emissions at 350 
nm were monitored. The experimental data were corrected and fitted using the equation 
as above in section 5.2.2. Based on the fitted data, the Kd for the interaction of the 
ceHsp90 with Cyp40 is 79.3 + 7.4 JLM (Figure 5.2). The Kd of ceHsp90-492 interaction 
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Figure 5.2. Interactions of C. elegans Hsp90 with bovine Cyp40. a) Trp fluorescence of CeHsp90-492 
with bovine Cyp40. The curve was fitted using equation 2. The Kd obtained is 140.3 ± 7.9 AM b) Trp 
fluorescence of full-length C. elegans. The data was treated in the same way as that above, the Kd of the 
interaction is 79.3 + 7.4 AM. 
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5.3.2.2. The dissociation constants (Kds) of the interaction between bovine Cyp40 
with ceHsp90-492 determined by SPR 
SPR was also utilised to obtain the affinity of the interaction between ceHsp90-
492 with bovine Cyp40. In the experiment, ceHsp90-492 protein was immobilised onto 
the CM5 sensor chip. The immobilisation was described in Chapter 2 section 2.4.2. 
Increasing concentrations of Cyp40 (50 to 800 M) were passed over the sensor chip 
containing the proteins as described in section 5.2.3.4. Each cycle was started by 
washing the surface of the sensor with running buffer. Then, Cyp40 was flowed over the 
surface and the binding was monitored through the response units (RU) and displayed as 
a sensorgram (Figure 5.3). The dissociation of Cyp40 was carried out by flowing the 
running buffer over the surface until the RU return to previous baseline (Figure 5.3). The 
cycle was then repeated with other concentrations of Cyp40. The graph of the RUs at 
steady state against concentrations of Cyp40 was plotted (Figure 5.3). The graph was 
then fitted with equation 7. 
Req = (Reqsat x [Cyp40]) I ([Cyp40] + 
	- equation 7 
where Req  is the equilibrium response of the interaction in RU units, Reqsat is the 
saturated equilibrium response for the chip surface which is 3100 RU, [Cyp40] is the 
total Cyp40 concentration in AM and 	is the equilibrium dissociation constant. The 
j<Eq obtained from the experiment is 107.1 + 18.8 AM. The on and off rates of the 
5-13 
40 

















K 	107.1 ±18.8 uM 
1000 - 
500 
0 	I 	 I 	 I 	 I 	 I 	 I 
0 100 200 300 400 500 600 700 800 
Cyp4O (uM) 
Figure 5.3. SPR of the interaction between cellsp90-492 with Cyp40. a) Sensorgram shows the binding 
of increasing concentrations of Cyp40 to the surface of the sensor containing immobilised ceHsp90-492. 
b) The steady state plot of the RUs against the concentrations of Cyp40. The graph was fitted with 
equation 7 to obtain the Kd 
 E, of 107.1± 18.8 tM 
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reaction were not available as the binding and dissociation of the complex were very 
rapid and can not be analysed. 
5.3.3. The interaction of C.elegans Hsp90 with small ligands 
The ligands used in the experiments were geldanamycin, novobiocin and ATP. In 
order to characterize the interaction of these ligands with C. elegans Hsp90, several 
techniques such as Trp fluorescence, Isothermal Titration Calorimetry (ITC) and 
ATPase assays were used. 
5.3.3.1. Trp fluorescence showed GA bind weakly to ceHsp90 
Geldanamycin (GA) is a well known ansamycin drug (Chapter 1, figure 1.16) 
that inhibits the N-terminal ATPase activity of Hsp90[15, 16, 20, 22]. However, 
C.elegans Hsp90 has been found to be resistant to GA following exposure of the whole 
nematode to the drug [8]. Affinity precipitation studies using chimeric worm-vertebrate 
fusion proteins or worm C-terminal truncations expressed in reticulocyte lysate revealed 
that the conserved nucleotide-binding fold of worm Hsp90 exhibits the novel ability to 
bind ATP but not GA [8]. In this study, the direct interaction between GA and the C. 
elegans Hsp90 was investigated. The study was carried out by titrating GA into a 1 JLM 
solution of ceHsp90. The changes in the emission at 355 nm were measured by 
excitation of the sample at 295 run. The data was corrected against the inner filter effect, 
background and for the dilution effect. Both of the slits used throughout the experiments 
were set at 2.5 mm. The corrected emissions were plotted against the concentration of 
GA using Kaleidagraph and the curve was fitted with equation 2 as before (section 
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5.5.2). The Kd of the interaction of ceHsp90 to GA is very weak, 298.0 ± 88.5 ItM 
(Figure 5.4). 
Geldanamycin (uM) 
Figure 5.4.Trp fluorescence experiment of GA binding to full length C. elegans Hsp90. The emission 
data was corrected with equation 1 and fitted with equation 2. The binding was very weak with a Kd of 
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Figure 5.5. Graph of the Trp fluorescence observed upon binding between CeHsp90-492 and 
novobiocin. The emissions data were corrected against dilution effects, the inner filter effect and the 
background fluorescence of novobiocin. The data was fitted to a two site binding model using equation 3. 
The fitted curve gives two Kd's indicating both specific and non specific binding of novobiocin. The 
specific Kd of the interaction is 2.48 ± 1.8 jLM 
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5.3.3.2. Trp fluorescence showed novobiocin bind to ceHsp90-492 
The next ligand used in the study was novobiocin. Novobiocin has been shown 
to bind to the C-terminal domain of Hsp90 [11, 12]. In this study, Trp fluorescence was 
used to monitor the interactions of ceHsp90-492. Fluorescence was carried out by 
exciting the samples at 295 nm and measuring the emission at 355 nm. The slits for the 
experiments were both set at 2.5 mm. The emission data were corrected against the inner 
filter effect and the background. The corrected emissions were plotted against the 
concentration of novobiocin and then fitted using equation 3. From the graph, the Kj of 
the interaction of ceHsp90-492 with novobiocin is 2.48 ± 1.8 jM (Figure 5.5) 
5.3.3.3. The interaction of ATP with both of the C.elegans protein constructs 
In addition to the ligands discussed above, determining the nature of the 
interaction between C. elegans Hsp90 and ATP was also of great interest. The 
interactions of ATP with various species of Hsp90 including human and yeast are well 
studied and documented, however little is known as to the nature of the potential 
interactions with the C. elegans Hsp90 homolog. The data obtained from such studies 
could be very useful in shedding light onto the differences between species. The 
interaction between ceHsp90 and ATP was investigated using fluorescence as described 
previously. The experimental method involved exciting the samples at 295 nm and 
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Figure 5.6. Graph of the Trp fluorescence observed upon binding of CeHsp90 with ATP. ATP was 
titrated into a 1 M solution of protein. The emissions at 355 nm were measured and corrected against the 
dilution factor. The data was plotted and fitted using equation 2. a) Graph of the interaction of ceHsp90 
with ATP .The Kd obtained was 80,1 ± 13.6 AM. b) The graph of the interaction of ceHsp90-492 with 
ATP. The Kd obtained was 81.4 ± 14.6 AM. 
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background fluorescence and the inner filter effect was consequently negligible. The 
corrected emissions were plotted against the concentration of ATP and the data fitted 
using equation 2. From the graph, the Kj of the interaction between ceHsp90 and ATP is 
80.1 ± 13.6 AM. The Kj for the interaction between the ceHsp90-492 and ATP is 81.4 + 
14.6 AM (Figure 5.6). 
5.3.3.4. ATPase activities showed in both of the C.elegans protein constructs 
ATPase activity assays of these proteins were also carried out using the 
malachite green assay. The experiments were carried out at 37°C. The incubation 
periods were 30 min for ceHsp90 and 60 min for ceHsp90-492. Malachite green was 
added after the incubation period and the absorbance of each of the samples at 620 nm 
was measured. The absorbance at 620 nm for each concentration was subtracted from 
the absorbance of ATP alone without the protein. The corrected data were plotted and 
fitted using equation 4. The experiments were repeated three times. From the ATPase 
assays, the 'cat  for ceHsp90 is 0.354 ± 0.05 min'. The Km for the reaction is 288 ± 11.6 
M (Figure 5.6). No ATPase activity was detectable when the experiment was repeated 
in the absence of Mg2 in the buffer suggesting that Mg2 was needed to coordinate the 
hydrolysis of ATP. The ATPase assay was also used to characterise the activity of 
ceHsp90-492, the Kcat of this reaction was 0.010 ± 0.00013 min 1 and the Km is 327 ± 
0.12 AM (Figure 5.7). 
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Figure 5.7. The ATPase activity of C. elegatis protein and its inhibition of by novobiocin and 
geldanamycin. a) The ATPase activity of ceHsp90 and ceHsp90-492 was determined using the malachite 
green assay. The Kcat  for ceHsp90 is 0.354 ± 0.05 min' The Km  for the reaction is 288 ± 11.6 AM. The 
Kcat for ceHsp90-492 was 0.010 ± 0.00013 mm' and the Km iS 327 ± 0.12 /LM. b) The inhibition of ce 
Hsp90 ATPase activity by novobiocin and GA. No significant inhibition was observed when GA was 
used. Inhibition of the ATPase activity was observed when novobiocin was used. The IC50 determined 
from the inhibition data gives a value of 6.61 ± 2.48 AM, the K1 of the reaction was 1.48 ± 0.55 AM. 
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5.3.3.5. The inhibition of ATPase activities of both of the C .elegans protein 
constructs 
Novobiocin was also used in ATPase inhibition experiments with both of the 
available constructs. In addition to the experiments with novobiocin, GA was also used 
to investigate inhibition of ceflsp90 ATPase activity despite a recent report [8] that this 
protein was resistant to the drug. Approximately 25 % of the ceHsp90 ATPase activity 
was inhibited by novobiocin (Figure 5.7). The IC50 determined from such an inhibition 
gives a value of 6.61 + 2.48 M. The IC50 was obtained by fitting the curve of the 
relative percentage rates of ATPase activity with equation 5. Using equation 6, the Ki of 
the reaction was determined to be 1.48 + 0.55 ItM. ATPase activity of ceHsp90-492 was 
80% inhibited by novobiocin (Figure 5.8) at maximum concentration of 50 jiM. The 
IC50 of the inhibition was 15.1 ± 4.9 jiM. Based on the IC50, the calculated K1 was 3.7 ± 
1.2 jiM. No such inhibition of ATPase activity was observed when GA was tested in the 
same assay system (Figure 5.7). The concentration of GA used ranged from 1 to a 
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Figure 5.8. ATPase activity and inhibition of ceHsp90-492. a) The ATPase activity of ceHsp90-492 
was determined using the malachite green assay method. The Kcat for ceflsp90-492 was 0.010 + 0.00013 
min-' and the K. is327 ± 0.12 ItM. b) Inhibition of the ATPase activity of ceHsp90-492 with novobiocin. 
The IC50 of the inhibition was 15.1 + 4.9 pM. Based on the IC50, the calculated K1 was 3.7 ± 1.2 ItM. 
5.3.4. Crystallization trials of C.elegans Hsp90 proteins 
All the proteins were subjected to crystallization trials using the hanging drop 
vapour diffusion method as outlined in Chapter 2, section 2.5.1. The plates initially set 
up explored a range of possible precipitants including AS, various PolyEthyleneGlycols 
5-23 
(PEGs) and a number of commercially available screening kit such as Structure screens 
1 and 2 (MDL), Premier, Classic and PEGS from (Nextal). The crystallization trials, 
unfortunately did not produce any crystals. Crystalline precipitate was observed in a 
number of drops, however optimization of the conditions around those producing 
crystalline precipitate still did not yield any crystals. 
5.4. Discussion 
5.4.1. CeHsp90-492 exists as a dimer 
As mentioned before, this chapter outlines the series of experiments used to 
investigate and characterise C. elegans Hsp90. The experimental design was similar to 
that used in Chapter 4 section 4.2.3 when characterising the C-terminal domain of Hsp90 
human a. There were however a number of significant differences in the approach taken 
between the two series of experiments, these will be discussed in greater detail later in 
this chapter. The purified proteins were produced as described in Chapter 3, section 
3.2.4. Gel filtration experiments of the ceHsp90-492 using a Superdex 200 column 
showed that the protein was running with an estimated molecular weight much larger 
than the sequence alone would have suggested (Figure 5.1), likely indicative of the 
protein having a more elongated shape rather than a compact globular shape, similar to 
the situation seen with human hHsp90-a52 1. It has been suggested that Hsp90 is an 
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asymmetrical and oblong molecule [23] Recent structural studies have shown that the 
structure of the C-terminal of yeast Hsp90 was almost identical with the structure of 
htpG [1, 10]. In both structures, the dimerisation domain is contributed by two helices in 
the region from 584 to 624 in htpG and region 632 to 677 in yeast Hsp90. In addition, 
residues 587-610 of yeast Hsp90 are also involved in the formation of dimer. Sequence 
alignments between the yeast Hsp90 and ceHsp90 showed that the dimerisation motif 
was conserved, thus suggesting ceHsp90-492 exists as a dimer. 
5.4.2. C. elegans Hsp90 binds to Cyp40 
C. elegans Hsp90 or daf-21 shares with the human protein the presence of the 
MEEVD motif at the extreme C-terminus of the protein. These residues have been 
shown to be important in the binding of Hsp90 to the TPR containing proteins [3, 6, 7] 
including Cyp40 [4, 24], Stil [9, 18], PP5 [7] and many others. Cehsp90 and ceHsp90-
492 were shown to bind to Cyp40 based upon the results of the Trp fluorescence 
experiments. CeHsp90 interacts with Cyp40 with a Kd of 79.3 ± 7.4 JtM whereas 
ceHsp90-492 interacts with Cyp40 with a Kd of 140.3 ± 7.9 JLM.(Table 5.1). The 
binding of ceHsp90- 492 with Cyp40 was also shown by the SPR. The Kd 
E,  of the 
reaction was 107.1 ± 18.8 M. The KdEq  from SPR was in agreement with the Kd from 
Trp fluorescence. However, the on and off rate of as well as the kinetic dissociation 
constant of the binding were unavailable. This is due to the rapid association and 
dissociation of the complex where it is not possible to monitor them. It is shown from 
the experiments above; that binding of full length daf-21 to Cyp40 was tighter than the 
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binding seen with the C-terminal domain alone. These results showed that the interaction 
was not only caused by the C-terminal alone but it can be enhanced by the wild type 
protein thus, suggesting there is cooperation between other regions in the N and middle 
domains of C. elegans Hsp90 that are involved in the promotion of the interaction 
between Hsp90 and its partner proteins. Inter domain co-operation could result in an 
altered conformation of the full length protein having greater affinity to Cyp40. The 
effect of conformational flexibility was observed in the binding of p23 to Hsp90 where 
the proteins can only interact when Hsp90 has ATP bound [1, 5, 26]. ATP binding to 
Hsp90 is also affected by the conformation changes seen when Hsp90 converts from 
dimer to monomer [14]. 
5.4.3. C. elegans Hsp90 binds ATP and exhibits ATPase activity 
As expected, ceHsp90 exhibited binding to ATP similar to that seen in other 
species such as yeast Hsp90 [14, 16] and human Hsp90 a [13 17, 18] The Kd of the 
interaction of ceHsp90 with ATP is 80.1 ± 13.6 jM.(Table 5.1) The Kd was obtained by 
fitting the curve with an equation using a single binding site model. The curve was also 
fitted using a two binding sites model equation which gave a very similar Kd but with a 
large error. There is also evidence that shows the second binding site at the C-terminal 
was hidden and only open when the N-terminal site was occupied [21]. Thus, suggested 
that, sequential binding occurs in the interaction. Observations from the data obtained in 
this series of experiments comparing the interactions of the ceHsp90 and ceHsp90-492 
suggested that the binding of ATP could occur sequentially between N and C-terminal 
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domains. However, Tip fluorescence measurement were of limited value in detecting 
sequential binding events, by simply fitting the curve with a two sites binding model 
equation did not provide strong evidence to support the model. Further experiments with 
the aim of confirming the sequential binding events were carried out by using isothermal 
titration calorimetry (ITC). However, the energy difference between the titrations was 
too small to be used for analysing the interaction. 
5.4.4. Inhibition of the ATPase activity 
The Kd obtained here was lower than that observed for Hsp90 human a, which 
is 240 ±14 jiM (from stop flow fluorescence experiments) [13, 14] and also for yeast 
(132 ±. 47 jIM) [14] which suggested that the interaction was slightly tighter with 
ceHsp90. The ATPase activity of ceHsp90 by malachite green assay showed a Kcat of 
0.354 ± 0.05 min-1 which is slower than yeast Hsp90 that has a Kcat of 0.4 min-1 [15, 
16] but faster than human Hsp90 which is 0.092 min' [14]. In the yeast Hsp90 ATPase 
cycle, it has been proposed that the binding or the resultant conformational change of 
Hsp90 is the rate limiting step [25]. However, there is also a finding suggesting that the 
cleavage of ATP is the rate limiting step in the Hsp90 ATPase cycle [14]. Our results 
show that ATPase activity was increased from human Hsp9O to ceHsp90/yeast and their 
binding affinity to ATP also increased suggesting that the binding of ATP probably 
helps to facilitate the ATPase cycle to become faster than the full length human Hsp90 
91 
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ATPase activity was also detected in the ceHsp90-492 construct but at a very low 
level. The ATPase activity at the C-terminus is only 5% of that seen with the whole 
protein. Indirectly, this also supported by the facts that the C-terminal Hsp90 also bind 
to ATP [11, 121. Our results also showed that 25% of the ATPase activity of the full 
length protein can be inhibited by novobiocin. Further experiments showed that 
novobiocin inhibited 80% of the cellsp90-492 ATPase activity. Previous studies showed 
that novobiocin can disrupt the Hsp90 dimer formation [2]. Therefore it is likely that the 
25% inhibition observed was probably as a result of the disruption of the dimer of 
Hsp90. However, the inhibitor constants (Ki) obtained from 25% of the inhibition is 
1.48 ± 0.55 ItM and is very similar to the Kd of novobiocin binding to ceHsp90-492 (as 
determined by fluorescence) which is 2.48 ± 1.8 jzM (Table 5.1). In agreement with this, 
the Ki obtained from the C-terminal of daJ21 (ceHsp90-492) ATPase inhibition was 3.7 
± 1.2 M (Table 5.1) which is once again very similar to the other dissociation constants 
derived from this series of experiments. Only 20% of the C-terminal Hsp90 dimer was 
disrupted at 100MM of novobiocin [2], but from our results 80% of the ATPase activity 
was inhibited when 50 IM of novobiocin is used. This suggested that the ATPase 
inhibition of the full length or the C-terminal Hsp90 was mainly caused by the binding 
of novobiocin to the same site for ATP. However, the disruption of dimer formation can 
also contribute to the ATPase inhibition especially if a high concentration of novobiocin 
was used. 
The effect of GA on the ceHsp90 ATPase activity was also investigated, but no 
effect was seen at the concentrations tested. Previous studies [8] indicated that the 
C. elegans Hsp90 was resistant to GA. This study showed that immobilized GA did not 
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bind to daf-21. In order to further investigate the interaction of ceHsp90 and GA, Trp 
fluorescence was used to examine the effect of titrating the drug into ceHsp90. 
Surprisingly, GA binds to ceHsp90 with Kd of 298.0 ± 88.5 jtM (Table 5.1). The 
binding was very weak and the ATPase inhibition was only tested up to 200 jM of GA 
which not enough to inhibit the ATPase activity. GA binds to yeast Hsp90 with a Kd of 
1.2 jiM [19]. Yeast Hsp90 ATPase activity was also 50% inhibited by GA with 1050 of 
4.8 ± 0.8 AM [20]. 
5.5. Conclusion 
In this chapter the results of the biochemical and biophysical characterisation of 
both full length cehsp90 and its C-terminal domain are presented. The interaction with 
immunophilins showed that the full length protein binds more tightly to its partner 
protein than the C-terminal domain alone suggesting there is cooperation between 
domains. In addition, full length protein was also properly folded which contributes to 
the better interaction with immunophilins compare to the C-terminal domain alone. The 
ATPase activity of the wild type was reduced by novobiocin which disrupts the dimer 
formation and inhibits the C-terminal domain ATPase activity. GA was shown to bind 
weakly to the C. elegans Hsp90 and did not inhibit the ATPase activity at concentration 
of GA up to 200 jiM, this is consistent with inhibitor not working very well to inhibit C. 
elegans Hsp90. The findings will help provide in understanding of the structural and 
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25 ATP Trp 81.4± 5.6 
fluorescence 14.6  
37 ATP Malachite 327±0.12 0.010 57 
green ATPase ±0.00013 &5.8 
assay  
25 Novobiocin Trp 2.48± 55 
ceHsp90-  flourescence 1.8  
492 37 Novobiocin Malachite 15.1 ± 4.9/ 5.8 
green ATPase 3.7 ±1.2 
assay  
25 Cyp40 Trp 140.3 5.2 
fluorescence ±7.9  
25 Cyp40 SPR 107.1± 5.3 
18.8  
25 ATP Trp 80.1± 5.6 
fluorescence 13.6  
37 ATP Malachite 288± 11.6 0.354± 57 
green ATPase 0.05 
assay  
25 Novobiocin Trp 
fluorescence  
37 Novobiocin Malachite 6.61 ± 2.48/ 5.7 
ceHsp90 green ATPase 1.48 ± 0.55 
assay  
25 Geldanamycin Trp 298 ± 5.4 
fluorescence 88.5  





Trp 79.3 ± T 5.2 fluorescence7.4  
Table 5.1. List of the results obtained from all the experiments carried out to the C. elegans Hsp90 in chapter 4 
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Chapter 6: General conclusions and future work 
6.1. Summary 
The thesis described the study of the Hsp90 proteins from homo sapiens (Hsp90 
human a) and Caenorhabditis elegans. The study involved the characterisation of the 
function of Hsp90. The aims of the study were 
. To characterise the interactions of the C-terminal and full length Hsp90 with 




	To characterise the interactions of C-terminal and full length Hsp90 with small 
ligands such as novobiocin, ATP and geldanamycin by biochemical and 
biophysical methods. 
Table 6.2 at the end of the chapter, summarises the main results of experiments 
described in the thesis. 
6.2. Sequence alignment of Hsp90 C-terminal domains 
From sequence alignment of Hsp90, the identities between species are about 60 
to 70% except with htpG which is significantly lower at 30%. The alignment of the C- 
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terminal sequence of ceHsp90-492, yeast Hsp90 and htpG to hHsp90-a521 give a 
identity of 74%, 50% and 25% respectively (Figure 6.1). From the alignment of the 
sequence, hHsp90a52 1 and ceHsp90-492 are very similar and are expected to have 
similar functions. 
10 	20 	30 	40 	SO 	60 	70 	80 
hsp90A 	IEPIDEYCVQQLKEFEGKTLVSVTKEGLELPEDEEEKKK- QEEKXTKFEllLC1flDILEXEK'JWSllRLVTS'CCIVTSTYtWTAfl 
hsp82 yeast TDPIDEYAFTQLKEFEGKTLVD IT! D-FELEETDEEKAE-REKEIKEYEPLTXALKEILGDQVEKVVVSIKLLOAPAAIRTGQFGWSAU 
cehsp90_492 CDP 1DEYCVQQLKEYD GMMVSVTKEGLELPETEEEIcX-FEEDKVAYEflLCRVIKO ILERVEKVGVS1TRLVS SPCC PJTSEYGWSAII 
htpGecoli SDRIDEWMTYLTEFDGKPFQSVSKVDESLEKLADEVDESAKEAEKALTPFIDRVKALLGERVEDVRLTHRLTDTPArVSTDADEIISTQ 
110 	120 	130 	140 	150 	160 	170 	180 	1 
hspgOA 	DIISTftGHJAKKHLEIlWDHSIIETLRQKAEAD-KUDKSVKDLVILLYE TALL SSGF SLED P QT){AIIRIYRftIKLGLGIDEDDPTADDT 
hsp82 yeast DSMSSYO1SSKKTFEISPKSPIIKELKKRVDE L;(;AQDKTVKDLTKLL1TALLTSGFSLDEPTSFASRINRLISLGLNIDEDEETETAP 
oehsp90_492 DSSTMGil.1AAKK1fLEINPDHAD(TLRDRVEVD-fOmKTVXDLWLLFETALLASGF SLEEP QSllASRIYRMIKLGLDIGDDEIEDSAV 
htpGecoli VP ------ EVKYIFELNPDEVLVKRAJkDTEDEA ----- KFSEWVELLLDQALLAERGTLEDP11LFIRR111!QLLVS-------------- 
210 
hsp90A 	EtDDDTSRUEEVD 
hsp82 yeast PAD--- TEMEEVD 
cehsp90_492 GAEEDASR11EVD 
htpG_ecoli 
Figure 6.1. The sequence alignment of C-terminal human 11sp90 a (hHsp90-a521), yeast hsp82, 
daf2l(C. elegans) and htpG 
The secondary structure prediction of the hHsp90-a521 and ceHsp90-492 
indicates that both of the sequences comprise six a helices and either three or four 1 
strands. However, the location of the helices and the f3-sheets were slightly different. 
Both of the proteins contain the C-terminal MEEVD motif and were shown to bind to 
the TPR containing protein Cyp40. 
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Figure 6.2. The secondary structure prediction for the C-terminal human Hsp90 a and C. elegans-
daJ21. The secondary structure predictions of both of the proteins were compared side by side. They both 
contain the same number of a helices with just one extra 0- sheet strand on ceHsp90 492. The location of 
the helices and f3-sheets also a bit different. However, both contain the MEEVD motif at the C-terminus. 
6-3 
6.4. C-terminal domains bind to Cyp40 
Both of the proteins were shown to bind to Cyp40 and biophysical analyses have 
been carried out to study the interactions by using SPR, Trp fluorescence and gel 
filtration. Based on these experiments, figure 6.3 illustrates the mechanism of interaction 
starting from the ATPase cycle. The illustration was adapted and modified from [17] 
with the addition of the Cyp40 cycle based on our study. 
The study described in chapter 4 (section 4.2.3) and chapter 5 (section 5.2.2) 
showed that Cyp40 binds to Hsp90 through its C-terminal with a stoichiometry of one 
monomer of Hsp90 to one monomer of Cyp40. The dissociation constants of the 
interactions obtained from our study were in the micromolar concentration range. The 
following sequence of events is suggested: ATP and Cyp40 binds to Hsp90. ATP also 
induces a conformational change. Later on, Cyp40 is released when ATP is hydrolysed 
to ADP. Evidence to support this scheme was obtained from a study of Stil and Cpr6 
binding to yeast Hsp90 [15]. However, Hsp90 can still bind to Cyp40 without its N and 
middle domains. The affinity of the binding can be enhanced with the use of full length 
protein as was shown with C.elegans Hsp90. There is also an evidence from the study of 
Hop where the N and the C-terminal domains of Hsp90 are needed to maintain its 












KdEq 95-107 uM 
TP hydrolysis 
Figure 6.3. Illustration of the binding of Cyp40 to the Hsp90. The kinetic and binding data were 
obtained from our study using SPR and tryptophan fluorescence. The illustration was adapted and 
modified from Richter and Buchner [17]. The illustration did not consider the binding of p23 to the N-
terminal domain during ATP bound form. 
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6.5. Sequence alignment predicted possible binding site for ATP and 
novobiocin 
From our results, hHsp90 a521 and ceHsp90 492 bind to ATP and novobiocin. 
Both of the proteins also have low ATPase activity and can be inhibited by low 
concentrations of novobiocin. However, we do not yet have information on how ATP 
binding and ATPase activity of the C-terminal Hsp90 influences the function or 
mechanism of Hsp90. In order to obtain more information on ATP binding and 
hydrolysis, the sequences of the C-terminal Hsp90 of four of the Hsp90 species which 
are yeast, human a, C. elegans daf-21and htpG E. Coli were aligned and analysed. 
The sequences were compared to ABC transporters that are known to bind and 
hydrolyse ATP.[3, 7, 9] ABC transporters have two nucleotide binding subunits (NBDs) 
which power the transport and hydrolysis of ATP. Several conserved sequence motifs 
such as Walker A and Walker B motifs can be found in the proteins [6]. In the NBD 
domains, the Walker A motif consists of the GXXGXGKS/T sequences. This Walker A 
motif or also known as the P loop, binds to the a and f3 phosphate of ATP or ADP. The 
Walker B motif consists of XXXXDE sequences where the X amino acids were usually 
aliphatic residues. The Walker B motif coordinates the binding of Mg2 via its Asp 
residue, which follows the motif binds to the attacking water and Mg 
2+  and may act as 
the catalytic base for the hydrolysis. There is also a Q loop which is made of by Gin 
followed by Glu which acts as the lid that bind to 7-phosphate as well as bind to the 
attacking water and Mg2 . In ABC transporters the linker motif LSGGQ binds to the - 
Table 6.1. Function of conserved motifs in the nucleotide binding domain of ABC transporter. The 
table was adapted and modified from [6] 
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phosphate of ATP but only in the dimer forms. Dimerisation is needed for the ABC 
transporters to become catalytically active as the LSGGQ motif binds to they phosphate 
of ATP. However, ATP needs to bind to each of the monomers before the LSGGQ motif 
can bind to the ATP. The conserved motifs in ABC's NBD were listed in Table 6.1 
which was modified from [6]. 
From alignment of the C-terminal Hsp90 sequences, only three residues 
(GKT/K) at the end of the Walker A motif were identified in the C-terminal Hsp90 
(Figure 6.4). The Walker B sequence was also identified in the C-terminal domains of 
the four species of Hsp90 that were used in the alignment, however the amino acid 
residues before Asp-698 is a glycine residue (Gly) whereas in ABC transporters it is 
either leucine (Leu) or isoleucine (Tie). The Walker B motif in the C-terminal sequence 
was followed with Glu-699, which is also present in ABC transporters. The putative Q-
loop is only found in human Hsp90 a and not in other species from the alignment. The 
LSGGQ motif was also found in the C-terminal of Hsp90 but in the sequence of LXSGF 
and overlaps with the novobiocin binding site. The motif was most similar to human 
Hsp90 a compared with Hsp90 from other species human Hsp90 a contains the 
sequence LSSGF instead of LSGGQ. 
The presence of the ATP-binding motifs identified in the C-terminal sequences, 
suggest the presence of an ATP binding pocket. Novobiocin probably binds to the 
LXSGF motif and inhibits the ATPase activity of the C-terminal. All the motifs 
mentioned in ABC transporters were more similar in human Hsp90 a rather than Hsp90 
C.elegans or other Hsp90 species. We suggest that this is the reason for higher ATPase 
activity of hHsp90 a521 compared to ceHsp90 492. In summary, we suggest that, based 
LS 
on the sequence comparison of Hsp90 with ABC transporter that ATP binds to the C-






hspB2 yeast TDPIDEIAFTLKEFEVDITKD-FELEETDEEKPJRE IKIEPLTI(ALXEILGDQVEKJWS1LLDPPAAIRTGII1SAIIN 
cehsp90 492 CDPIDEYCVLKEID VSVTKEftELPETEEEXKIFE DXVAYE1LCKVIXUEVS111LVSSPCC1VTSEYGWSA11N 
hsp90 A 	IEPIDEIVLKEFE 	KKTKFE11LCKBDILEKVEKWS11ILVTSPCCIVTSTYGWTAI1I 
l{tpg e,eeli ------------------------------------------------S1IDRVKPLLGEKDVRLT}tRLTDTPAIVSTDADEHSTQH 
ncvobiocin hiding dite 	Walker B 
I I 	 __ 
hsp82 yeast SMSS1SSKKTFEISPKSPIIKEL 	DEADKTVKDLTKL TALLTSGFLUtP SFASRIllPLILL1lIDEETETPPE 
cehsp90 492 SSTh AA1LEIllPDllABlKTLfliEVD-KNFKTVKDLWL ETALLAS(F SLEEP SlfISRIY1MI4L1LDIG*EIEDsAVP 
hsp90 A 	llS11fAA1cKlILEIllPDHSIIETLlKEAD-KNbKSVKDLVIL TALLSSF SLEDP T1{ANRIYRMI4LGLGIDDPTADDTS 
Htpq e.coli P------EflYIFELWPDH1LVAfl)EDEA-----KESEWEL DALLAERGELEDP LFIRRMNLL4S---._J--------- 
hsp82  yeast AD --- TEMEEVD 
eehsp90 492 AEEDASPHEEVD 
hsp90A 	GDPDTSPMEEVD 
Htpg e,coli ------------ 
Figure 6.5. Sequence alignments of yeast, daJ21, human a and htpG C-terminal Hsp90 to show the 
motifs involved in ATP binding and hydrolysis. The motifs are boxed and labelled on top for clarity. 
66. Possible mechanism for ATP binding and novobiocin inhibition 
Recently, the crystal structure of the full length yeast Hsp90 has been solved and 
published l]. By using the solved structure as the template, the C-terminal domain of 
MOO 
human Hsp90 a was submitted to Swiss-Model to obtain the structural model. The C-
terminal of C.elegans should be very similar to the human as their sequence is 75% 
identical. This modelling part was done by Mr. Liam Worral. The template for 
modelling utilised the closed (PDB Id 2CG9) and open (PDB Id 2CGE) yeast crystal 
structures recently deposited. The closed structure refers to the ATP bound state of the 
N-terminal domain. From the modelled structure, the binding site for ATP and 
novobiocin were predicted by using MEdock software [4]. 
Novobiocin has the preference to bind to the YETALLSSGF motif (Figure 6.7.). 
Biologically, the site was predicted to bind to novobiocin [10, 11] and later on, 
novobiocin was shown to disrupt the dimer formation of C-terminal Hsp90 [2]. From the 
htpG structure, the novobiocin binding site is also located in the helices that form the 
dimerisation motifs. In addition, our modelling structure also showed that novobiocin 
binds to the YETALLSSGF motif. Therefore, it seems likely that novobiocin binds to 
the YETALLSSGF motif and can cause the disruption of the dimer. 
Our results showed that ATPase activity can be inhibited with novobiocin and 
from the sequence alignment the novobiocin binding site consists of the LSSGF residues 
that resembles the LSGGQ motif needed for ATP binding and hydrolysis in ABC 
transporter. Therefore, by considering all of the information the YETALLSSGF motif is 




Figure 6.7. Novobiocin binds to the C-terminal human Hsp90 a model structure. a) Surface view of 
the model structure with novobiocin binds to the binding pocket. The red colour shows the 
YETALLSSGF motif. b) Ribbon view of the model structure with novobiocin binds at the binding site. c) 
Cartoon view shows novobiocin binding to the binding pocket. 
to identify the possible binding site for ATP. The closed structure was used as the 
template because it is thought that the binding to the C-terminal will resemble the closed 
conformation of the yeast crystal structure. Interestingly, two ATP molecules were 
found to dock on the dimer molecule (Figure 6.8). One of the ATP molecules occupied 
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the same binding site for novobiocin which is at the YETALLSSGF motif. The other 
binding site for ATP was also near the same motif (Figure 6.8). Therefore, ATP did bind 
to the same binding site as novobiocin. In addition there is also another binding site for a 
second ATP. The possible reason for this is that when the first ATP binds to the same 
site as novobiocin, it makes the second site available to bind to another ATP molecule, 
thus suggesting that second ATP binds to the dimer sequentially. After that, both of the 




Figure 6.8 .Two molecules of ATP bind to the C-terminal binding pocket.of human Hsp90 a a) 
Surface view of novobiocin binding pocket without novobiocin molecule. b)Surface view of l ATP 
binds to the binding pocket. The second binding pocket becomes available. c) Cartoon view of the 1st 
ATP in the binding pocket. d) Surface view shows both ATP molecules in the binding pocket. e) Cartoon 
view shows the binding of both ATP to their binding pocket. Red colour in all the panels show the 
position of the YETALLSSGF motif. 
Further increase in the novobiocin concentrations will disrupt the dimer. The 
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Figure 6.9. Illustration of the mechanism of ATP binding to the C-terminal.of Hsp90. 1) C-terminal 
dimer formation at its free state without novobiocin or ATP bound (see figure 6.8a). Only one binding 
pocket available 2) In the presence of ATP, the dimer binds to 1st  ATP (see figure 6.8b and c) and makes 
the second binding pocket available. 3) Both of the binding pockets occupied by ATP molecules (see 
figure 6.8d and e). 4) ATP hydrolysis occurs and ADP are released. In the presence of novobiocin, the 
dimer moves from 1 to 5 by binding to novobiocin (see figure 6.7). ATP is inhibited from binding to the 
C-terminal as the binding pocket is occupied by novobiocin. 6) Novobiocin disrupts the dimer formation 
as previously suggested [2]. 
In earlier discussion in this chapter, we predicted several motifs involve in the 
binding and hydrolysis of ATP such as Walker A and Walker B, and from the structure 
C-terminal Hap90 
dlni.r 
modelling it is almost convinced only LSGGQ was involved and not the other motifs 
mentioned above. However, it is still unsure if the other motifs were totally secluded in 
the binding of ATP and novobiocin. There is no other proof available yet to verify this. 
In future, more experiments are planned to go deeper to prove this. 
6.7. Future work 
The binding of Cyp40 to the C-terminal Hsp90 was confirmed in these studies. 
Furthermore, ATP binding and hydrolysis were also shown by various methods. Further 
study will be to verify the significance of the binding sites of ATP in the C-terminal 
Hsp90.This can be done by site directed mutagenesis on the residues that may be 
important for the binding or by producing protein constructs that have the residues 
deleted. More information can also be obtained if the full length human Hsp90 is 
available and utilised in the mutagenesis study to investigate the roles of ATP binding 
site on the C-terminal to overall structure and function of Hsp90. 
It is also of interest to investigate the relationship of the ATP binding site at the 
C-terminal domain with the binding of co-chaperones at the MEEVD motif. This can be 
done by using SPR to study the mode of binding of both components to the C-terminal 
of Hsp90 as well as ATPase activity assay. Novobiocin was shown to bind to C-terminal 
Hsp90 and compete with ATP binding. It will also be of interest to investigate if 
novobiocin can inhibit the binding of co chaperones at the C-terminal and get more 
MWO 
information on the kinetic of the interaction. This can be done by using the SPR and also 
ITC. Furthermore, the effect to the structure of C-terminal during the binding or 
inhibition can also be monitored by using circular dichroism. 
GA was shown to bind weakly to the full length of daJ21 and our attempt to 
produce the N-terminal of Hsp90 of C.elegans daJ21 was not successful since the 
protein was very difficult to purify. Further future experiments should also include 
recloning the protein with C-terminal histidine tag using other vectors. Hopefully, the 
protein can be purified and can be used in crystallisation to see the difference in its 
structure compare to the other N-terminal structure that have been solved. The protein 
could also be used for further characterisation in finding other ligands more potent than 
GA but less toxic. 
Since the structure of htpG and yeast Hsp90 were solved, reliable models of the 
C-terminal domains of other species of Hsp90 can be generated. The models should 
provide suggestions for site-point mutations that could lead to the design of more stable 
Hsp90 C-terminal domains as well as mutants that lack of the unstable loop can be made 
to produce proteins that suitable for crystallisation. 
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Protein T Ligand or Methods Kd (tM) ICSO/Ki Km (IiM) k0 (M' s) k0ff (s') Kd in (jiM) kcat Kjimer Figure! 
(°C) inhibitor  (UM)  (min 1) QiM) ref 
4 ATP Hummel-Dreyer 300 ± 90  4.11 
25 ATP Trp fluorescence 101± 15  4.10 
37 ATP Malachite green 377 ± 101 0.021 4.12 
ATPase assay  ±0.002  
25 Novobiocin Trp flourescence 1.26± 4.13 
0.46  
20 Novobiocin ITC 3.7 ± 4.13 
0.04  
37 Novobiocin Malachite green 10.8 ± 4.14 
hHsp90 ATPase assay 6.8/ 
a521 2.79 
±2.02  
25 Cyp40 Trp fluorescence 66 ± 17  4.7 
25 Cyp40 SPR 95.7 ± 0.018± 1.3 ±0.3 76 ± 19.5 4.9 
19.5  0.002  
Cyp40 Gel filtration  4.6 
4 ATP Hummel-Dryer No 
binding 
observed 
37 ATP Malachite green No 
ATPase assay ATPase 
hHsp9O______  activity  
a631 25 Cyp40 Trp fluorescence 39 ± 7.4  4.7 
4 Cyp40 Gel filtration  4.5 
4 Gel filtration 4.98 ± 4.4 
2.12 
25 ATP Trp fluorescence 81.4 ± 5.6 
14.6  
37 ATP Malachite green 327± 0.12 0.010 5.7 
ATPase assay  ±0.00013  &5.8 
25 Novobiocin Trp flourescence 2.48± 5.5 
1.8 1 _ 
MR 
ceHsp90 37 Novobiocin Malachite green 15.1 ± 5.8 
492 ATPase assay 4.9/ 
3.7 ±1.2  
25 Cyp40 Trp fluorescence 140.3 5.2 
±7.9  
25 Cyp40 SPR 107.1± 5.3 
18.8  
25 ATP Trp fluorescence 80.1 ± 5.6 
13.6  
37 ATP Malachite green 288 ± 0.354 ± 5.7 
ceHsp90  ATPase assay  11.6  0.05  
25 Novobiocin Trp fluorescence  
37 Novobiocin Malachite green 6.61 + 5.7 
ATPase assay 2.48/ 
1.48 ± 
0.55  
25 Geldanamycin Trp fluorescence 298 ± 5.4 
88.5  
37 Geldanamycin Malachite green No 5.7 
ATPase assay inhibitio 
n 
25 Cyp40 Trp fluorescence 79.3 ± 5.2 
7.4  
10 AMP-PNP 





Stopped flow 284±26 
1.0(±0.1)xl 
16.3±2.3 161±24 
 fluorescence 0 [13] 
25 AMP-PNP ITC 148±12  
Human 25 ATP 




Hsp90 Stopped flow 
25 ADP fluorescence 7.2±0.3 
37 ATP 
Stopped flow 840±6o 
0.09± [12] 
fluorescence 0.006 
37 AMP-PNP ITC 790±45  
6-19 
37 ADP ITC 41±4  
Stopped flow 3.7(±0. 7.2±1.61)xl 
[13] 
25 ADP 11±2 2.7±1.6 fluorescence 
Human 25 AMP-PNP ITC 7.4±0.9  
Hsp90+G 25 ATP ITC 15±1  
R 25 ADP ITC 41±6  
25 AMP-PNP ITC 80±40  
Human 
Stopped flow 0.0072 ± Hsp90AC 37 ATP fluorescence 
230±10 0.003. 
[8] 
Pig Brain ATP ITC 100 
Hsp90  
ATP Trp fluorescence 40  
37 ATP  0.78  [16] 
25 ATP  132±47  100  500  [14] 
25 ADP  9±3  150 
25 MABA-ATP 
1.6(±0.3)x 2.9±0.2 18.0±0.7 
[19] 
W  
8 .7± [18] 
 Yeast_______ 25 17-AAG_______________ ________________ _________ 2.3  
Hsp90 25 Radicicol 
0.9 ± 
4.8 ± 
25 Geldanamycin 0.8  
Table 6.2. List of the results obtained from the experiments that were carried out throughout the thesis. The results of the data that already been published 
were also listed 
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Appendix A. Crystallographic study of cyclophilin-ligand 
interactions 
A.I. Introduction 
One major aim of the work carried out in this thesis was to structurally 
characterise Hsp90 and its protein partners. Structural information from such studies will 
provide an excellent starting point for structure-based drug discovery. There are already 
some interesting published studies of small molecule Hsp90 ligands of potential medical 
relevance [1, 3, 7, 9].One of the binding partners for Hsp90 human is cyclophilin40 and 
it is of biological and possibly medical interest to study the role of cyclophilin inhibitors 
on the interaction of the large immunophilins with Hsp90. 
A second general theme of this thesis is to explore different approaches of 
studying protein ligand interactions using different biophysical techniques. The work 
described in this section outlines a novel method of studying ligand-protein interactions 
by using X-ray protein crystallography. In this study cyclophilin 3 (Cyp3) protein 
crystals were used. The ligand in this study is a dipeptide (Gly-Pro). This work is a 
continuation of the study that has been done with Cyp3 and Ala-Pro [6]. The aim of the 
study is to obtain the ligand binding constants of the interaction. The study also aims to 
compare the detailed binding differences between the two dipeptide ligands, namely 
Gly-Pro and Ala—Pro. 
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A.2. C.e!egans cyclophilin 3 (Cyp3) 
Cyclophilin 3 is the most abundant cyclophilin isoform that is expressed in the 
free living nematode Caenorhabditis elegans (C. elegans) [2]. All cyclophilins show 
peptidyl-prolyl isomerase (PPIase) activity. PPlases help the folding of the protein by 
catalyzing the cis-trans isomerization of Xaa-Pro peptide bonds (where Xaa is the 
preceding amino acid) in oligopeptides, thus accelerating the slow rate-limiting steps in 
the refolding of several proteins in vitro [4, 5, 8]. In vitro, cyclophilin accelerates the 
cis/trans prolyl isomerisation step in the folding pathway of proline rich proteins [2]. It 
has also been suggested that cyclophilin affects the dynamics of protein-protein 
interaction by preventing aggregation of early folding intermediates of protein 
substrates, possibly by acting as a chaperone. 
Cyp3 used in this study was produced in house. The crystal structure of the 
protein has already been solved and published [2]. Basically, two crystal forms were 
obtained, both as tetragonal plates. The native structure of Cyp3 is shown in figure A. 1. 
A-2 
Figure A.I. Cyclophilin 3 crystal structure. The Arg62 residue was labelled as it is the key focus on the 
study of this appendix. The structure was modified from PDB file Id I DYW by using pymol. 
A.3. X-ray crystallographic ligand binding studies using Cyp3 
Cyclophilin is a very good template to study protein and ligand interactions as 
they show a conserved backbone conformation on binding. The protein was selected as 
the template for this binding study because of the availability of high symmetry, well-
diffracting crystals which were suitable for ligand soaking experiments [2, 6]. Previous 
A-3 
studies showed that the PPIase activity can be inhibited weakly by Ala-Pro that 
exhibited a Kj of about 23.3 mM. 
These studies [6] also showed for the first time that protein crystallography could 
be used in a novel way to determine so called Kd, values - the dissociation constant of 
the ligand in the crystal. This technique involves soaking the protein crystal in a given 
concentration of ligand solution. The refined X-ray structure provides an 'occupancy' of 
the ligand in the crystal. A series of crystal structures in which the crystals have been 
soaked at different ligand concentrations can then be used to calculate the apparent 
dissociation constant by relating the refined crystallographic occupancy of the ligand 
with the ligand concentration in the soaking solution. The Kdc for Ala-Pro which was 
obtained from the ligand soaking experiment was 26.8 mM, showing close agreement 
with the value obtained from its biochemical assay [6]. 
The study described in this appendix is aimed to explore further this X-ray 
crystallographic technique and extend the series of Xaa-Pro dipeptides ligands (Gly-Pro, 
Ala-Pro and Ser-Pro) in attempt to dissect the individual contribution of the components 
to the binding interaction. Figure A.2 shows the ligands involved in the study. The other 
aim of the study is to investigate the side-chain of the Xaa moiety. The Xaa-Pro 
dipeptide ligand in this series increases in a modular fashion - H to CH3 to CH2-OH - 
with the proline moiety and the peptide bond to the Xaa amino acid common to all three. 
Therefore, any differences in binding affinities, assuming the energetic contribution of 
proline in all cases is equivalent and that the microscopic water structure around the 
binding site is also equivalent, can be attributed to the addition of a CH3 or an OH group. 
In general, the study can be used as a starting point for rational drug-design and protein 
A-4 
engineering. However, only the ligand soaking study contributed by Gly-Pro is 











Figure A.2. The Xaa-Pro dipeptide utilised in the study. The inhibitors utilised were Gly-, Ala- and 
Ser-Pro. The dipeptide ligands were different in the side chain which changes in modular fashion from H 
to CH3 to CH2-OH. 
A.4. Materials and methods 
A.4. I. Expression, purification and crystallization of C. elegans Cyp3 
The expression, purification and crystallization of C. elegans Cyp3 was carried 
out based on Doman et. al., [2]. Basically, the plasmid containing Cyp3 genes were 
transformed into BL2 1 (DE3 pLysS) cells (Novagen). Cyp3 was expressed following a 
4 h induction with 0.4 mM isopropyl-1-thio--13-D-galactopyranoside. The cell pellets were 
solubilized in lysis buffer containing 50 mM HEPES, 5 mM benzamidine, 5 mM EDTA, 
5 mM 2-mercaptoethanol, pH 7.5. Lysozyme (Sigma) was added to 0.1% w/v and 
incubated on ice for 1 h. The cell was lysed and the supernatant was obtained by 
centrifuging at 22,000 rpm for 1 hr and the pH of the supernatant was adjusted to 
6.8. Protein extract was purified to homogeneity using two purification steps: SP-
Sepharose cation exchange chromatography with the following buffers: Buffer A, 50 mM 
HEPES, 5 mM EDTA, 5 mM 2-mercaptoethanol, pH 6.8, and Buffer B, Buffer A + 0.5 M 
NaCl (pH 6.8). Column fractions were tested on 15% SDS-polyacrylamide 
electrophoresis gels and fractions containing the protein of interest were dialyzed 
overnight against Buffer A. Protein solution was filtered through a 0.2 jm filter and 
applied to Resource S resin (Amersham Pharmacia Biotech). Cyp3 was eluted from this 
resin with the following buffers: Buffer A, 20 mM HEPES, pH 6.8, Buffer B, Buffer 
A + 0.5 MNaC1. 
A.4.2. Crystallization and Gly-Pro soaking experiment 
Cyp3 was crystallized at 18°C by the hanging drop vapour-diffusion method using 
29 - 31 % poly(ethylene glycol) methyl ether 5000 (MPEG 5000) as precipitant 
[Doman, 1999 #141. Native Cyp3 crystals were soaked in 10 jil drops of well solution 
containing increasing concentrations of Gly-Pro. Crystals were soaked for between 1 
A-6 
and 3 hours. The composition of the cryoprotectant was glycerol (0.2 mL), MPEG 5000 
(0.7 mL), 1.0 M sodium citrate/citric acid (0.1 mL, pH 5.6). Crystals were mounted in a 
0.2 - 0.3 mm cryoloop (Hampton Research, Inc.), dipped in cryoprotectant for a few 
seconds, and frozen by plunging into liquid nitrogen. The frozen crystal was then 
transferred to a magnetic goniometer head in a stream of nitrogen at 100 K. All 
diffraction data were collected on a 300-mm MarResearch imaging plate system 
mounted on an ENRAF Nonius FR57 1 rotating anode generator operating at 40 kV, 80 
mA, and producing CuK radiation from a graphite crystal monochromator. 
A.4.3. Crystal data refinement 
The Cyp3 native structure was used as a starting model. Positional and B-factor 
refinement were performed using SHELX97 and the methodology described [Wu Sy, 
2001 #37]. The coordinates of Arg62, Arg621, Xaa-Prodipeptide, Wa, Wb, W, and Wd 
were fixed during occupancy refinement. Arg62n  represents the Arg62 conformation in 
the native (free) form of Cyp3 and Arg621 represents the Arg62 conformation with Xaa-
Pro dipeptide bound to Cyp3. The B-factors of Arg62, Wa, Wb, W, and Wd were fixed 
to the same B-factor values as those of the native structure. Individual atomic B-factors 
for Arg621 and Xaa-Pro were refined together with occupancy. The restraints applied in 
the occupancy refinement are summarized below: 
QArg62n + Qg621 1 
QArg62l = 
A-7 
QArg62n = Qwa = Qwb = QWc = Qwd 
Where QArg62n  is the occupancy of the Arg62 conformation in the native (free) protein, 
QArg621 is the occupancy of the Arg62 conformation with Xaa-Pro bound, and Qi  is the 
occupancy of Xaa-Pro. By regarding the crystal soaking experiment as a simple 
equilibrium in which each protein molecule in the crystal lattice can be bound or free, 
the ligand occupancy (Qi)  is related to the dissociation constant by equation 4; 
Qi = (Qrnax x [U) / ([U] + Kd) 	- 	equation. 4 
where Q is the occupancy of ligand (fraction of the protein sites in the crystal occupied 
by ligand), Kdc is the crystal dissociation constant, [L] is the concentration of the ligand 
(it is assumed that the concentration of ligand in the 10 Al drop is constant throughout 
the soaking experiment and Qmax  is the maximal fractional occupancy of the ligand at 
saturation (fixed at 1). 
A.5. Results and discussion 
Native crystals of Cyp3 were obtained after at least three days incubation at 
180C. At least two crystals were picked and soaked with series of concentrations of the 
Gly-Pro ligand. The concentrations of Gly-Pro used were 0, 6, 12, 100 and 150 mM. The 
crystal was soaked between 30 min to 2 hrs. The soaking time was dependent on the 
survival of the crystal inside the soaking solution. The crystal was observed every 30 
GlyPro 
150mM 100mM 12mM 6mM 
Space group P41212 a=b= 62.7 a=b= 61.6 a=b= 60.9 a=b= 61.5 
Cell (A) c=122.8 c=123.1 c=123.3 c=123.1 
Resolution range (A) - 35.56 -  43.44 -  3.44 -
1.78 
4  
1.72 1.60 1.60 
Number of observations 103431 117343 185734 191993 
(13246) (14723) (12950) (13360) 
Number of unique reflections 22426 24133 29409 28256 
Completeness (%) 92.6 93.1 93.6 88.5 
lI(l) 11.2 13.08 19.5 22.84 
Multiplicity 4.3 4.6 6.0 6.4 
(4.2) (4.2) (3.2) (4.4) 
R-factor (F>4SIG(F)) 0.22 0.21 0.26  0.21 
(0.20) (0.19) (0.20) (0.26) 
Rfree (F>4SIG(F)) 
0.24 0.25 0.23 0.29 
(0.22) (0.23) (0.22) (0.29) 
RMS bond lengths (A) 0.007 0.008 0.09 0.007 
RMS angle distances (A) 0.023 0.024 0.025 0.030 
Cyclophilin 3 31.895 23.377 19.887 15.358 
Dipeptide 30.043 29.387 26.995 20.052 
Table A.1. Crystallographic statistics of the four Cyp3 structures 
min and was taken out from the soaking solution if the crystal looked damaged. 
If the crystal remained stable and not damaged, it was left in the solution for 2 hrs before 
being removed. The observation was made by observing the crystal under microscope. 
The crystal was handled as in section A.2.2. The diffraction data was processed by using 
Mosfim and further refined to obtain the occupancy. Table A.l showed the 
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crystallographic statistics of the Gly-Pro complexes. The graph of occupancy over the 
ligand concentrations was plotted by using Kaleidagraph 3.5. The graph was then fitted 
with equation 4 (Figure A.3). The crystal dissociation constants (K) of the interaction 
of Cyp3 to Gly-Pro dipeptide based from crystal soaking was 37.6 ± 22.8 mM. 
The 2FO-Fc density maps around the binding sites of Cyp3 complexes show the 
position of Arg62 at the lowest concentrations of Gly-Pro (6mM) and the highest 
concentration of the ligand used (150 mM) (Figure A.4). At 6 mM of gly- pro, the Arg62 
exhibited a mixture of native Cyp3 and also the ligand bound form of the complex. At 
the highest concentrations of Gly-Pro (150 mM), Arg62 was observed to exhibit the 
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Figure A.3. Refined occupancy of different crystal soaked in the series of Gly-Pro concentrations. 
Each of the points represents each of the occupancy of the ligands. The crystals were soaked in 0, 6, 12, 
100 and 150 mM of ligand concentrations. The crystal dissociation constant (KdC) obtained from the graph 




Figure A.4. Two density maps of Cyp3 soaked with Gly-Pro a) and b) The (2F0-F) density maps 
show the position of Arg62 when the crystals were soaked with 6 and 150 mM Gly-Pro. The Gly-Pro 
peptide totally displaced the water molecules when the Gly-Pro concentration was 150 mM. At 6mM Gly-
Pro, the Arg62 position was a mixture between the native form and the bound form. Three of the water 
molecules (WI, W2 and W4) were still available. The pictures were generated by using ccp4mg. 
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Based on the crystal soaking data of the Gly-Pro and Ala-Pro X-ray structures, a 
decrease in the K from 37.6 mM to 26.8 mM is observed. A recent soaking of Ser-Pro 
(D. Kan, unpublished results), gives a K1 of 6.1 mM. As the Xaa-Pro dipeptide ligands 
move from glycine to serine, there is an increase in a modular fashion - H to CH3 to 
CH2-OH (Figure A.5). Therefore any changes in the interaction between these ligands 
must be contributed by the side chain of the peptide. The interaction of the three 
dipeptide ligands used also show a tighter binding as the side chain becomes bulkier. 
Cyp3 catalyses the PPIase activity through this site and by considering the effect on the 
side chain of the dipeptide on the activity suggested that the bulkier the side chain, the 
more efficiently the Xaa-Pro dipeptide acts as a PPIase inhibitor. However, this 
conclusion is based on the results of only three dipeptides used and must be confirmed 
further with the same experiments by utilising Xaa-Pro dipeptides with bulkier side 
chains. 
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Figure A.5. Superposition of Xaa-Pro dipetide:Cyp3 structures. The position of 5 composite waters 
are shown as red spheres. Arg 62 (R62) positions in all structure was in the ligand bounded formations. 
The three dipeptide also did not exhibit any different except for the side chain. 
A.6. Conclusion 
Based on the Gly-,Ala-, and Ser-Pro dipeptide utilised in the experiments, the 
involvement of the side chain in the ability to bind to Cyp3 can be investigated. The 
A-14 
increases from - H to CH3 to CH2-OH were enough to cause the interaction become 
tighter. A summary of the Kdc and Kds values for the available Xaa-Pro ICyp3 
complexes is given in Table A.2). It is remarkable that the solution binding constants are 
so similar to the K(jc values in the crystal. These results show that protein crystal 


















Table A.2. A summary of the K1 and the Kd values of the the Xaa-Pro interaction with Cyp3. The 
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